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PROLOGUE
Introduction and outline of the thesis 

Introduction
Lower urinary tract dysfunction Non-neurogenic lower urinary tract dysfunction is a 
common urological problem that strongly affects quality of life. Patients can complain 
of urgency and frequency, urge incontinence, chronic pelvic pain or present with 
urinary retention. In most patients the etiology of these complaints remains unclear. 1
Conservative treatment options for bladder overactivity, that is the urgency and 
frequency syndrome and/or urge incontinence, consist of behavioral techniques with 
or without biofeedback, bladder re-education, pelvic muscle exercises or 
pharmacotherapy involving anticholinergics, antispasmodics and tricyclic anti-
depressants. Patients with non-obstructive urinary retention can perform clean 
intermittent or permanent catheterization. For refractory cases of overactive bladder 
more aggressive surgical procedures, including bladder distension, ileocystoplasty or 
urinary diversion have been advocated. However, high recurrence and complication 
rates limit the widespread application of these treatments. 
Therefor, other treatment modalities, able to fill the gap between conservative 
measures and surgical procedures, are urgently needed. The increased popularity of 
intravesical Botulinum toxin injection therapy, first in neurological patients only 2, but 
now in non-neurological patients with overactive bladder as well 3, can be seen in 
that light. The same goes for neuromodulation, especially for its most successful 
representative so far: continuous sacral root stimulation (Medtronic, Inc., 
Minneapolis, Minnesota). 4-6 Although highly effective in selected patients, this 
technique is expensive and requires explicit surgical skill. Not surprisingly, the quest 
for better alternatives is ongoing. 
Percutaneous tibial nerve stimulation Inspired by previous work on 
transcutaneous tibial nerve stimulation by McGuire et al. 7, Marshall Stoller started 
research on percutaneous tibial nerve stimulation (PTNS) as neuromodulative 
treatment in lower urinary tract dysfunction. After initial testing in pig-tailed monkeys 
8, PTNS was later investigated in humans with promising results. 9
PTNS is performed in patients placed in the supine position with the soles of the feet 
together and the knees abducted and flexed (‘frog-position’). A 34 gauge stainless 
steel needle is inserted approximately 3 to 4 cm, about 3 fingerbreadths cephalad to 
the medial malleolus, between the posterior margin of the tibia and soleus muscle. A 
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stick on electrode is placed on the same leg near the arch of the foot. The needle 
and electrode are connected to a low voltage (9 volts) stimulator (Urosurge, 
Coralville, Iowa) with an adjustable pulse intensity of 0 to 10 mA., a fixed pulse width 
of 200 microseconds and a frequency of 20 Hz. The amplitude is slowly increased 
until the large toe starts to curl or toes start to fan. If the large toe does not curl or 
pain occurs near the insertion site, the stimulation device is switched off and the 
procedure is repeated. If the large toe curls or toes start to fan stimulation is applied 
at an intensity well tolerated by the patient. If necessary the amplitude can be 
increased during the session. In the original studies patients underwent 12 weekly 
outpatient treatment sessions, each lasting 30 minutes. If a good response occurred 
the patient was offered chronic treatment. 10 
After Stoller’s presentation of the first clinical data on the European Urological 
Association in 1999 9, further studies on this new promising treatment option were 
conducted, especially by research groups in Europe, resulting amongst others in this 
thesis.
Outline of the thesis 
Chapter 1: Historical perspective Neurostimulation and neuromodulation 
techniques are not new. From the discovery of electricity, its possible use in medicine 
was explored. Starting from intravesical application, electrical pulses in urology were 
used to target the bladder, pelvic floor or different nerves in order to improve voiding 
and/or storage problems. Nevertheless, the many techniques discovered all had their 
disadvantages. Chapter 1 of this thesis consists of a review on the use of electrical 
devices in treating bladder dysfunction. It creates a background against which the 
development of yet another treatment option, namely Percutaneous Tibial Nerve 
Stimulation (PTNS), as well as its clinical value can be better understood. 
Chapter 2: Feasibility and clinical results To explore the possible value of PTNS, 
a feasibility study was performed in 49 patients with overactive bladder or non-
obstructive urinary retention, indications well known from other neuromodulative 
treatment options. Results were obtained using (micturition) diaries and quality of life 
questionnaires, while the definition of success was based on subjective parameters. 
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Next, several indications were studied in more detail. Overactive bladder and non-
obstructive urinary retention were evaluated by Vandoninck et al. 11-12, the results of 
which are not included in this thesis. Research on chronic pelvic pain was performed 
in 33 patients, again using visual analogue scales for pain diaries and quality of life 
questionnaires, but now also objective parameters for success were included. Finally, 
the potentially beneficial effect of successful PTNS treatment of lower urinary tract 
dysfunction on sexual functioning in the three evaluated indication groups combined 
(121 patients) was investigated. All three studies in this chapter are indicative of the 
clinical relevance of percutaneous tibial nerve stimulation. 
Chapter 3: Urodynamic data Although one can obtain rather objective parameters 
from especially (micturition) diaries, urodynamic studies may provide more robust 
data on the effectiveness of percutaneous tibial nerve stimulation. Therefore, studies 
on urodynamics prior to PTNS as well as after completing treatment were performed 
in 90 patients with overactive bladder and 39 with non-obstructive urinary retention, 
respectively. Basic urodynamic parameters in concordance of International 
Continence Society standards were used as outcome measures, so were special 
bladder indices. The studies in this chapter further objectively affirm PTNS 
significance. 
Chapter 4: Prognostics and maintenance In chapter 4 two studies are presented 
regarding refinement of PTNS therapy. First, for all indication groups clinical 
parameters with prognostic value for successful treatment outcome have been 
assessed. Amongst others general patient characteristics, stimulation parameters, 
items like duration of complaints and previous therapies tried, urological symptom 
measurements, quality of life and psychological issues, but also data regarding a 
history of sexual and/or physical abuse were evaluated for their predictive value. 
Thereafter, a study was performed to investigate the necessity for maintenance 
therapy once successful outcome had been obtained. Both studies lead to 
recommendations for better patient selection as well as an optimization of PTNS 
therapy in order to improve treatment outcome. 
Chapter 5: Towards an implantable device To enable flexible, individualized 
treatment schedules and chronic maintenance therapy, both independent of 
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outpatient department support, an implantable device was developed for radiographic 
subcutaneous tibial nerve stimulation. Chapter 5 presents a feasibility study (follow 
up: 12 months) regarding this implantable device. It should convince the reader that 
much effort is made to keep improving tibial nerve stimulation, including its major 
drawback: maintenance therapy.
Summary and future perspectives In this part of the thesis all studies included are 
summarized and discussed. Furthermore, the future role of percutaneous tibial nerve 
stimulation as well as thoughts on further research is reflected upon.
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CHAPTER 1
Historical perspective 

The use of electrical devices in the treatment of 
bladder dysfunction: a review of methods 
M.R. van Balken 
H. Vergunst 
B.L.H. Bemelmans
Published in adapted form in J Urol 2004; 172: 846-851 

Introduction
In humans, the hypogastric plexus, originating from spinal levels Th10-L2, 
sympathetically innervates the bladder. Stimulation of these nerves results in 
relaxation of the detrusor muscle and contraction of the intrinsic sphincter, thereby 
inhibiting micturition. Stimulation of the pelvic plexus, parasympathetic nerves 
originating from spinal level S2-S4, has an opposite effect. Pudendal nerves, coming 
from the same spinal level as the pelvic plexus, innervate the pelvic floor and the 
external sphincter. In the spine and on the supraspinal level pathways and 
interactions are much more complex. Especially studies by de Groat 1,2 and Blok 3-5
have given us some insight in the processes involved. 
Actual damage of the peripheral or the central nervous system (CNS), like in 
neurological patients, or disruption of the fine-tuned balance between inhibitory and 
excitatory stimuli, as occurs in some non-neurological patients, may result in lower 
urinary tract dysfunction. This dysfunction can lead to voiding disorders (like impaired 
micturition or urinary retention) and/or storage disorders (like urgency/frequency (UF) 
and/or urge incontinence(UI)). Both conditions can strongly influence quality of life. 
Therapeutic options for these patients vary from conservative treatments as pelvic 
floor training, biofeedback, medical treatment and self-catheterization to invasive 
surgical procedures, with serious side effects and limited success. 6
Over a century, electrical neurostimulation and neuromodulation have been 
investigated as alternative treatment options. In neurostimulation nerves or muscles 
are directly stimulated by electrical stimuli to obtain immediate responses. As could 
be expected, neurostimulation techniques have been used in neurological patients 
mainly. In neuromodulation electrical stimuli are exerted in order to alter present 
transmission processes. Neuromodulation therapy is used in patients with non-
neurological lower urinary tract dysfunctions. Recently, not only an increasing 
amount of reports about the application and refining of current stimulation and 
modulation techniques have been published, but there is also a renewed enthusiasm 
to develop alternative modalities, like percutaneous tibial nerve stimulation (PTNS) 7,
magnetic stimulation of the pelvic floor 8 or pudendal nerve stimulation (PNS). 9 In 
order to be able evaluate the clinical effectiveness of to these new treatment options 
we review the application of the various electrical devices for treatment of bladder 
dysfunction with respect to mechanism of action and clinical outcome. 
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Electrical stimulation of the bladder 
Intravesical electrical stimulation Saxtorph first used Intravesical electrostimulation 
in 1878 for the treatment of urinary retention. A dedicated catheter was inserted 
transurethrally in the bladder with a metal-electrode inside and a neutral electrode 
placed suprapubically. 10 From then time passed till 1959, when Katona et al 
described a technique of intraluminal electrotherapy for various disorders of the 
gastrointestinal tract. 11 Later on the same technique has been applied for the 
treatment of neurogenic bladder dysfunction. 12 Since then intravesical 
electrostimulation has been described by others with inconsistent results (Table 1). 
Intravesical electrostimulation involves direct intraluminal electrical stimulation via a 
catheter with a special stimulation electrode. The bladder is filled with sodium 
chloride to serve as a cathode and an indifferent electrode is placed on the thigh or 
arm. The technique has been used mostly in children with incomplete nerve lesions 
resulting in absence of bladder sensation and/or insufficient detrusor contractions.  
Normally micturition is initiated by depolarization of intramural mechanoreceptors, 
which through complex CNS reflexes elicit detrusor contractions. This is 
accompanied by the occurrence of sensation. 10 Intravesical current is thought not to 
activate the detrusor myocytes directly but to stimulate bladder mechanoreceptor 
afferents, enhancing bladder sensation and subsequent (stronger) detrusor 
contractions. Supporting this theory are the findings that for direct stimulation of 
efferent nerves to the bladder much higher (and painful) current intensities are 
needed, and that intravesical anesthesia by lidocaine abolishes the detrusor 
response. 13 Long-term results of intravesical stimulation may be due to potentation 
of excitatory synapses in the central micturition reflex pathway. 14
Intravesical electrical stimulation of the bladder remains, however, controversial. 
Although in most studies enhanced bladder sensation and (stronger) detrusor 
contractions can be found after intravesical electrotherapy, this does not necessarily 
result in an improvement of volitional voiding. The increases of bladder capacity 
widely differ in the aforementioned publications. Besides, there are certain other 
disadvantages: the technique is time-consuming and requires well-trained personnel 
and adequate equipment. More importantly, there is no simple test to predict clinical 
outcome. Therefore, the first 10-15 stimulation sessions are considered as a trial, 
only to be continued when a positive response is registered. Duration and intensity of
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Table 1 Publications on intravesical electrostimulation 
Treatment parameters Author y.o.p. Pts. Type of 
study 
Indication Treatment scheme 
Intensity Pulses 
(msec) 
Freq.
(Hz) 
Outcome
(%)
Adults or age not mentioned: 
Katona 15 1975 420 NRCT NBD/VD-SD 90 min. daily,
No. of sessions n.m. 
1-5 mA 5-10 70-100 75c
Farnsworth 16 1976 15  NRCT NBD/VD n.m. n.m. n.m. n.m. 33i 
Madersbacher 17 1982 29 NRCT NBD/VD 90 min. daily,  
23-132 sessions 
1-10 mA 6-8  70-100 59i, 34c 
Primus 18 1996 48 NRCT NBD/VD 90 min., 5x/week,  
10-108 sessions 
10 mA 4  20 54c 
Children: 
Nicholas 19 1975 20 NRCT NBD/SD 90 min., 5 x/week,  
up to 3 months 
1 mA n.m. 90 0i
Janneck 20 1975 14 NRCT NBD/VD-SD 30-60 min. daily,  
No. of sessions n.m 
n.m. 5  50 71i 
Berger 21 1978 31 NRCT NBD/VD-SD 90 min. daily,   
22-300 sessions 
5-6 mA 5-6  50-60 38i, 26c 
Seiferth 22 1978 28 NRCT NBD/VD 60 min., 2-3x/week,  
6-9 months 
1-70 V 5  25 43i 
Madersbacher 23 1978 8 NRCT NBD/VD-SD 90 min., 5x/week,  
? 60 sessions 
n.m. n.m. n.m. 25c 
Kaplan 24 1986 24 NRCT NBD/VD 90 min., 5-6x/week, 
1-110 sessions 
1-10 mA 2-6  60-90 17c 
Kaplan 25 1988 42 NRCT NBD/VD 90 min., 3-5x/week,   
? 15 sessions 
n.m. n.m. n.m. 33-80i 
Decter 26 1992 21 NRCT NBD/VD 90 min. daily,  
1-3x 5-30 sessions  
1-10 mA 2-6  60-90 5i 
Boone 27 1992 31 RBPCT NBD/VD 90 min., 5x/week,  
15 or 30 sessions 
1-7 mA 4-6  40-80 0i 
Lyne 28 1993 17 NRCT NBD/VD 90 min., 5x/week,  
15-108 sessions 
1-10 mA 2-5  60 29i, 0c 
Decter (1) 29 1994 25 NRCT NBD/VD 90 min. daily,  
1-6x 15-30 sessions 
1-10 mA 2-6  60-90 0i 
Y.o.p. = year of publication, Pts. = Patients, Freq. = Frequency, NRCT = Non Randomized Clinical Trial, RBPCT = Randomized 
Blinded Placebo Controlled Trial, NBD = Neurogenic Bladder Dysfunction, VD = Voiding Disorder, SD = Storage Disorder, No. = 
Number, n.m. = not mentioned, i = improved, c = cured,  (1) = follow-up report on publication of 1992: mostly the same patients
are described 
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the stimulation highly differ between individuals and protocols, thus lacking a 
standardized treatment scheme. Frequencies used in humans vary between 40 and 
100 Hz despite recent data obtained in cats and rats showing that much lower 
frequencies (? 20 Hz) seem to be of more benefit. 13,14 In patients with neurogenic 
bladder dysfunction repeated stimulation is often needed, whereas in non-neurogenic 
bladder dysfunction initial treatment most of the time will be sufficient. Intravesical 
electrostimulation usually will be combined with intensive bladder training, which may 
account partly for the successful outcome. 10 
Thus far, intravesical electrostimulation has not gained widespread acceptance 30,31,
reflected by the small amount of clinical reports in recent years. Further research on 
its precise mode of action continues to be performed. 13,14
Direct bladder stimulation Advancing technology resulted in miniature powerful 
transistorized devices in the early 1960’s, which ultimately enabled human use of 
implantable stimulators. 32 In 1962 Bradley described the use of an implantable 
receiver-stimulator with disk (Grass stimulator) and tape (Medtronic stimulator) 
electrodes applied directly to the bladder of dogs 33, followed one year later by a less 
encouraging report on its application in humans. 34 Further research resulted in the 
Avco stimulator using 2-4 silastic coated stainless steel electrodes embedded in the 
anterior or lateral wall of the bladder, whereas the receiver-stimulator is placed 
subcutaneously in the lower abdomen. 35 In an attempt to decrease the risk of erosion 
and dislocation of electrodes the Susset stimulator was developed, using 8 platinum 
disk electrodes placed in two circles on the bladder in pockets made under the 
superficial muscular layer. 32 The Mentor stimulator consists of helical electrodes 
placed around the vesical neuromuscular pedicle with the bladder wall imbricated 
over these electrodes, and a bladder stimulator placed subcutaneously in the left 
lower quadrant of the abdomen. 36
The working mechanism of all the abovementioned devices is based on direct 
stimulation of the detrusor muscle in order to provoke a contraction. The clinical 
results are summarized in table 2. Stimulation is usually combined with bladder 
training performed by clamping the indwelling catheter for increasing periods. In this 
way reflex activity may be provoked in patients with areflexic bladders. 
The use of the Avco device in patients with upper motor neuron lesions causes 
external sphincter spasms during stimulation, thereby preventing effective bladder
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Table 2 Publications on direct bladder stimulation 
Treatment parameters Author y.o.p. Pts. Type of 
study 
Indication Stimulator
Intensity 
(V)
Pulses
(msec) 
Freq.
(Hz) 
Outcome
(%)
Adults or age not mentioned: 
Bradley 34 1963 7 NRCT NBD/VD Grass or Medtronic 
stimulator
5-15 1-5 n.m. 29i
Boyce 37 1964 3 NRCT NBD/VD Grass stimulator 20-40 n.m. 60 33i 33c 
Stenberg 35 1967 4 NRCT NBD/VD Avco stimulator 2.5-18 4 20 75i 
Hald 38 1967 4 NRCT NBD/VD Avco stimulator ? 15 4 20 75i 
Susset 32 1968 1 NRCT NBD/VD Susset stimulator 10-20 1 10-40 100i 
Halverstadt 39 1971 8 NRCT NBD/VD Avco stimulator n.m. n.m. n.m. 25i, 50c 
Merrill 36 1974 5 NRCT NBD/VD Mentor stimulator n.m. n.m. n.m. 40i 
Merrill 40 1975 5 NRCT (N)NBD/VD  Mentor stimulator n.m. n.m. n.m. 60i 
Jonas 41 1978 11 NRCT NBD/VD-SD  Mentor or Susset 
stimulator
n.m. n.m. n.m. 67i 
Children: 
Kantrowitz 42 1965 3 NRCT NBD/VD-SD Avco stimulator 4.4-10 4 20 67i
Merrill 43 1974 2  NRCT NBD/VD Mentor stimulator n.m. n.m. n.m. 100i 
Wheatley 44 1982 8  NRCT NBD/VD Mentor stimulator n.m. n.m. n.m. 38i 
Y.o.p. = year of publication, Pts. = Patients, Freq. = Frequency, NRCT = Non Randomized Clinical Trial, NBD = Neurogenic 
Bladder Dysfunction, NNBD =  Non Neurogenic Bladder Dysfunction, VD = Voiding Disorder, SD = Storage Disorder, n.m. = not 
mentioned, i = improved, c = cured 
emptying. Neither more cephalad placement of the electrodes on the bladder in order 
to decrease spread of current to the pelvic floor 39, nor using other stimulation 
devices solved this problem. Therefore, implantation of a bladder stimulator has 
sometimes been combined with the implantation of a Mentor pelvic floor stimulator 
and/or a subarachnoidal spinal phenol block 36 or with bladder neck incisions and/or 
sphincter resections to decrease detrusor-sphincter-dyssynergia. 41 Other authors 
consider upper motor neuron lesions a clear contraindication for extravesical bladder 
stimulation. 32
Other disadvantages of extravesical bladder stimulators are painful sensations 
experienced during stimulation, a high technical failure rate usually related to 
electrode erosion, and in the long term a decreasing response due to bladder 
fibrosis. 38
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Notwithstanding acceptable clinical outcome in selected cases the technique of direct 
bladder stimulation has finally been abandoned because of the occurrence of 
detrusor-sphincter-dyssynergia in patients with upper motor neuron lesions and the 
pain accompanying stimulation in patients with incomplete lower motor neuron 
lesions 43 or non-neurogenic hypotonic bladders. 40
Electrical stimulation of pelvic nerves In an attempt to treat voiding disorders, 
unilateral pelvic nerve stimulation was tested in dogs as early as in 1957 by Ingersoll 
et al. 45 Unfortunately, results of pelvic nerve stimulation appeared to be 
disappointing because pudendal nerves are stimulated at the same time, resulting in 
increased outflow resistance by sphincter contractions. Besides, pelvic nerves cannot 
be stimulated chronically, and early splitting of its fibers in the pelvis, forming a broad 
plexus, makes the application of an electrode unsuitable. 46
Electrical stimulation of pudendal nerves 
Transvaginal stimulation In 1963 Caldwell reported the successful implantation of 
an anal sphincter stimulator in a patient with faecal incontinence. Shortly thereafter, a 
similar stimulator was implanted in another patient for urinary incontinence. 47 Later 
on, a plug for intra-anal use was developed 48 that was subsequently modified. 49
Based on the experiences with anal stimulation for faecal and urinary incontinence, 
transvaginal stimulation for urinary incontinence was evaluated by Fall et al in 1977. 
50 Since then, Fall and co-workers have published several reports about transvaginal 
electrical stimulation in non-neurogenic patients with urinary incontinence and 
interstitial cystitis (IC). 51,52 In animal experiments performed to illuminate the working 
mechanism of this technique 53, they demonstrated that bladder inhibition (relaxation 
of the detrusor) was accomplished by reflexogenic activation of sympathetic 
hypogastric inhibitory neurons and by central inhibition of pelvic parasympathetic 
excitatory neurons, the pudendal nerves forming the afferent pathways for these 
effects.
Although the technique is easily applicable and can be performed by patients at 
home, there are some disadvantages. Usually, treatment has to be given for a long 
period of time and eventually not all patients can stop therapy. There are also 
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considerable discrepancies between symptomatic cure or improvement on one hand 
and urodynamic findings at follow-up on the other. Overall, the transvaginal way of 
treatment is not well accepted by most patients. To achieve an acceptable outcome 
of therapy, stimulation at high intensity is needed which cannot be easily tolerated by 
women with normal sensation in the pelvic region. Consequently, further reports on 
this treatment modality are scarce (table 3). 54-56
Table 3 Publications on transvaginal stimulation 
Treatment parameters Author y.o.p. Pts. Type of 
study 
Indication Treatment scheme 
Intensity Pulses
(msec) 
Freq.
(Hz) 
Outcome
(%)
Fall 50 1977 15 NRCT NNBD/SD Continuously during daytime, ? 3 
months
? 12 V 1 10 100i
Fall 51 1980 4 NRCT NNBD/SD Continuously during daytime, 6 to 
23 months 
n.m. 2 10 25i 
Fall 52 1984 30 NRCT NNBD/SD Continuously during day- or night-
time or 24 hours, up to 23 months  
n.m. n.m. 10 73i 
Bent 54 1993 31 NRCT NNBD/SD 15 min., twice daily, 6 weeks ? 30 V 1 20 52-70i 
Brubaker 56 1997 61 RBPCT NNBD/SD 20 min., twice daily, 8 weeks ? 100 mA 0.1 20 49c 
Yamanishi 55 2000 68 RBPCT NNBD/SD 15 min., twice daily, 4 weeks n.m. 1 10 81i, 22c 
Y.o.p. = year of publication, Pts. = Patients, Freq. = Frequency, NRCT = Non Randomized Clinical Trial, RBPCT = Randomized 
Blinded Placebo Controlled Trial, NBD = Neurogenic Bladder Dysfunction, NNBD =  Non Neurogenic Bladder Dysfunction, SD = 
Storage Disorder, n.m. = not mentioned, i = improved, c = cured 
Functional or Maximal Electrical Stimulation In 1967 Moore and Schofield 57
stimulated anesthetized patients with urinary stress incontinence with faradic 1 msec 
pulses between an unipolar electrode placed on the perineum and an indifferent 
electrode on the sacrum with intensities at which the pelvic floor muscles contracted 
maximally. This was repeated 4-6 times during the session. Godec et al 58 described 
their technique to improve the results of this type of stimulation, called chronic 
Functional Electrical Stimulation (FES). Using an anal plug or needle electrodes, 
stimulation was performed while measuring EMG responses and vesical as well as 
urethral pressure changes. In a later report 59, the same authors changed their 
technique, calling it Acute Maximal Functional Electrical Stimulation (AMFES). In 
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AMFES, very high stimulation levels were possible because of sensory losses 
associated with spinal cord injury. 
Other authors 60-66 tried to maximize stimulation in a procedure called Maximal 
Electrical Stimulation (MES), stimulating with an intensity as high as tolerable and 
also increasing the number of stimulation sites when possible. Women were 
therefore stimulated anally as well as transvaginally at the same time. Sometimes 
even needles directed to the pudendal nerve were added. 62 The results vary 
considerably, also because different criteria for success were used (Table 4).
Table 4 Publications on functional or maximal electrical stimulation 
Treatment parameters Author y.o.p. Pts. Type of 
study 
Indication Treatment scheme 
Intensity 
(mA)
Pulses
(msec) 
Freq.
(Hz) 
Outcome
(%)
Godec 58 1976 126 NRCT (N)NBD/SD Anal or needles, cont., 1-3 
months
10-15 1 20 92i
Godec 59 1979 18 NRCT NBD/SD Anal ± needles, cont. or 15-20 
min./2-3 days, 4-10x in total 
10-15 or 
100-150
1  20  45i, 36c 
Merrill 67 1979 20 NRCT NBD/SD Anal, cont. for 5-12 months n.s n.m. n.m. 20i 
Plevnik 60 1979 98 NRCT (N)NBD/SD Anal or vaginal,  
20 min./week, 4 weeks 
30-100 1 20 48i 
Plevnik 61 1984 6 NRCT NBD/VD Anal ± vaginal, 15-20 min., 2-
4x/month
50-90 1 20 83i 
Ohlsson 62 1989 29 NRCT (N)NBD/SD Anal ± vaginal + needles, 20 
min./week, 4 weeks 
2-120 1 10 38-100i 
Fossberg 63 1990 91 NRCT NNBD/SD Anal ± vaginal, 12x 20 min. ? 100 1 5-10 56i 
Caputo 64 1993 57 NRCT NNBD/SD Vaginal, 6x 15 min./week  n.m n.m 20 70-73i 
Petersen 65 1994 13 NRCT NBD/SD Anal, 2x 30 min./day, 12 days n.m. 0.3 40 17i 
Geirsson 66 1997 84 NRCT (N)NBD/SD Anal ± vaginal or penile, 2x 20 
min./week, 4x in total  
5-82 0.75 5 54i, 5c 
Y.o.p. = year of publication, Pts. = Patients, Freq. = Frequency, Cont. = Continuously, NRCT = Non Randomized Clinical Trial, 
NBD = Neurogenic Bladder Dysfunction, NNBD =  Non Neurogenic Bladder Dysfunction, VD = Voiding Disorder, SD = Storage 
Disorder, n.m. = not mentioned, i = improved, c = cured 
Especially the physical and psychological discomfort of this treatment modality 
experienced in these studies by many patients who often not finished the studies or 
were not willing to continue chronic therapy, limited acceptance of functional or 
maximal electrical stimulation.
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Penile and clitoral stimulation Being the most superficial branch of the pudendal 
nerve the dorsal nerve of the penis is very near to the skin surface. 68 Squeezing the 
glans penis has been shown to suppress bladder contractions 69, but electrical 
stimulation of the penis did not cause a significant change in intravesical pressure at 
urodynamics during the filling phase. 70 The pudendal pelvic nerve reflex has been 
proposed as a mechanism of bladder inhibition 1,2 because pudendal nerve afferents 
from the dorsal nerve of the penis course to sacral cord segments S2 to S4, the 
same sacral segments from which detrusor afferents, the pelvic nerves, arise. 71 The 
increase in PNS either stimulates the sympathetic system that suppresses bladder 
activity via the ?-adrenergic system or it stimulates the spinal interneurons that 
release inhibitory neurotransmitters (such as enkephalins, glycine or ?-aminobutyric
acid). 1,2
In experimental studies acute effects of dorsal penile nerve stimulation seem 
promising, especially in improving bladder capacity. However, clinical studies lack 
significant effects (Table 5) and many patients experience bothersome sensations 
during stimulation even at threshold levels. 72 It is believed that chronic low frequency 
stimulation with high current intensity (up to or even exceeding 99 mA) may improve 
treatment outcome 73,74, but the very unpleasant feeling or pain resulting from this 
stimulation will limit its application.   
Selective pudendal nerve stimulation To deliver more potent electrical stimuli than 
can be applied by anal or vaginal stimulation, Vodušek et al 75 introduced selective 
PNS (Table 6). In this method, a concentric needle electrode is inserted into the 
periurethral sphincter muscle under auditory and oscilloscopic control, and two teflon-
coated bare-tip needle electrodes are introduced ipsilaterally into the proximity of the 
pudendal nerve (at the ischial spine) through the perineum, 2-3 cm apart. Clear 
vesicoinhibitory responses could be found, with subsequent increase of micturition 
thresholds. Although the author proposed the development of an implantable 
stimulator, no further publications arose.  
With the development of the Bion? device (Advanced Bionics, Sylmar, California, 
USA) 9 new interest in selective PNS may be anticipated. 
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Table 5 Publications on penile/clitoral electrostimulation 
Treatment parameters Author y.o.p. Pts. Type of 
study 
Indication Treatment scheme 
Intensity Pulses
(msec) 
Freq.
(Hz) 
Outcome
(%)
Nakamura 68 1984 22 NRCT (N)NBD/SD ‘continuous’ (portable 
stimulator)
5-50 V 0.5 10-20 18c
Vodušek 76 1986 10 AUCE NBD/SD Urodynamics before, during 
and after stimulation 
20-37 mA 0.2-0.5 5-10 - 
Wheeler 71 1992 6  AUCE NBD/SD Urodynamics before, during 
and after stimulation 
25-70 mA 0.35 5 - 
Wheeler 72 1994 9 NRCT NBD/VD-SD ‘continuous’ (portable 
stimulator)
40 mA 0.25 5 22c 
Previnaire 77 1996 10 AUCE NBD/SD Urodynamics during 
stimulation
14-40 mA 0.5 5 - 
Previnaire 73 1998 6 NRCT NBD/SD 20 min./day, 5 days/week, 4 
weeks 
35-99 mA 0.5 5 33i 
Kirkham 74 2001 14 AUCE NBD/SD Urodynamics before and 
after stimulation 
20-60 mA 0.2 15 - 
Y.o.p. = year of publication, Pts. = Patients, Freq. = Frequency, NRCT = Non Randomized Clinical Trial, AUCE = Acute 
Urodynamically Controlled Experiment, NBD = Neurogenic Bladder Dysfunction, NNBD =  Non Neurogenic Bladder Dysfunction, 
VD = Voiding Disorder, SD = Storage Disorder, n.m. = not mentioned, i = improved, c = cured 
Table 6 Publications on selective pudendal stimulation
Treatment parameters Author y.o.p. Pts. Type of 
study 
Indication Treatment scheme 
Intensity
(mA)
Pulses
(msec) 
Freq.
(Hz) 
Outcome
(%)
Vodušek 75 1988 3 AUCE NBD/SD Stimulation during urodynamics 1-2 0.2 5 -
Y.o.p. = year of publication, Pts. = Patients, Freq. = Frequency, AUCE = Acute Urodynamically Controlled Experiment, NBD = 
Neurogenic Bladder Dysfunction, SD = Storage Disorder, i = improved, c = cured 
Transcutaneous electrical nerve stimulation (TENS) 
Suprapubically In 1980, Fall et al. 51  were the first to report on a study in IC patients 
using suprapubical transcutaneous electrical nerve stimulation (TENS) to relief pain 
and symptoms of bladder overactivity. Favorable outcome was considered to be due 
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to pain relief and thereby the possibility to increase bladder filling and postpone 
voiding. However, influence of TENS on the autonomic system might be another 
explanation. As clinical results were promising, especially in relieving pain and 
decreasing voiding frequency, follow-up studies were performed not only in case of 
IC, but also in patients with idiopathic lower urinary tract dysfunction 78-81 (Table 7). 
Table 7 Publications on TENS over the suprapubic region 
Treatment parameters Author y.o.p. Pts. Type of 
Study 
Indication Treatment scheme 
Intensity 
(mA)
Pulses
(msec) 
Freq.
(Hz) 
Outcome
(%)
Fall 51 1980 9 NRCT NNBD/SD 2x/day 15 min. to 2 hours for 1-6 
months
n.m. 0.2 50 22-100i
Fall (1) 78 1987 35 NRCT NNBD/SD 2x/day 2 hours for 6 weeks, 
intermittently up to 7 years  
n.m. 0.2 2-50 37i, 14c 
Fall (1) 82 1994 60 NRCT NNBD/SD 2x/day 30 min. to 2 hours, to 
intermittently, up to 10 years 
n.m. 0.2 2-50 26-54i 
Hasan 79 1996 36 AUCE NNBD/SD Urodynamic experiment only n.m. 0.2 50 - 
Bower 80 1998 ? of 79 AUCE NNBD/SD Urodynamic experiment only n.m. 0.2 150 - 
Bower 81 2001 2 NRCT NNBD/SD 2x/day 1 hour for 1 to 5 months n.m. 0.2 150 73i 
Y.o.p. = year of publication, Pts. = Patients,  Freq. = Frequency, NRCT = Non Randomized Clinical Trial, AUCE = Acute 
Urodynamically Controlled Experiment, NNBD =  Non Neurogenic Bladder Dysfunction, SD = Storage Disorder, n.m. = not 
mentioned, i = improved, c = cured, (1) = extension of original patient group 
In this form of TENS two carbon-rubber electrodes are positioned suprapubically, 10-
15 cm. apart. Stimulation is given at maximum tolerable intensity up to 2 hours twice 
daily as there proves to be a carry-over effect, i.e. a lasting improvement after the 
withdrawal of stimulation. Frequencies used highly differ from 2 Hz, considered to 
stimulate pudendal nerve afferents to 50 Hz, considered to engage the striated 
paraurethral musculature. 53,83 Even 150 Hz has been used, probably having a 
mainly sensory effect. 
Low frequency TENS is reported to give earlier results in some patients, but the 
muscle twitches are highly unpleasant. 82 The 150 Hz current may lead to a decrease 
of detrusor contractility by influencing the anterior cutaneous branch of the 
iliohypogastric nerve (Lumbar I level), or by inhibiting afferents of the pelvic splanchic 
nerves that join the inferior hypogastric plexus. 80
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Compared to placebo there are conflicting publications reporting no significant 
changes in urodynamics 79 versus significant changes in first desire to void, 
maximum cystometric capacity and threshold volume in the suprapubic TENS group. 
80 TENS is an easy applicable and non-invasive treatment option, but has to be used 
intermittently for long periods of time. 78,82
S2 or S3 dermatome As suprapubic TENS proved to be an easy applicable 
treatment modality with minimal side effects, and direct electrical stimulation of S3 
sacral segmental nerve roots by surgically implanted electrodes showed encouraging 
results 84, it was thought that application of TENS over the S2 or S3 dermatome 
might improve clinical results. This treatment option has been studied extensively 
using clinical as well as urodynamic parameters. S2-3 TENS was compared to no 
TENS 79,85,86, sham TENS (just an apparatus with a flashlight 80 or TENS on T12 
79,85,86, suprapubic TENS 79,80, TENS on the tibial nerve 79, direct S3 stimulation 79,
and medical treatment with oxybutynin 87 (Table 8).
Table 8 Publications on TENS over the S2 and S3 dermatome 
Treatment parameters Author y.o.p. Pts. Type of 
study 
Indication Treatment scheme 
Intensity
(V)
Pulses
(msec) 
Freq.
(Hz) 
Outcome
(%)
Adults or age not mentioned: 
Webb 85 1992 24 RPCT NNBD/SD 1 week, scheme n.m. n.m. n.m. n.m. 54i
Hasan 86 1994 20 NRCT NNBD/SD 3 weeks, scheme n.m.  n.m. 0.2 50 71i, 25c 
Hasan 79 1996 59 NRCT NNBD/SD 2 to 4 weeks, scheme n.m. n.m. 0.2 50 37-73i 
Bower 80 1998 ? of 79 AUCE NNBD/SD Urodynamic experiment only n.m. 0.2 10 - 
Walsh 88 1999 25 NRCT NNBD/SD 12 hours/day for 1 week n.m. 0.2 10 56-76i 
Soomro 87 2001 43 RCT NNBD/SD Up to 6 hours/day for 6 weeks n.m. 0.2 20 2-24i 
Children: 
Bower 81 2001 15 NRCT NNBD/SD 2x/day 1 hour for 1 to 5 months n.m. n.m. 10 73i
Hoebeke 89 2001 41 NRCT NNBD/SD 2 hours/day, for 1 to 6 months n.m. 0.15 2 76i, 56c 
Y.o.p. = year of publication, Pts. = Patients, Freq. = Frequency, RPCT = Randomized Placebo Controlled Trial, NRCT = Non 
Randomized Clinical Trial, AUCE = Acute Urodynamically Controlled Experiment, RCT = Randomized Clinical Trial, NBD = 
Neurogenic Bladder Dysfunction, NNBD =  Non Neurogenic Bladder Dysfunction, SD = Storage Disorder, n.m. = not 
mentioned, i = improved, c = cured 
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The aforementioned studies reveal a positive effect on detrusor instability, delaying 
the first desire to void and increasing bladder capacity on urodynamics. Some of the 
patients with detrusor instability become stable on urodynamics, while in others the 
volume at first contraction improves significantly. 79,80,85,86 However, for permanent 
diminishing incontinence, TENS alone appears insufficient. 81,89 Compared to 
oxybutynin, TENS has less side effects, but treatment outcome is in favor of 
medication. 87 As in suprapubic TENS, continuation of treatment for long periods of 
time is necessary to prevent recurrence of complaints. 88 And even in case of a 
successful outcome, a majority of patients is unwilling to purchase a stimulation 
device because of the costs or the fear being lost to medical supervision and follow-
up. 88
Electrical stimulation of the sacral spine and roots 
Direct sacral spine stimulation In an attempt to achieve micturition by spinal cord 
stimulation, animal experiments were done by Nashold 90 and Friedman 91, in which 
the sacral segments of the conus medullaris were activated directly. It was found that 
the region of optimal stimulation is at the level of S1-S3 and that the frequency of 
stimulation determines effectiveness. Stimulation  with surface electrodes proved to 
be of no use, only deep stimulation resulted in high bladder pressures. Unfortunately, 
simultaneous external sphincter relaxation could not be obtained. Following these 
reports, stimulators were implanted in humans 92,93 (Table 9). 
Further animal studies by Jonas et al. 94-97 with several types of electrodes did not 
result in successful voiding. Although detrusor contractions arose, they were 
accompanied by concomitant contractions of the external sphincter, allowing only 
minimal voiding at the end of the stimulation, the so-called post stimulus voiding. 
Later research 98 revealed that at the sacral spinal level the parasympathetic nucleus 
is located in the vicinity of the pudendal nucleus, which means that it is almost 
impossible to stimulate the bladder and sphincter separately at this location. 
Therefore, direct spinal cord stimulation has been abandoned.
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Table 9 Publications on direct spinal cord stimulation 
Treatment parameters Author y.o.p. Pts. Type of 
study 
Indication Stimulator
Intensity 
(V)
Pulses
(msec) 
Freq.
(Hz) 
Outcome
(%)
Grimes 93 1974 10 NRCT NBD/VD n.m. 10-15 n.m. 15-20 60i
Grimes (1) 92 1975 10 NRCT NBD/VD n.m. 10-15 0.2 15-20 60i 
Y.o.p. = year of publication, Pts. = Patients, Freq. = Frequency, NRCT = Non Randomized Clinical Trial, NBD = Neurogenic 
Bladder Dysfunction, VD = Voiding Disorder, n.m. = not mentioned, i = improved, (1) = the same patients as in the publication 
of 1974 are described 
Sacral anterior root stimulation after dorsal rhizotomy After several experimental 
studies in baboons, Brindley first reported in 1982 on the implantation of a sacral 
anterior root stimulator in paraplegic patients 99, soon to be followed by the 
description of a further 50 cases. 100 The sacral anterior root stimulator consists of an 
implantable receiver with stimulation wires and an external transmitter (Finetech Ltd, 
Hertfordshire, United Kingdom). The surgical technique has been modified by 
Sauerwein, who combined sacral anterior root stimulation with complete posterior 
sacral root rhizotomy to abolish all reflex activity of the detrusor. 101 Usually, after 
laminectomy from  L3-4 to S2, the sacral roots are identified intradurally and 
separated in their anterior and posterior parts using a hook electrode. After 
transsection of the posterior roots S2 to S4(-5), the remaining anterior roots are 
placed in the electrodes and the dura is closed. The receiver is placed in a ventral 
subcutaneous pocket. 102 The procedure can also be performed extradurally 103,104
and may have beneficial effects on erectile function and defecation. 100 Incomplete 
rhizotomy of the posterior roots results in poor bladder compliance, contrary to 
patients in which a complete transsection has been performed, making patients with 
intact sacral sensibility less suitable for this procedure. 102 This need for complete 
dorsal rhizotomy was also confirmed in experimental studies in canines. 105,106 As 
stimulation induces simultaneous contractions of the detrusor muscle and the 
external sphincter, micturition occurs by post stimulus voiding as the relaxation time 
of the sphincter is shorter than that of the smooth detrusor muscle. Therefore, bursts 
of impulses are given to empty the bladder to repeat this phenomenon. Variation in 
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stimulation parameters have been studied to reduce the problem of sphincter 
contraction. 107 Nevertheless, sometimes a sphincterotomy is still needed. 108 
A lot of research has been done by members of the Dutch Study Group on Sacral 
Anterior Root Stimulation 102,107,109-112 (Table 10).
Table 10 Publications on sacral root stimulation after dorsal rhizotomy 
Treatment parameters Author y.o.p. Pts. Type of 
Study 
Indication Stimulator
Intensity
(mA)
Pulses
(msec) 
Freq.
(Hz) 
Outcome
(%)
Brindley 99 1982 11 NRCT NBD/VD-SD Finetech-Brindley 
stimulator
? 20 0.1 8-30 64i
Brindley (1) 100 1986 50 NRCT NBD/VD-SD Finetech-Brindley 
stimulator
n.m. n.m. n.m. 67i 
Robinson 108 1988 22 NRCT NBD/VD-SD Finetech-Brindley 
stimulator
n.m. n.m. n.m. 68i 
Tanagho 104 1989 22 NRCT NBD/VD-SD n.m. 3-8 0.18-0.2 15-20 45I, 36c 
Koldewijn 102 1994 27 NRCT NBD/VD-SD Finetech-Brindley 
stimulator
n.m. n.m. n.m. 93i 
Van der Aa 112 1995 17 NRCT NBD/VD-SD Finetech-Brindley 
stimulator
n.m. n.m. n.m. 71i 
Van Kerrebroeck (2) 109 1996 52 NRCT NBD/VD-SD Finetech-Brindley 
stimulator
n.m. n.m. n.m. 91i 
Van Kerrebroeck (3) 110 1997 52 NRCT NBD/VD-SD Finetech-Brindley 
stimulator
n.m. n.m. n.m. 73-86i 
Egon 103 1998 96 NRCT NBD/VD-SD Finetech-Brindley 
stimulator
n.m. n.m. n.m. 88i 
Rijkhoff 107 1998 12 AUCE NBD/VD-SD Finetech-Brindley 
stimulator
? 6 0.2-0.7 25 - 
Van der Aa (4) 113 1999 38 NRCT NBD/VD-SD Finetech-Brindley 
stimulator
n.m. n.m. n.m. 63-82i 
Y.o.p. = year of publication, Pts. = Patients, Freq. = Frequency, NRCT = Non Randomized Clinical Trial, AUCE = Acute 
Urodynamically Controlled Experiment, NBD = Neurogenic Bladder Dysfunction, VD = Voiding Disorder, SD = Storage 
Disorder, n.m. = not mentioned, i = improved, c = cured, (1) = follow-up report on publication of 1982, partly the same patients
are described, (2) = follow-up report on publication of Koldewijn, partly the same patients are described, (3) = partly the same
patients as in the publication of 1996 are described, (4) = partly the same patients as in the publication of 1995 are described
Cost-effectiveness and quality-of-life analysis is performed, revealing a financial 
break-even point at about 8 years and significant changes in psychological well-being 
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and feelings concerning micturition and bladder emptying. General quality-of-life 
indicators do not significantly change after the implantation. 111
Sacral anterior root stimulation after dorsal rhizotomy is now a well accepted 
treatment option in patients with a complete supra-sacral spinal cord lesion leading to 
incontinence, recurrent urinary tract infections or upper urinary tract deterioration. 
Sacral root stimulation by implant In 1981, the urological department of the 
University of California at San Francisco started a clinical program to evaluate the 
results of sacral root electrode implantation in humans, leading to the first 
publications on this subject by Tanagho and Schmidt. 114,115 Since then a progressive 
amount of reports has been published as the technique gained popularity. The 
surgical technique, described in detail by Thon 116 and Siegel 117, consists of 
implantation of a wire electrode in one of the sacral foramina, usually S3, which is 
then connected to a stimulator device (InterStim®, Medtronic, Minneapolis, 
Minnesota, USA) placed in a subcutaneous pocket in the abdomen. This stimulator 
device can be controlled radiographically. Because the implantation procedure is 
expensive and invasive and clear predictors of success are absent 118, surgery is 
preceded by Peripheral Nerve Evaluation (PNE) to select patients who might improve 
after implantation of a permanent stimulator device. Guided by anatomical landmarks 
119, a temporary wire electrode is percutaneously inserted in the sacral foramen and 
connected to an external stimulator for a couple of days. 97 In case of an 
improvement in predefined parameters of >50%, implantation of a permanent 
stimulator is indicated. 
Initially it was thought that sacral neuromodulation mainly was effective on the pelvic 
floor muscles by inducing muscle hypertrophy. A change in histochemical properties 
120 was supposed to lead to improved pelvic floor efficiency. 121 As neuromodulation 
takes place below the threshold for direct motor responses, this theory is not 
convincing. Nowadays it is well accepted that effects of sacral root neuromodulation 
take place at the spinal and supraspinal level, by inhibition of spinal tract neurons 
involved in the micturition reflex, of interneurons involved in spinal segmental reflexes 
and of postganglionic neurons. 122 Furthermore, there may be inhibition of the 
primary afferent pathway, and indirect suppression of guarding reflexes by turning off 
bladder input to internal sphincter sympathetic or external urethral  sphincter 
interneurons. 97 Also in urinary retention, the obtained effects are believed by some 
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authors to be the result of changed pelvic floor behavior directly  123,124, or as part of 
retuning of a brainstem ‘on-off’ switch mechanism. 122,125
Although several authors have reported on mixed groups of patients with chronic 
voiding disorders 126-130 most publications concern one of the three main indications 
for sacral neuromodulation: UF syndrome, UI or chronic urinary retention (Table 11). 
A decrease of pelvic pain as a symptom accompanying UF or UI has been reported 
by several authors 131-133, but results are disappointing if sacral neuromodulation is 
performed solely on pelvic pain as a primary complaint. 134-135 With expanding 
experience also other indications are being explored, like for example sacral 
neuromodulation in multiple sclerosis patients 136,137, children 138 or patients with IC. 
133,139
In order to refine the technique and improve treatment results, new stimulation 
devices are being developed 140 and modifications to the current technique have 
been described. To shorten operation time and reduce pain complaints at the 
stimulator site, buttock placement of the stimulator was advocated by Scheepens et 
al. 141 Bilateral stimulation with cuff electrodes as well as a tailored laminectomy have 
been described 142-145, but because of progressive improvement of the results of 
unilateral stimulation treatment outcome during recent years, these techniques never 
became very popular as they are also more laborious. For patients with repeatedly 
failed PNE-tests, the two-stage procedure has been described by Janknegt et al. 
146,147 In this procedure a permanent lead is implanted and connected to an external 
stimulator for an evaluation period of 4 days. In case a more than 50% improvement 
occurs, a permanent subcutaneous stimulator is implanted. Oliver et al. 148 described 
the use of conditional neuromodulation, that is neuromodulation applied only at 
moments of an increased level of urge, that might expand battery lifespan. Finally, 
minimally invasive techniques are being developed, by which the permanent lead can 
be implanted through a very small paramedian incision, fixing the electrode with the 
use of bone anchors 149 or even percutaneously, fixing the lead with the twist-lock 150
or grip-lock system. Percutaneous implantation of the electrodes is especially 
desirable in patients with spinal cord injury treated by sacral nerve stimulation as the 
localization of the skin incision frequently involves decubitus. 151
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Table 11 Publications on sacral root stimulation by implant 
Treatment parameters Author y.o.p. Pts. Type of 
study 
Indication Stimulator
Intensity
(V)
Pulses
(msec) 
Freq.
(Hz) 
Outcome
(%)
Thon 126 1991 57 NRCT NNBD/SD Medtronic stimulator 2-4 0.18-0.21 14-18 75i
Vapnek 125 1991 7 NRCT NNBD/VD Medtronic stimulator  n.m. n.m. n.m. 71c 
Dijkema 127 1993 23 NRCT NNBD/VD-SD Medtronic stimulator  0.5-4 0.15-0.21 5-10 22i, 61c 
Elabbady 128 1994 17 NRCT NNBD/VD-SD Medtronic stimulator in 
17 of 50 patients 
1.5-5.5 0.21 10-15. 37-85i 
Koldewijn 118 1994 100 NRCT (N)NBD/VD-SD Percutaneous evaluation 
only, ? 3 days 
? 10 mA 0.20 25 13i, 34c 
Bosch 152 1995 18 NRCT NNBD/SD Medtronic stimulator in 
18 of 31 patients 
2.7±0.4 0.21 10-15 22i, 61c 
Bosch 136 1996 6 NRCT NBD/SD Medtronic stimulator in 4 
of 6 patients 
2.8-4.2 0.21 10 25i, 50c 
Janknegt 146 1997 10 NRCT NNBD/VD-SD Electrode implantation 
(‘two-stage’) 
n.m. n.m. n.m. 80i 
Ishigooka 151 1998 4 NRCT NBD/VD-SD Medtronic stimulator, 
percutaneous implant 
? 10 0.5 10 50i, 25c 
Shaker 131 1998 18 NRCT NNBD/VD-SD Medtronic stimulator n.m. n.m. n.m. 22i, 44c 
Shaker 153 1998 20 NRCT NNBD/VD Medtronic stimulator n.m. n.m. n.m. 100i 
Weil 129 1998 36 NRCT NNBD/VD-SD Medtronic stimulator in 
36 of 100 patients 
0.5-4 0.21 15 53i 
Schmidt 154 1999 86 RCT NNBD/SD Medtronic stimulator in 
86 of 155 patients 
n.m. n.m. n.m. 29i, 47c 
Chai 139 2000 6 NRCT NNBD/SD Percutaneous evaluation 
only, 5 days 
n.m. n.m. n.m. 70i 
Weil 155 2000 44 RCT NNBD/SD Medtronic stimulator in 
44 of 123 patients 
? 0.1 0.21 15 75c 
Hassouna 132 2000 51 RCT NNBD/SD Medtronic stimulator n.m. n.m. n.m. 56-88i 
Jonas 156 2001 68 RCT NNBD/VD Medtronic stimulator in 
68 of 177 patients 
n.m. n.m. n.m. 14i, 69c 
Maher 133 2001 15 NRCT NNBD/SD Percutaneous evaluation 
only, 7-10 days 
? 10 0.21 15 73i 
Janknegt 157 2001 96 NRCT NNBD/SD Medtronic stimulator n.m. n.m. n.m. 36i, 26c 
Spinelli 130 2001 196 NRCT (N)NBD/VD-SD Medtronic stimulator n.m. n.m. n.m. 39-66c 
Aboseif 158 2002 64 NRCT NNBD/VD-SD Medtronic stimulator n.m. n.m. n.m. 80i 
Aboseif 159 2002 20 NRCT NNBD/VD Medtronic stimulator n.m. n.m. n.m. 90i 
Hedlund 160 2002 14 NRCT NNBD/SD Medtronic stimulator in 
14 of 53 patients 
n.m. n.m. n.m. 36i, 57c 
Amundsen 161 2002 12 NRCT NNBD/SD Medtronic stimulator in 
12 of 25 patients 
n.m. n.m. n.m. 83i, 17c 
Spinelli 150 2003 22 NRCT (N)NBD/VD-SD Medtronic stimulator in 
22 of 32 patients 
n.m. n.m. n.m. 5i, 91c 
Y.o.p. = year of publication, Pts. = Patients, Freq. = Frequency, NRCT = Non Randomized Clinical Trial, RCT = Randomized 
Clinical Trial, NBD = Neurogenic Bladder Dysfunction, NNBD =  Non Neurogenic Bladder Dysfunction, VD = Voiding Disorder, 
SD = Storage Disorder, n.m. = not mentioned, i = improved, c = cured 
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Electrical stimulation of the lower limb 
Electrical stimulation of the thigh muscle In 1986, Wheeler et al. 162 reported on 
urodynamic changes after 4-8 weeks of thigh muscle reconditioning by surface 
electrical stimulation. Within a year, Shindo et al. 163 reported on beneficial changes 
in bladder function allowing effective ‘dry’ periods in patients treated with thigh 
muscle stimulation for severe lower limb spasticity (Table 12). More recently, thigh 
muscle stimulation was studied with the sole purpose to treat detrusor overactivity. 
164
Table 12 Publications on thigh muscle stimulation 
Treatment parameters Author y.o.p. Pts. Type of 
study 
Indication Treatment scheme 
Intensity 
(mA)
Pulses
(msec) 
Freq.
(Hz) 
Outcome
(%)
Shindo 163 1987 32 NRCT NBD/SD 9-35 min. a day, 6 weeks n.m. 0.2 30-40 50i
Okada 164 1998 19 NRCT (N)NBD/SD 20 min. a day, 2 weeks n.m. 0.2 30 32i 
Y.o.p. = year of publication, Pts. = Patients, Freq. = Frequency, NRCT = Non Randomized Clinical Trial, NBD = Neurogenic 
Bladder Dysfunction, NNBD =  Non Neurogenic Bladder Dysfunction, SD = Storage Disorder, n.m. = not mentioned, i = 
improved, c = cured 
The mechanism by which stimulation of the thigh muscles inhibits detrusor 
overactivity is unclear. Most probably a reflex-mediated central inhibition of the 
bladder occurs, which normally prevents urine leakage during physical exertion. 165
Manipulation of peripheral input to spinal motor neurons may increase segmental 
inhibitory tone 166 relieving not only spasticity of limbs in patients with spinal cord 
injuries, but also regulating micturition reflexes in patients with an overactive bladder. 
164 A satisfactory neurophysiological explanation for the carry-over effect could not be 
given. It is, however, suggested that prolonged electrical stimulation may lead to 
some reorganization of the neuronal systems controlling the bladder, either 
peripherally or centrally, and as a result of this plastic change normal reflex patterns 
may restore. 165,167
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The treatment is not associated with known adverse effects. If symptoms recur, 
repeated stimulation again may be effective. 164 Nevertheless, thigh muscle 
stimulation in the treatment of detrusor overactivity is not commonly performed. 
Electrical stimulation of the tibial nerve During experimental studies in non-human 
primates with spinal cord injury to improve bipolar anal sphincter stimulation, 
McGuire et al found inhibition of detrusor activity equally achieved by applying a 
positive current to the anal sphincter, with a negative electrode placed over the 
posterior tibial nerve. Similar results were obtained by applying current via a 
transcutaneous positive stick-on electrocardiograph type electrode with a foam 
backing placed over the common peroneal or posterior tibial nerve and a ground 
electrode placed over the same nerves contra laterally. The idea of stimulating these 
nerves was based on the traditional Chinese practice using acupuncture points over 
the common peroneal or posterior tibial nerves to inhibit bladder activity. 168
Transcutaneous posterior tibial nerve stimulation was then evaluated in clinical trials 
with variable results 168-170 (Table 13). 
Nonetheless, PTNS (Urgent PC™, CystoMedix, Anoka, Minnesota, USA) was FDA 
approved in 2000. A 34-gauge stainless steel needle is to be inserted approximately 
5 cm cephalad from the medial malleolus and just posterior to the margin of the tibia. 
A stick-on electrode is placed on the medial surface of the calcaneus. 171,172 Recent 
reports describe the results after an initial treatment period of 10-12 weeks (Table 
5.2). In case of a good response patients are offered tapered chronic treatment. As in 
sacral root neuromodulation, PTNS seems less effective in treating chronic pelvic 
pain. 173
More substantial data, especially on objective parameters and long-term follow-up, 
are needed, just like studies on the underlying neurophysiological mechanisms of this 
treatment modality. One possibility might be the reduction of spinal neuronal cell 
activity, as suggested by Chang et al. 174 Bladder instillation of 1% acetic acid in rats 
induces expression of the metabolic marker c-fos protein in the spinal micturition 
center, while PTNS reduces this expression.  
Although PTNS is minimally invasive, easily applicable and well tolerated, the main 
disadvantage seems to be the necessity to pertain chronic treatment. The 
development of an implantable subcutaneous stimulation device might enlighten this 
problem.
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Table 13 Publications on tibial nerve stimulation 
Treatment parameters Author y.o.p. Pts. Type of 
study 
Indication Treatment scheme 
Intensity 
(mA)
Pulses
(msec) 
Freq.
(Hz) 
Outcome
(%)
Transcutaneous: 
McGuire 168 1983 22 NRCT (N)NBD/SD n.m. n.m. n.m. n.m. 32i, 55c 
Geirsson 169 1993 8 RCT NNBD/SD 30 min./day, 4 weeks n.m. 0.2 1 25i 
Hasan 170 1996 36 AUCE NNBD/SD Stimulation during 
urodynamics 
n.m. 0.2 50 - 
Percutaneous:
Stoller 171 1999 90 NRCT NNBD/SD 10 times 20-30 min., 
once a week 
? 10 0.2 20 81i
Govier 175 1999 n.m. NRCT NNBD/SD 12 times 30 min., 
once a week 
? 10 0.2 20 80i 
Klingler 176 2000 15 NRCT NNBD/SD 12 times 30 min.,  
4 times a week  
? 10 0.2 20 20i, 47c 
Govier 172 2001 53 NRCT NNBD/SD 12 times 30 min., 
once a week 
? 10 0.2 20 71i 
Vandoninck 177 2001 8 AUCE (N)NBD/SD Stimulation during 
urodynamics 
? 10 0.2 20 - 
Van Balken 178 2001 49 NRCT NNBD/VD-SD 12 times 30 min., 
once a week 
? 10 0.2 20 60i 
Vandoninck 179 2003 35 NRCT NNBD/SD 12 times 30 min., 
once a week 
? 10 0.2 20 70i, 46c 
Y.o.p. = year of publication, Pts. = Patients, Freq. = Frequency, NRCT = Non Randomized Clinical Trial, RCT = Randomized 
Clinical Trial, AUCE = Acute Urodynamically Controlled Experiment, NBD = Neurogenic Bladder Dysfunction, NNBD =  Non 
Neurogenic Bladder Dysfunction, VD = Voiding Disorder, SD = Storage Disorder, n.m. = not mentioned, I = improved, c = cured 
Conclusions
The use of electrical neurostimulation and neuromodulation to treat patients with 
lower urinary tract dysfunction has been widely investigated. Nevertheless, in many 
reports important information is missing and good randomized placebo controlled 
studies have seldom been performed 180,181, even concerning invasive techniques 
that make use of implantable electrodes and stimulators. Besides this, there are 
many other problems making it very difficult to judge the different treatment 
modalities on their true merits. 
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First of all, there is considerable variety in the treatment parameters and schedules 
reported, hampering comparison of both studies concerning different and identical 
techniques. For example, pulse intensity, reported in mA as well as in V, is more or 
less uniformly set at a well tolerable level, but frequency, known to be optimal at 
unpleasantly low levels (5-6 Hz) 165, varies from 5-20 Hz and even frequencies up to 
150 Hz are reported. The same goes for pulse duration, usually varying from 0.2-0.5 
msec, but in some studies set at more than 1 msec. Furthermore, the treatment 
schedules are highly different, where they vary from continuous stimulation to 
treatment once daily or once or several times a week, for the duration of mostly some 
weeks or months.
Secondly, criteria for success differ widely. Cure is sometimes defined as complete 
disappearance of a predefined parameter, but also as over 90% improvement. 
Success differs from subjective satisfaction to statistical significant changes of more 
objective parameters. These outcome measures are rarely uniformly set, consisting 
of various urodynamic parameters and parameters obtained from micturition diaries 
and/or questionnaires. Long-term data on the clinical outcome are usually lacking. 
Finally, patients included in these studies have different characteristics, especially 
concerning the definition and duration of their symptoms and the various treatments 
applied before. This not only makes it difficult to compare different trials, but also 
hampers the determination of prognostic factors that might improve treatment 
outcome.
However, in general one might say that electrical neurostimulation and 
neuromodulation on an intention-to-treat basis result in a 30 to 50% clinical success. 
Influencing lower urinary tract innervation at the level of the sacral root seems to 
stand the test of time in both neurological and non-neurological patients. It has the 
advantage of pre-testing possibilities to improve patient selection and thereby 
treatment outcome, but it has the drawback of invasiveness. Non-invasive techniques 
lack screening tests and in case of success patients almost always need 
maintenance therapy.
In conclusion, not only randomized clinical trials to compare different techniques and 
to evaluate placebo effects overcoming the earlier mentioned methodological flaws 
are urgently needed, but also further studies to elucidate the mode of action to 
improve stimulation application and therapy results. The introduction of new 
stimulation methods may not only provide alternative treatment options, but may also 
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be of help in answering these more basic questions on electrical neurostimulation 
and neuromodulation.
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Abstract
Objective Recently, intermittent percutaneous posterior tibial nerve stimulation was 
introduced as a treatment modality filling the gap between conservative and surgical 
therapies in patients with certain types of lower urinary tract dysfunction. 
Patients and methods In a prospective multicenter trial posterior tibial nerve 
stimulation was evaluated in 37 patients who presented with symptoms of bladder 
overactivity, that is the urgency and frequency syndrome and/or urge incontinence, 
and 12 with non-obstructive urinary retention. Results were recorded in voiding 
diaries and on quality of life questionnaires before and after treatment. Patients were 
classified in responders, including those in whom therapy was successful and chose 
to continue treatment after the initial 12 weeks, and non-responders, those who 
chose to stop treatment. 
Results Overall, a positive response was seen in 60% of all patients. In patients with 
bladder overactivity a statistically significant decrease was observed in leakage 
episodes, number of pads used, voiding frequency and nocturia, and an equal 
increase in mean and smallest volume voided. Improvements were also seen in non-
obstructive urinary retention, including number of catheterisations, total and mean 
volume catheterized, and total and mean volume voided. Disease specific quality of 
life and some domains of general quality of life improved, especially of bladder 
overactivity. Only mild side effects were observed. 
Conclusion Posterior tibial nerve stimulation is a minimally invasive and successful 
treatment option for patients with certain types of lower urinary tract dysfunction.
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Introduction
Non-neurogenic lower urinary tract dysfunction is a common urological problem that 
strongly affects quality of life. Patients can complain of urgency and frequency, urge 
incontinence or present with urinary retention. In most patients the etiology of these 
complaints remains unclear. 1 Conservative treatment options for bladder 
overactivity, that is the urgency and frequency syndrome and/or urge incontinence, 
consist of behavioral techniques with and without biofeedback, bladder reeducation, 
pelvic muscle exercise or pharmacotherapy involving anticholinergics, 
antispasmodics and tricyclic antidepressants. Patients with non-obstructive urinary 
retention can be treated with clean intermittent or permanent catheterization. For 
refractory cases more aggressive surgical procedures, including bladder distension, 
ileocystoplasty or urinary diversion have been advocated. However, a high 
recurrence and complication rate limits the widespread application of these 
treatments.
Recently, continuous sacral root stimulation (Medtronic, Inc., Minneapolis, 
Minnesota) has been proposed as an alternative, less invasive therapeutic option for 
patients with non-neurogenic lower urinary tract dysfunction, not responding to 
conservative treatment. 2  Although highly effective in selected patients, this 
technique is expensive and requires explicit surgical skill. Posterior tibial nerve 
stimulation (PTNS) is technically less demanding and probably more cost-effective 
for management of lower urinary tract dysfunction. We present our initial experience 
with this new neuromodulation technique in a prospective clinical trial.  
Patients and methods 
Methods Between November 1999 and March 2000, 15 male and 34 female patients 
were enrolled in a prospective clinical multicenter trial that received approval by the 
institutional review board. All patients were evaluated for urgency and frequency, 
urge incontinence and non-obstructive retention by history, voiding diaries consisting 
of frequency-volume charts, and physical as well as urological examination, including 
urodynamics.
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Urgency and frequency was defined as greater than 8 voids per 24 hours and the 
sudden urge to void could hardly be suppressed. Urge incontinence was 
characterized by urgency leading to urinary leakage occurring at least 3 times weekly 
and/or phasic involuntary bladder contractions with concomitant incontinence on 
cystometry. Non-obstructive retention was distinguished by urinary retention, 
necessitating intermittent catheterization at least 4 times daily without urodynamic 
signs of outflow obstruction as defined on the Abrams-Griffiths nomogram. 3
The use of parasympaticolytic medication or other pharmaceuticals influencing 
bladder function, including antidepressant agents, should have been stopped 2 
weeks or longer before PTNS or continued without dose changes during the entire 
study. Specific exclusion criteria for our study are given in table 1. 
Table 1 Exclusion criteria 
Younger than 18 years 
Symptoms existing for less than 6 months 
Pregnancy or intention to become pregnant during the course of the study 
Active urinary tract or recurrent urinary tract infection  (5 or more recurrent infections during the last 12 months), 
carcinoma in situ, bladder malignancy, interstitial cystitis 
Bladder or kidney stone 
Severe cardiopulmonary disease 
Use of pentosan polysulfate sodium or bladder installations, including dimethyl sulfoxide, Bacillus Calmette-Guerin,  
chloropectin or heparin 
Uncontrolled diabetes 
Diabetes with peripheral nerve involvement 
Neurological disease like multiple sclerosis, Parkinson’s disease, cerebrovascular accident, bifid spine or spinal 
cord lesion 
Physiotherapy during the study 
Bladder outlet obstruction (Abrams-Griffiths nomogram) 
Transurethral instrumentation 4 weeks or less before or during the study 
Patients A total of 10 men and 27 women with a mean age of 52.5 years (range 23-
74) were treated for bladder overactivity. These patients lived with symptoms for a 
median of 4 years (range 1 to 30). The symptoms were said to be induced by 
childbirth in 3, pelvic surgery in 9, including 7 hysterectomies, 1 anterior prolapse 
correction, 1 Burch colposuspension, and other events in 3 patients, including 
fracture of the coccygeal bone, urinary tract infection, bowel infection. The remaining 
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patients had no history of any pelvic event before the onset of symptoms. Of the 37 
patients 32 (91.4%) received unsuccessful prior medical therapy, including 
anticholinergics, with a mean number of 1.9 (range 1 to 5) drugs used. Almost half of 
all (48.6%) patients underwent up to 3 surgical procedures, most frequently 
colposuspension, for symptoms. Other unsuccessful therapies included 
physiotherapy and/or biofeedback in 22 (59.4%), electrical stimulation, including 
Transcutaneous Electrical Nerve Stimulation (TENS) or Peripheral Nerve Evaluation 
(PNE-tests), in 5 (13.5%) and alternative therapies, such as Chinese herbs in 5 
(13.5%) patients. Physical examination did not show overt (neurourological) 
abnormalities in any of the patients.
There were 5 men and 7 women with a mean age of 50.8 years (range 36 to 64) 
treated for non-obstructive retention. These patients had symptoms for a median of 
3.5 years (range 1 to 36 years). Initiation of symptoms was related to childbirth in 1, 
pelvic surgery, including Wertheim’s-Meighs operation in 1 and Burch colpo-
suspension in 1, other surgery, including hip replacement in 1 and inguinal hernia 
repair in 1 and benign prostate hyperplasia without any effect of transurethral 
prostatic resection in 1 patient. The remaining 6 patients had no history of any pelvic 
event before the onset of symptoms. Of the 12 patients 11 (92%) received 
unsuccessful medical therapy previously, including ?-blockers or sympathico-
mimetics. Almost half the patients (5 of 12) had undergone lower urinary tract 
surgery, mostly urethradilatation or urethrotomy, for symptoms previously. Other 
unsuccessful therapies included physiotherapy and/or biofeedback in 3 (25%) and 
electrical stimulation in 1 patient. All patients had clean intermittent catheterisation. In 
addition, physical examination did not show overt (neurourological) abnormalities in 
these patients. Urodynamic investigations revealed hypocontractile detrusors in all 
patients.
Method of treatment PTNS was applied according to Stoller. 4 Patients are in supine 
position with the soles of the feet together, and knees abducted and flexed (‘frog-
position’). A 34 gauge stainless steel needle is inserted approximately 3 to 4 cm., 
about 3 fingerbreadths cephalad to the medial malleolus, between the posterior 
margin of the tibia and soleus muscle. A stick on electrode is placed on the same leg 
near the arch of the foot. The needle and electrode are connected to a low voltage (9 
volts) stimulator (Urosurge, Coralville, Iowa) with an adjustable pulse intensity of 0 to 
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10 mA., a fixed pulse width of 200 microseconds and a frequency of 20 Hz. The 
amplitude is slowly increased until the large toe starts to curl or toes start to fan. If the 
large toe does not curl or pain occurs near the insertion site the stimulation device is 
switched off and the procedure is repeated. If the large toe curls or toes start to fan 
stimulation is applied at an intensity well tolerated by the patient. If necessary the 
amplitude can be increased during the session.
Patients underwent 12 weekly outpatient treatment sessions, each lasting for 30 
minutes. If a good response occurred the patient was offered chronic treatment. 
Evaluation of results After providing informed consent all patients completed a 
voiding diary, as well as general and disease-specific quality of life questionnaires at 
study entry and completion of the 12-week treatment. In the 24-hour voiding diary 
frequency and voided volumes, number and volume of catheterizations, number of 
leakage periods, leakage severity as well as the number of pads or diapers used 
were recorded. The leakage severity was scored on a scale of 0 to 3and included 0-
no leakage, 1-leakage of some drops, 2-loss of a small amount and 3-loss of a 
massive amount, that is change of clothes. General and disease-specific quality of 
life questionnaires were evaluated with the 36-item short-form health survey (SF-36) 
and the (adjusted) I-QOL questionnaire, respectively. 5,6 The SF-36 consists of 36 
items regarding 8 distinct health status concepts and 1 item measuring self-reported 
health transition, including physical function, role physical, pain, general health, 
emotional well-being, role emotional, social functioning, energy and fatigue and 
change in general health. The maximum score of each domain is 100 and a higher 
score relates to a better quality of life. The I-QOL questionnaire consists of 22 items, 
each with a  5 point response scale. As with the SF-36, a high score means good 
quality of life.
Success was defined as the patient request for continued chronic treatment for 
maintenance. Analysis was done on an intention-to-treat basis. Within group 
comparisons of parametric results at baseline and 12-week treatment were 
conducted with the paired sample t-test. Statistical analysis was performed with 
commercial software. 
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Results
Bladder overactivity Of the 444 treatment sessions stimulation was performed on 
the right posterior tibial nerve with a mean pulse intensity of 3.7 mA. (range 1.4 to 
6.8) per session in 265 (60%). Complications, including minor bleeding or a 
temporary painful feeling at the insertion site, were seen only rarely. Of the 37 
patients PTNS in 7 men and 15 women (59.4%) was considered successful because 
they requested continuation of therapy after completion of the 12-week treatment 
(group 1, responders). In 3 male and 12 female patients treatment was unsuccessful 
since they did not choose maintenance therapy (group 2, non-responders). 
At completion of the 12-week treatment all 33 patients with urgency and frequency 
had significant improvement of voiding frequency during the day and night (table 2 
and figure 1A). When discriminating group 1 (21 responders) from group 2 (12 non-
responders), these improvements appeared to be significant only in group 1. The 
smallest mean values and mean volumes voided also improved, whereas the largest 
volumes voided did not change in this group. 
A statistically significant overall decrease in incontinence was seen in the 30 patients 
who were urge incontinent (table 3 and figure 1B). When comparing group 1 (18 
responders) with group 2 (12 non-responders), improvements found in leakage 
episodes and number of pads used appeared to be greater in group 1. Leakage 
severity scores showed improvement in all patients who were urge incontinent, and 
groups 1 and 2. General quality of life improved in regard to physical and social 
functioning in all patients with bladder overactivity. Mean physical functioning plus or 
minus standard deviation (SD) was 53.7 ? 27.9 (mean change +9.1, 95% confidence 
interval [CI] +14.1, +4, p<0.005) and social functioning 64.7 ? 31.2 (mean change 
+10.3, +16.5, +4.1, respectively, p<0.005) at 0 weeks. In group 1, both scores also 
increased. Mean physical functioning plus or minus SD was 61.6 ? 26.3 (mean 
change +11.2, 95% CI +18.8, +3.5, p<0.05) and social functioning 70.6 ? 26.7 (mean 
change +11.6, +20.9, +2.3, respectively, p<0.05) at 0 weeks. Only social functioning 
improved (55.9 ? 35.9, mean change +8.4, 95% CI +16.6, +0.2, respectively, p<0.05) 
at 0 weeks in group 2. Disease specific quality of life showed improvement in all 
patients (60.3 ? 19.3, mean change +12.3, 95% CI +17.3, +6.8, p=0.00004), as well
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Table 2 Voiding parameters in 33 patients with urgency and frequency  
   
Voided volumes 
 Frequency Nocturia Smallest  Largest  Mean 
      
All patients      
Mean ? SD (0 wks.) 16.5 ? 6.8 2.6 ? 2.3 65 ? 49.3 289.8 ? 161 140 ? 82.2 
Mean change (95% CI) -2.8 (-0.8;-4.9) -1 (-0.2;-1.8) 14.2 (32.8;-4.5) 13.9 (48.7;-20.9) 19.3 (40.3;-1.7) 
p- value p < 0.05 p < 0.05    
      
Group 1      
Mean ? SD (0 wks.) 16.1 ? 6.1 2.5 ? 2.7 62.6 ? 52.1 268.8 ? 146.4 133 ? 82.8 
Mean change (95% CI) -4.8 (-2.7;-6.8) -1.4 (-0.4;-2.3) 29.8 (49.2;10.3) 9.5 (50.6;-31.6) 35.1 (62.6;7.7) 
p- value p < 0.0005 p < 0.05 p < 0.005  P < 0.05 
      
Group 2      
Mean ? SD (0 wks.) 17.1 ? 8.3 2.7 ? 1.6 71 ? 44.8 334 ? 188.5 153.6 ? 83.7 
Mean change (95% CI) 0.8 (5;-3.3) -0.2 (1.3;-1.6) -18.5 (19.4;-56.4) 23 (100.6;-54.6) -14 (8.5;-36.5) 
Group 1 = responders, group 2 = non-responders, SD = standard deviation, CI= Confidence Interval 
Table 3 Voiding parameters in 30 patients with urge incontinence
Leakage episodes Pads used Leakage severity 
    
All patients    
Mean ? SD (0 wks.) 9.8 ? 5.6 6.3 ? 3.2 1.7 ? 0.5 
Mean change
(95% CI)  
-4.8
(-2.2;-7.5) 
-2.5
(-1.2;-3.9) 
-0.7
(-0.4;-1.0) 
p- value p < 0.005 p < 0.005 p < 0.005 
    
Group 1    
Mean ? SD (0 wks.) 9.8 ? 6.4 5.8 ? 2.6 1.6 ? 0.5 
Mean change
(95% CI) 
-6.2
(-2.9;-9.5) 
-3.3
(-1.5;-5.1) 
-0.8
(-0.3;-1.3) 
p- value p < 0.005 p < 0.005 p < 0.005 
    
Group 2    
Mean ? SD (0 wks.) 9.8 ? 4.4 7.1 ? 3.9 1.9 ? 0.5 
Mean change
(95% CI) 
-2.4
(2.4;-7.3) 
-1.3
(0.9;-3.4) 
-0.5
(-0.2;-0.8) 
p- value   p < 0.05 
Group 1 = responders, group 2 = non-responders, SD = standard deviation, CI= Confidence Interval 
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Figure 1 Micturition frequency (A) and number of leakage episodes (B) before and 
after PTNS for all patients, responders and non-responders. Error-bar: standard 
deviation. n.s.: not significant. 
  A           B
   
Figure 2 I-Qol scores in patients with bladder overactivity (A) and non-obstructive 
retention (B) before and after PTNS for all patients, responders and non-responders. 
Maximum I-Qol score: 110.  Error-bar: standard deviation. N.s.: not significant.
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as in group 1 (60.6 ? 18.2, mean change +14.4, +22.3, +6.6, p<0.005) and group 2 
(59.9 ? 21.5, mean change +8.5, +15.1, +2, respectively, p<0.05) at 0 weeks (figure 
2A).
Non-obstructive retention Of the 144 treatment sessions stimulation was performed 
on the right posterior tibial nerve with a mean pulse intensity of 4 mA. (range 2.5 to 7) 
per session in 87 (60%). As seen in patients treated for urgency and frequency 
and/or urge incontinence, complications were rarely noted.  Of the 12 patients PTNS 
was considered successful in 1 man and 6 women (58.3%) because they requested 
continuation of therapy after completion of the 12-week treatment (group 3, 
responders). Treatment was unsuccessful in 4 men and 1 woman since they did not 
choose maintenance therapy (group 4, non-responders). 
Table 4. Voiding parameters in 12 patients with non-obstructive retention 
At completion of 12-week treatment all patients clearly had a decrease in the number 
of catheterizations, and mean and total volumes catheterized, and an increase in 
mean and total volumes voided. However, statistical significance could not be 
obtained (table 4). When discriminating group 3 (7 responders) from group 4 (5 non-
responders) these changes could also be observed in group 3, but not in group 4.
All patients Group 3 Group 4 
Mean ? SD
(0 weeks) 
Mean change 
(95% CI) 
Mean ? SD 
(0 weeks) 
Mean change 
(95% CI) 
Mean ? SD 
(0 weeks) 
Mean change 
(95% CI) 
       
No. catheterizations 5.3 ? 2,4 -0.8 (0.6;-2.3) 5.9 ? 2.6 -1.4 (1.2;-4.1) 4.4 ? 2 0 (0.9;-0.9) 
Mean volume 
catheterized
336 ? 171 -83.3
(27.4;-194) 
325 ? 181 -131.9
(63.2;-326.9) 
351 ? 176 -15.4
(87.5;-118.4) 
Total volume 
catheterized
1552 ? 776 -537
(175;-1249) 
1707 ? 915 -921.4
(284.5;-2127.4) 
1335 ? 547 1
(659.7;-657.7) 
Mean volume 
voided
206 ? 192 5.9
(113.2;-101.4) 
141 ? 107 94.3
(233.3;-44.7) 
297 ? 258 -117.8
(16.5; 252.1) 
Total volume 
voided
919 ? 658 173.8
(639.2;-291.7) 
758 ? 567 482.1
(1164.7;-200.4) 
1145 ? 774 -258
(374.6;-890.6) 
Group 3 = responders, group 4 = non-responders, SD = standard deviation, CI= Confidence Interval 
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In regard to quality of life hardly any significant improvement could be found, neither 
with the adjusted disease specific quality of life questionnaire (I-QOL, figure 2B) or 
general quality of life questionnaire (SF-36). The only exceptions appeared to be the 
SF-36 score for emotional well-being, which increased (58.3 ? 12.2, mean change 
+14.3, 95% CI +20.6, +7.9, p<0.005) in patients who thought treatment was 
successful (group 3), and the score for change of health, which significantly 
increased in all (45.8 ? 27.9 mean change +22.9, +44.9, +1, p<0.05), but not in group 
3 or 4 at 0 weeks, respectively.
Discussion
For treatment of refractory urinary tract dysfunction various methods of intermittent 
neuromodulation have been advocated, including intravesical, anal, vaginal, penile 
and perineal stimulation, and transcutaneous electrical stimulation (TENS) of the 
suprapubic or sacral region and the posterior tibial nerve. 7-15 Because of poor results 
or uncomfortable stimulation sites, most of the aforementioned treatment modalities 
did not gain widespread acceptance. In the 1980s implantable neurostimulation 
electrodes became available for modulation of the sacral spinal nerves, especially 
S3. 16 Stimulation could be performed continuously, leading to better results but 
drawbacks included invasiveness of the procedure, the high costs involved and the 
limited service life of the stimulation device, which was 7 to 10 years. In addition, 
symptoms appear to recur almost immediately after discontinuation of the 
stimulation. 2 Therefore, the development of an easy applicable, non-invasive or 
minimally invasive, cost-effective neuromodulation device, with good treatment 
outcome was anticipated. The recent advent of PTNS may offer urologists a 
treatment modality that meets the aforementioned criteria. 4,17
Stimulation of the tibial nerve was first described by McGuire et al in 1983. 15 In 
studies of non-human primates with spinal cord injury bipolar anal sphincter 
stimulation resulted in the inhibition of detrusor activity. Similar results could be 
obtained by applying current through a transcutaneous electrode over the common 
peroneal or posterior tibial nerve, with a ground electrode being contralaterally placed 
over the same nerves. The idea of stimulating these nerves was based on the 
traditional Chinese practice of using acupuncture points over the common peroneal 
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or posterior tibial nerves to affect bladder activity. 15 Electrical stimulation of the tibial 
nerve was subsequently performed in 22 patients with detrusor instability, interstitial 
or radiation cystitis or neurological diseases with promising results, including 
continence in 12 and urodynamic improvement in 7. However, in a prospective study 
by Geirsson et al in patients with interstitial cystitis, transcutaneous tibial nerve 
stimulation or traditional Chinese acupuncture treatment revealed no difference in 
voiding frequency, mean and maximal voided volumes and visual analogue symptom 
scores before or after either treatment modality .18
In our study percutaneous stimulation resulted in a success rate of about 60% of 49 
patients with bladder overactivity or non-obstructive urinary retention. Although our 
definition of success was a subjective one, responders differed significantly from non-
responders in almost every semi-objective parameter. The same result was observed 
in disease specific and several domains of general quality of life scores. 
Because our study was not placebo-controlled, the observed improvements might 
theoretically be the result of regression to the mean, synchronous other treatment or 
placebo effect, rather then a positive response to PTNS. Regression to the mean is 
not likely as all patients included had to present with symptoms for at least 6 months 
(median 4 years). To prevent interference of other treatment modalities, concomitant 
physiotherapy during PTNS was not permitted as was the case with starting 
parasympaticolytic medication or other pharmaceuticals influencing bladder function, 
including antidepressant agents, within 2 weeks before treatment. In patients who 
were already using any of the aforementioned drugs, medication had to be stopped 2 
weeks before beginning PTNS or continued without dose changes during the entire 
12 weeks. In placebo controlled studies success rates in the placebo group are 
usually much lower than the response rate of about 60% in our study. Because most 
patients had symptoms for a long period and undergone various treatments before 
trying neuromodulation, it is not likely that they were highly susceptible to the placebo 
effect of this treatment modality.  Nevertheless, to validate these data a properly 
designed placebo controlled study is warranted. However, it can be anticipated that 
the feasibility of such studies will be difficult. 
Not withstanding the promising results and only mild complications of this 
neuromodulation technique found in our study, this therapy also has some 
disadvantages, including percutaneous insertion of the stimulation electrode, 
necessity of regular visits to the outpatient clinic and, thus far, unknown results of 
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chronic treatment of initially successful cases. In the near future most 
aforementioned problems may be solved with an implantable subcutaneous 
electrode, which can be radiographically stimulated by the patients themselves at 
home and on a regular basis. Studies regarding long-term results are ongoing, but 
results are not yet available. 
In conclusion, although thorough research is anticipated to improve patient selection 
criteria, optimize the technique and help learn more about the precise mode of 
action, PTNS is a promising, cost-effective and easily applicable treatment option for 
patients with lower urinary tract dysfunction.
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Abstract
Objective Neuromodulative therapies have been used with moderate success in 
patients with chronic pelvic pain. Intermittent Percutaneous Tibial Nerve Stimulation 
(PTNS) is a new, minimally invasive treatment option, which has shown to 
significantly decrease accompanying pain complaints in patients with lower urinary 
tract dysfunction, such as urge incontinence or urgency/frequency. In our study we 
evaluate the objective results of PTNS in patients with chronic pelvic pain as their 
main complaint.
Patients and methods In a prospective multicentre trial PTNS was evaluated in 33 
patients with chronic pelvic pain. Effects were recorded by Visual Analogue Scale 
(VAS) for pain diaries, the McGill pain questionnaire and the SF-36 general quality of 
life questionnaire at baseline and after 12 weeks of treatment. Subjective (patients’ 
request to continue chronic treatment to keep the obtained success) and objective 
responses (decrease in mean VAS >50% and VAS <3 after treatment) were 
evaluated.
Results A subjective response was seen in 42% of all patients. In 7 patients (21%) 
mean VAS decreased >50%, in 6 cases (18%) the decrease was >25%. After 12 
weeks of treatment 7 patients (21%) ended up with a mean VAS <3. In all patients 
quality of life (SF-36) significantly improved, as did the total pain rate intensity 
(McGill)
Conclusions Despite very modest overall success rates and the need for placebo 
controlled studies, PTNS may have a place in the treatment of patients with chronic 
pelvic pain who have already tried many other therapies and are left with no further 
options.
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Introduction
Chronic pelvic pain is a common problem with a high impact on patients’ quality of 
life. Unfortunately, pelvic pain is hard to measure, assess or localize, causing great 
difficulties in diagnosis and treatment 1, as well as frustration in both patients and 
physicians. The use of descriptive ‘diagnoses’ and the high referral rate amongst 
medical specialties covering only certain aspects of the pelvic region furthermore 
illustrate our difficulties coping with this complex problem.  
As aetiology and pathophysiology are mostly unknown, treatment is often empirical 
and polypragmatic. Non-steroidal anti-inflammatory drugs, steroids, benzodia-
zepines, anti-depressants, anti-convulsants, ?-blockers, local anaesthetics, GABA- 
and NMDA-receptor agonists 2 and antibiotics all have been described to have some 
effect. When faulty pelvic floor behaviour is suspected physiotherapy may be of use. 
Neuromodulation has been reported in reducing pelvic pain by means of sacral nerve 
stimulation 3,4, while there are also reports on positive effects of neuromodulation in 
pain complaints accompanying conditions like interstitial cystitis (TENS 5, vaginal 
stimulation 6 or maximal electric pelvic floor stimulation 7).
Recently Percutaneous Tibial Nerve Stimulation (PTNS) has come to use for the 
treatment of lower urinary tract dysfunction, e.g. urge incontinence, urgency/ 
frequency and non-obstructive retention. 8-11 Although accompanying pain complaints 
were reported to decrease 9,10, this minimally invasive treatment option has not yet 
been described for the use in distinct pelvic pain syndromes. In our study we 
evaluate the objective results of PTNS in patients with chronic pelvic pain as their 
main complaint.
Patients and methods 
Methods Between November 1999 and August 2000 33 patients (22 men, 11 
women) with chronic, therapy resistant pelvic pain were enrolled in a prospective 
clinical multicentre trial after approval by the Institutional Review Boards. All patients 
were evaluated for chronic pelvic pain by history, Visual Analogue Scale (VAS) for 
pain and physical as well as urological examination.
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Chronic pelvic pain was defined as complaints of pain for at least 6 months in the 
bladder, groin, genitals or lower abdomen and/or perineal or (peri)anal pain without 
clear abnormalities on urological examination. On the Visual Analogue Scale for pain 
(0-10), the score should be over 5. The use of analgesics should have been stopped 
two weeks or longer prior to Percutaneous Tibial Nerve Stimulation (PTNS) or had to 
be continued without dose changes during the entire study. Physiotherapy or 
electrotherapy like Transcutaneous Electrical Nerve Stimulation (TENS) should have 
been stopped for at least 3 months prior to the PTNS treatment. Specific exclusion 
criteria for this study are given in table 1. 
Table 1 Exclusion criteria 
Age under 18 
Symptoms existing for less than 6 months 
Pregnancy or intention to become pregnant during the course of the study 
Active urinary tract or recurrent urinary tract infections  (recurrent infections: ? 5 during the last 12 months)  
Bladder or kidney stone 
Bacterial prostatitis, sexually transmitted disease 
Carcinoma in situ, bladder malignancy, interstitial cystitis 
Uncontrolled diabetes or diabetes with peripheral nerve involvement 
Severe cardiopulmonary disease 
Neurological disease like MS, M. Parkinson, CVA, bifid spine or spinal cord lesion 
Use of Elmiron or bladder installations like DMSO, BCG, Chloropectin or Heparin 
Change in analgesics within 2 weeks prior to or during the study  
Physiotherapy at the same time as the study 
Electrotherapy (for example TENS) at the same time as the study 
Patients 22 men and 11 women with a mean age of 51.6 years (range 25-79) were 
treated for chronic pelvic pain (see table 2). These patients had their complaints for a 
median period of 5 years (range 2-30). Twenty-eight of 33 patients (85%) reported 
unsuccessful previous medical therapies, mostly analgesics and ?-blockers, with a 
mean number of drug types used of 2.3 (range 1-4). Eight patients (24%) underwent 
up to two surgical procedures like (partial) epididymectomy, bladder neck incision, 
transurethral resection of the prostate or transurethral microwave therapy for their 
complaints. Other unsuccessful therapies included physiotherapy and/or biofeedback  
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Table 2 Patient characteristics 
Patient
number
Sex Age Main localization pain Surgical procedures (abdomen, pelvis, genitals)  
prior to PTNS 
1 Male 33 Lower abdomen None
2 Male 34 Lower abdomen, scrotum None 
3 Male 39 scrotum, groin (left) None 
4 Male 54 Lower abdomen, scrotum (left) Epidydimectomy 1
5 Male 34 Perineum None 
6 Male 34 scrotum, groin (left) Vasectomy, epidydimectomy 1
7 Male 40 scrotum, groin (left) Varicocele correction 
8 Male 43 Perineum, perianaly, suprapubic/bladder region TW 1, TURP 1
9 Male 43 Perineum, scrotum Inguinal hernia repair, varicocele correction
10 Male 46 Perineum, scrotum Dorsal penile vene ligation, epidydimectomy 
11 Male 48 Suprapubic/bladder region Vasectomy, inguinal hernia repair, TUMT 1
12 Male 49 Suprapubic/bladder region, perineum Vasectomy, nephrectomy 
13 Male 49 Perineum, scrotum None 
14 Male 50 Suprapubic/bladder region Appendectomy, inguinal hernia repair,  
varicocele correction, TW 1, Otis 1
15 Male 50 scrotum, groin (left) Inguinal hernia repair 
16 Male 53 Perineum, lower abdomen Vasectomy, chemonucleolysis L5-S1 
17 Male 56 Suprapubic/bladder region Cholecystectomy, Sachse urethrotomy 1
18 Male 62 Perineum, perianaly TUMT 1
19 Male 67 Suprapubic/bladder region None 
20 Male 70 Perineum, perianaly Inguinal hernia repair, TURP 1
21 Male 77 Perineum, scrotum TURP 
22 Male 79 Suprapubic/bladder region Appendectomy, TURP 
23 Female 30 Vagina  None 
24 Female 54 Groin (left) None 
25 Female 66 Vagina None 
26 Female 72 Lower abdomen, vagina None 
27 Female 25 Lower abdomen, groin (right) None 
28 Female 41 Suprapubic/bladder region Hysterectomy, Mitrofanoff 
29 Female 50 Perineum, vagina None 
30 Female 55 Suprapubic/bladder region None 
31 Female 60 Suprapubic/bladder region None 
32 Female 61 Perineum, vagina None 
33 Female 79 Perineum, vagina Hysterectomy, excision coccyx, ileocaecal  
resection 1, rectal prolapse repair 1
1operations were performed after the complaints had already started  
in 17 (52%), electrical stimulation like TENS in 8 (24%) and alternative therapies like 
local injection therapy, corsets, sexuological evaluation, acupuncture, aura-therapy 
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and hot water baths in 18 patients (55%). Physical examination did not show overt 
(neurourological) abnormalities in any of the patients.
Method of treatment PTNS was applied according to Stoller 8 and Govier et al. 10
Patients lie in supine position with the soles of the feet together and their knees 
abducted and flexed (‘frog-position’). A 34-gauge stainless steel needle is inserted for 
approximately 3 to 4 cm cephalad to the medial malleolus, between the posterior 
margin of the tibia and the soleus muscle tendon. A stick-on electrode is placed on 
the same leg near the arch of the foot. Both needle and electrode are connected to a 
stimulator (Urgent PC®, CystoMedix, Anoka, Minnesota, USA) with an adjustable 
pulse intensity (0-10 mA). Fixed parameters are a pulse width of 200 μsec and a 
frequency of 20 Hz. The stimulator contains a battery of 9 V. The amplitude is slowly 
increased until plantar flexion of the large toe or fanning of the other toes occur. If 
this response can not be obtained or pain occurs near the insertion site the 
stimulation device is switched off and the procedure is repeated. In most patients the 
motor response was accompanied by a sensory response as a radiating sensation 
spreading in the sole of the foot. The current was set at a well-tolerable level. 
Elevation of the current was allowed whenever fading of this sensation was 
experienced due to adaptation. Patients underwent 12 weekly outpatient treatment 
sessions, each lasting for 30 minutes. In case of a good response patients were 
offered chronic treatment. 
Evaluation of results After informed consent, all patients had to fill out pain diaries 
as well as general and disease-specific quality of life questionnaires at study entry 
and at completion of treatment at 12 weeks. Pain diaries consisted of 7 Visual 
Analogue Scales for pain, one for every day of the week, recording the maximum 
pain felt during the day. The lowest, highest and mean VAS were calculated from 
these diaries. General and disease-specific quality of life was evaluated using the 
SF-36 questionnaire 12 and the McGill Pain Questionnaire (Dutch Language Version) 
respectively. 13,14 The SF-36 questionnaire consists of 36 items covering eight distinct 
health status concepts and one item measuring self-reported health transition: 
physical function, role-physical, pain, general health, emotional well-being, role-
emotional, social functioning, energy/fatigue and change in general health. The 
maximal score of each domain is 100. A higher score relates to a better quality of life. 
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The McGill Pain Questionnaire uses 20 sets of descriptive words for pain, which can 
either be sensoric, affective or evaluative. One is allowed to choose maximal 1 word 
out of every set, resulting in a ‘number of words chosen’ score and a ‘pain rate 
intensity’ score. The higher the scores, the worse the condition.
Subjective success was defined as the request of the patient to continue chronic 
treatment to keep the obtained outcome, objective success as a decrease in mean 
Visual Analogue Scale for pain of over 50%. A decrease of over 25% was considered 
to be a partial response. Moreover, the number of patients with a VAS below 3 after 
12 weeks of treatment was recorded. Within-group comparisons of parametric results 
at baseline and twelve weeks of treatment were conducted using the paired-samples 
T-test (5% level statistical difference). Statistical analysis was performed using SPSS 
9.0 software (SPSS, Chicago, USA). 
Results
After 12 weeks of PTNS, 14 (10 men, 4 women) out of 33 patients (42%) were 
considered subjective responders, as these patients requested continuation of 
therapy. An objective response occurred in 7 patients (21%) of all patients and 
almost only in the subjective responder group (see table 3). Mean VAS for pain 
changed from 6.5 (range 5.3-7.7) at baseline to 5.4 (range 4.2-6.8) after 12 weeks of 
treatment (95% Confidence Interval (CI): -0.2, -2.0, p<0.05). Seven patients (21%) 
ended up with a mean VAS below 3. In the subjective responder group, mean VAS 
decreased from 5.9 (range 4.5-7.3) at baseline to 3.8 (range 2.7-5.2) after 12 weeks 
of treatment (95% CI: -0.5, -3.7, p<0.05). No changes were seen in the subjective 
non-responders.
In  patients with an objective improvement of ? 25% as well as in patients without an 
objective response certain patient characteristics were recorded that may have an 
influence on treatment outcome (see table 4). Although we did not try to statistically 
identify prognostic factors, a high number of  previous tried treatment modalities, a 
long period of complaints and a more superficial localization of the pain seem to have 
a negative influence on PTNS results. 
FEASIBILITY AND CLINICAL RESULTS                 77
Table 3 Decrease of mean VAS for pain (1 week) after 12 weeks of PTNS 
All patients (%) Subjective responders (%) Subjective non-responders (%) 
 N=33 N=14 N=19 
? 50% 7 (21%) 6 (43%) 1 (5%)
? 25%, < 50% 6 (18%) 3 (21%) 3 (15%) 
No improvement 20 (61%) 5 (36%) 15 (80%) 
Table 4 Characteristics in patients with and without a ? 25% decrease of the mean 
VAS for pain
? 25% decrease No response 
Sex 6 f
7 m
(46%) 
(54%) 
8 f
12 m 
(40%) 
(60%) 
Mean age in years (range) 55,2  (25-79) 49,1 (33-79) 
Median duration of symptoms in years (range) 4  (2-15) 5,5  (2-30) 
Mentioned localizations of  pain 1
groin/scrotum
lower abdomen/suprapubic-/bladder region 
perineal/(peri)anal/vaginal region 
2
5
8
(15%) 
(38%) 
(62%) 
10
11
7
(50%) 
(55%) 
(35%) 
Mean VAS before PTNS 65 (range 60) 65 (range 77) 
Mean number of drug types used (range) 2,82  (1-4) 2 (1-4) 
Number of patients having had an operation for pain complaints   1 (8%) 7 (35%) 
Number of patients having used physiotherapy 5  (38%) 12 (60%) 
Number of patients having used electrotherapy 3 (23%) 5 (40%) 
Number of patients having used alternative therapy 5  (38%) 12 (60%) 
1more than one localization per patient possible 
The SF-36 quality of life questionnaire showed statistically significant changes in the 
domains ‘physical functioning’ (51.5 to 57.1 (95% CI: +0.9, +10.3, p<0.05)), ‘role 
physical’ (15.2 to 28 (95% CI: +0.1, +25.6, p<0.05)), ‘pain’ (37.4 to 47.8 (95% CI: 
+2.3, +18.5, p<0.05)) and ‘change of health’ (37 to 57 (95% CI: +7, +33, p<0.05)) as 
well as in the total score (46.1 to 52.7 (95% CI: +2.6, +10.5, p<0.05)). 
In the McGill Pain Questionnaire (MPQ) 8 domains were evaluated: Number of 
Words Chosen (NWC) sensoric, affective, evaluative and total, and Pain Rate 
Intensity (PRI) sensoric, affective, evaluative and total. Changes after 12 weeks of 
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PTNS were not significant with the exception of PRI total: a decrease was seen from 
21.5 to 17.2 (95% CI: -0.3, -8.3, p<0.05). 
Discussion
Posterior tibial nerve stimulation was first described in 1983 by McGuire et al. 15 in 22 
patients with incontinence, using a transcutaneous electrode over the common 
peroneal or posterior tibial nerve and a contralaterally placed ground electrode over 
the same nerve. Later on, Stoller 8 adjusted this method by using a percutaneous 
needle electrode and placing the ground electrode on the ipsilateral extremity. Since 
then, several publications report promising early results regarding urge incontinence, 
urgency/frequency and non-obstructive urinary retention. 9-11 As a positive side effect, 
pain reduction has been described in a group of 15 patients, with a decrease in VAS 
from a mean (standard deviation) of 7.6 (5 to 10) to 3.1 (1 to 7) (P<0.0005) 9, as well 
as in a group of  53 patients, with a reduction in pelvic pain intensity of 30% (p<0.05). 
10 This decrease in pelvic pain as a symptom accompanying urgency/frequency or 
urge incontinence is also well known in sacral neuromodulation: in many reports 
there is, alongside relief of other symptoms, a significant decrease in Visual 
Analogue Scale for pain or likewise pelvic pain scores. 16-18
When looking at neuromodulation in patients with chronic pelvic pain as their main 
symptom, only a few reports can be found. In a prospective, non-randomized 
feasibility study sacral nerve stimulation resulted in a substantial clinical benefit in 6 
of 10 patients with chronic, intractable pelvic pain. 4 Everaert et al. 3 describe the 
implantation of a sacral neuromodulator in 11 of 26 PNE tested patients with therapy-
resistant pelvic pain syndromes. Nine patients were satisfied and one needed an 
explantation because of infection of the prosthesis, reducing the success rate to 8 out 
of 11 and the intention to treat percentage to 31%. At a follow-up of 36 ? 8 months no 
further failures were seen. Other neuromodulation modalities reported are intrarectal 
or vaginal electrostimulation in deep pelvic pain syndromes and TENS in superficial 
pelvic pain. Results are very modest and fail to reach statistical significance. The 
same treatment options 5,6 as well as maximal electric pelvic floor stimulation 7, are 
described for the more specific cases of interstitial cystitis, in which pain cure rates 
vary between 26 and 54%. 
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The mechanism of action of neuromodulation is still unknown, although many 
theories exist. In lower urinary tract dysfunction neuromodulation most probably 
causes rebalancing of inhibitory and excitatory impulses that govern bladder function 
in the central nervous system. 19 For pain it can be suggested that, according to the 
gate control theory, stimulation of large somatic fibres could modulate/inhibit the 
thinner afferent A-delta or C fibres, thus decreasing pain perception. 20 Another mode 
of action may be the elevation of endorphins at a spinal level, as can be seen in 
TENS and acupuncture. 21,22 However, the most important evidence of effects of 
neuromodulation on nociceptive pathways in the spinal cord comes from Chang et al. 
23: after instillation of acetic acid in rat bladders, a rise in c-fos, a neurotransmitter for 
pain in the central nervous system, was seen in the sacral micturition centre. Rats 
that underwent acetic acid installation as well as PTNS, showed a significant lower c-
fos expression. 
In our study PTNS had a positive effect in 39% of 33 pelvic pain patients (objective 
success and partial response together), who were refractory to all other previous 
treatments. A subjective response was seen in 42% of all cases. As can be 
suspected, most patients with objective changes considered themselves a subjective 
success as well (69%).  Not all patients with an objective response were satisfied 
enough to continue treatment after the initial 12 weeks. On the other hand, five 
patients, with no objective response on pelvic pain whatsoever, considered 
themselves a therapeutic success. All had experienced some pain relief after several 
PTNS sessions, which disappeared at the end of the course. 
To minimize the effects of regression to the mean, only patients who had had 
complaints for over 6 months (median 5 years) were included in our study. On the 
other hand, cyclic changes in pain patterns could not completely be ruled out, 
although quick changes were met by keeping diaries during one week and recording 
not only highest and lowest VAS, but also the mean VAS over 7 days. To prevent 
interference by other treatment modalities, concomitant physiotherapy was not 
allowed as was the case with starting probable influencing medication. When drugs 
were already in use, patients had to stop 2 weeks prior to PTNS or to continue this 
medication during the entire 12 weeks. As our study was not placebo-controlled,  a 
placebo effect cannot be ruled out. Percutaneous stimulation of the tibial nerve is 
prone to these effects because of a great deal of personal attention and care within 
many outpatient clinic visits. Unfortunately, it is most likely that a good placebo 
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controlled PTNS study is not feasible. We found patients with years of medical 
history and many failed therapies very well informed on new treatment techniques, 
making any placebo too different from PTNS useless. Also, placement of a 
percutaneous needle alone, without  electrical stimulation may already have some 
effect. Maybe placebo acupuncture needles will provide a future possibility for 
placebo controlled studies. 24
An important way to improve treatment results in the future is the determination of 
clear selection criteria. Although 33 patients is too small a number to reliably 
determine prognostic factors, evaluating some characteristics in patients with or 
without a ? 25% objective improvement of the mean VAS for pain seems to reveal 
that age, sex or mean VAS for pain prior to PTNS is not of great importance. Patients 
with a shorter period of complaints and less failed therapies in the past tend to do 
better. Also, in patients with an objective improvement, deep pain (perineal, 
(peri)anal and vaginal) seemed to be the most present feature, whereas patients 
without objective improvement primarily seemed to suffer from more superficial pain 
(suprapubic region, groin, scrotum). This seems not surprising as the visceral organs 
neurologically overlap better with stimulated level S3 than the superficial regions do.
Furthermore, the technique may be improved by changing the treatment schedule. In 
patients with an overactive bladder, Klingler et al 9 stimulated 12 times at a rate of 4 
per week, obtaining much better results than other authors stimulating once a week 
for 12 weeks. 10,11 And, as in sacral nerve stimulation bilateral stimulation seems to 
improve results 25,26, stimulating both posterior tibial nerves concomitantly is an 
interesting future study objective. 
Conclusions
Although success rates found in our study are very modest, they are comparable with 
what has been found in other forms of neuromodulative treatment. Nevertheless, 
there is a clear need for placebo-controlled data, however difficult a placebo study 
design. Furthermore, research is needed on the mode of action, optimal treatment 
scheme, long term effects of the treatment and selection criteria, to increase the 
benefit of percutaneous tibial nerve stimulation in patients with chronic pelvic pain. In 
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our study, PTNS was found to be minimally invasive and easy applicable in pelvic 
pain  patients. In this patient group PTNS might be effective, but the lack of a 
controlled study cannot allow any larger assessment. 
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Abstract
Objective In this study we evaluated the effect of lower urinary tract dysfunction and 
its neuromodulative therapy on sexual functioning. 
Patients and methods We studied 121 patients with an overactive bladder (N=83), 
chronic pelvic pain (n=23) and non-obstructive retention (n=15) which were treated 
with neuromodulation (i.e. percutaneous tibial nerve stimulation, PTNS). To obtain 
information on their sexual function a self-administered standardized questionnaire 
was filled out prior to therapy as well as after 12 weeks of treatment. 
Results Prior to therapy different aspects of sexual life were considered not normal 
in 25.3 to 45.6% of the cases. This improved significantly after treatment. Patients 
most likely to benefit were women, patients with an overactive bladder and subjective 
responders. The aspects of sexual life which mostly improved were overall 
satisfaction, libido and the frequency of sexual activities. 
Conclusions Sexual dysfunction is observed in a lot of patients with lower urinary 
tract disorders and may improve on successful therapy for the latter.
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Introduction
Non-neurogenic lower urinary tract dysfunction (LUTD) is a common urological 
problem that strongly affects the quality of life. Although, in general quality of life 
issues gain more attention in studies performed, effects of disorders and therapies on 
sexual life are only rarely investigated. This is particularly true for patients with an 
overactive bladder (OAB), chronic pelvic pain (CPP) and non-obstructive urinary 
retention. Most publications that do consider sexual impairment in incontinence 
patients regard female patients only and describe groups suffering from stress or 
mixed incontinence. 1,2
For our study, we hypothesized that a considerable amount of patients with LUTD 
has impaired sexual life and that patients with impaired sexual life benefiting from 
therapy for their urological complaints also improve with regard to sexual functioning. 
Therefore, patients with OAB, CPP and non-obstructive urinary retention undergoing 
Percutaneous Tibial Nerve Stimulation (PTNS) were to be evaluated with self-
administered standardized questionnaires regarding sexual functioning prior to and 
after finishing therapy. 
Patients and methods 
Between November 1999 and August 2001 121 patients (45 male, 76 female) with 
CPP, non-obstructive urinary retention or OAB were enrolled in a prospective clinical 
multicenter trial to evaluate the effect of PTNS on these lower urinary tract disorders. 
The trial got approval by the Institutional Review Boards. Reports on clinical outcome 
were published recently. 3-6 As part of this study sexual functioning has been 
evaluated as well as possible effects of PTNS on sexual impairment.  
Patients A total of 45 male and 76 female patients, mean age 53.6 years (range 21 
to 82) have been treated for LUTD. Mean age of male (54.4 years, range 21 to 76) 
and female  patients (53.1 years, range 23 to 82) did not differ significantly. Fifteen 
patients (6 male, 9 female) were treated for non-obstructive retention, 23 (17 male, 6 
female) for CPP and 83 (22 male, 61 female) for OAB. Median duration of lower 
urinary tract complaints was 4 years (range 1 to 56 years). No statistical significant 
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differences in median duration of symptoms were seen between sexes or subgroups. 
Physical examination did not show overt (neurourological) abnormalities in any of 
these patients (see table 1). 
Table 1 Patient characteristics
All OAB CPP NOUR 
 N=121 N=83 N=23 N=15 
Men/women 45/76 22/61 17/6 6/9
Mean age 1 53.6 (21-82) 54.4 (21-82) 52.7 (25-79) 50.9 (25-68) 
Median history 1 4 (1-56) 4 (1-56) 5 (2-30) 3 (1-36) 
Previous medications 2 2 (0-5) 2 (0-5) 2 (1-4) 1 (0-2) 
Previous operations 2 0 (0-3) 0 (0-3) 0 (0-2) 0 (0-1) 
Previous physiotherapy 60 (49.6%) 39 (47.0%) 18 (78.3%) 3 (20.0%) 
Previous electrotherapy 18 (14.9%) 9 (10.8%) 8 (34.8%) 1 (6.7%) 
    
Frequency 3  15.0 (4-41)   
Incontinence episodes 3   6.4 (0-22)   
Catheterizations 3    4.9 (2-10) 
VAS for Pain 4   64.9 (22-100)  
     
I-Qol 4  60.8 (22-100)   
Adjusted I-Qol 4    81.8 (38-100) 
PRI-total (McGill) 4   21.7 (5-50)  
     
Mean stimulation 5 3.4 (1.3-7) 3.4 (1.4-6.8) 3.1 (1.3-5.5) 3.7 (1.3-7) 
     
Subjective response 51.2% 55.4% 39.1% 46.7% 
Objective response 35.5% 41.0% 21.7% 26.7% 
OAB = Overactive Bladder , CPP = Chronic Pelvic Pain, NOUR = Non-obstructive Urinary retention, VAS = Visual analogue 
Scale, I-QoL = Incontinence Quality of Life, PRI = Pain Rate Intensity, 1years (range), 2number (range), 3mean number/24 
hours (range), 4mean score (range), 5mA (range) 
Method of treatment PTNS was applied according to Stoller 7 and Govier. 8 A 
percutaneous inserted 34 gauge needle approximately 3-4 cm cephalad to the 
medial malleolus and a stick-on electrode placed on the same leg near the arch of 
the foot have been used for electrical stimulation with an adjustable pulse intensity 
(0-10 mA), a fixed pulse width of 200 ?sec and a frequency of 20 Hz. The stimulator 
contained a battery of 9 V (Urgent PC?, CystoMedix, Anoka, MN, USA). In case of a 
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good motor response, generally accompanied by a specific sensory response, 
stimulation current was set at a well-tolerable level. Patients underwent 12 weekly 
outpatient treatment sessions of half an hour each without in-between stimulations. In 
case of a good response on their lower urinary tract symptoms patients were offered 
chronic treatment. 
Evaluation of results After informed consent, all patients had to fill out micturition or 
pain diaries as well as general (SF-36 9) and disease-specific quality of life 
questionnaires (McGill Pain Questionnaire Dutch Language Version 10 and I-Qol 11)
at study entry and at completion of treatment at 12 weeks. Subjective response was 
defined as the request of patients to continue chronic treatment to keep the obtained 
response, objective success as a decrease in symptoms (i.e. number of voids/24 
hours, number of incontinence episodes/24 hours, number of catherizations/24 hours 
or score on the Visual Analogue Scale for pain) of over 50%.
The sexual functioning prior to PTNS as well as after 12 weeks of treatment was 
studied by means of a standardized questionnaire to be filled out by the patients. 
This ‘Nine questions regarding Sexual Functioning, Dutch language version’ (NSF-9) 
was constructed by Vroege 12, has been described in English literature by Francken 
et al 13 and is available in equally constructed versions for men and women. In the 
NSF-9 sex is considered as ‘coitus, but also other forms of contact that you find 
sexually arousing’. (See also appendix). 
Within group analysis of results have been conducted by the non-parametric 
Wilcoxon signed ranks test for two related samples,  subgroup analysis  by the non-
parametric Mann-Whitney U-test for two independent samples. Tests have been 
performed on a two-tailed basis and the level of significance was set at 5%. 
Statistical analyses have been performed using Statistical Package for the Social 
Sciences version 9.0 software (SPSS, Chicago, ILL, USA).  
Results
After 12 weeks of PTNS treatment, 62 out of 121 patients (51.2%) were considered 
subjective responders as these patients requested continuation of therapy. For OAB 
this was 55.4% (46 out of 83 patients), for CPP 39.1% (9 out of 23 patients) and for 
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non-urinary retention 46.7% (7 out of 15 patients). An objective response was seen in 
only 35.5% of all patients with 41% for OAB, 21.7% for CPP and 26.7% for non-
urinary retention (see table 1).
At baseline, 88.4%% filled out the NSF-9, after 12 weeks of PTNS this percentage 
decreased to 86%. To the question, prior to PTNS, to what extent patients were 
satisfied with their current sex life, 40 patients answered ‘dissatisfied’ or ‘very 
dissatisfied’.
In this group satisfaction over all improved significantly (p<0.005). Improvement was 
mainly seen in female patients (N=22, p<0.005), OAB patients (N=22, p<0.05) and 
subjective responders (N=16, p<0.05) (see table 2).Patients answering (prior to 
PTNS) ‘neutral’ to ‘very satisfied’ with their sex life remained as satisfied after the 
treatment (p=0.2). 
Table 2 Change in dissatisfaction with current sexual life 
Prior to PTNS After PTNS
Patient group Number  p-value overall 
satisfaction whole 
(sub-)group 
Pts (very) dissatis-fied 
/ respondents 
Pts still (very) dis-
satisfied / pts that felt 
so before PTNS 
p-value
All N=121 ns 40/103 20/35 p=0.002
      
Women N=76 p=0.024 22/60 9/19 p=0.003 
Men N=45 ns 18/43 11/16 ns 
      
OAB  N=83 ns 22/68 8/18 p=0.017 
CPP N=23 ns 11/23 9/11 ns 
Retention N=15 ns 7/12 3/6 ns 
      
Subjective responders N=62 ns 16/52 6/14 p=0.008 
Objective responders N=43 ns 8/37 4/7 ns 
OAB = Overactive Bladder , CPP = Chronic Pelvic Pain, PTNS = Percutaneous Tibial Nerve Stimulation, ns = not significant, 
Pts = Patients 
The improved satisfaction with their current sex life also resulted in a change in 
frequency of ‘feeling like having sexual contact’ as well as ‘actually having sexual 
contact’ (p<0.005 in 46 and 47 patients respectively, formerly answering these 
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questions with ‘not at all’ and ‘once in the past month’). As in the question on 
satisfaction, changes were predominantly observed in female patients (N=30 and 
N=29, p<0.005). The same applies to OAB patients (N=34, both) and subjective 
responders (N=20 and N=22): all p<0.05 (see table 3). Patients that ‘felt like having 
sexual contact’ at least several times a month or ‘actually had sexual contact’ at least 
several times a month prior to PTNS, remained doing so afterwards (p=0.3 and 
p=0.8).
Table 3 Change in frequency of ‘feeling like’ or ‘actually having sex’ 
The aforementioned improvements could not be related to changes in pain in the 
genital regions during sexual contact or disturbances in vaginal lubrication or erectile 
functioning. However, together with changes in frequency of wanting or having sex 
Prior to PTNS After PTNS 
Patient group Number p-values 
overall
frequency 
feeling like/ 
having sex 
whole 
(sub)group  
Pts that 
wanted sex 
? once a 
month / 
respon-dents
Pts that had 
sex  
? once a 
month / 
respon-dents
Pts still 
wanting sex 
? once a 
month / pts 
that did so 
before PTNS 
Pts still 
having
sex ? once a 
month / pts 
that did so 
before PTNS 
p-value
All N=121 ns/ns 46/104 47/103 26/42 31/47 p=0.003 p=0.001
         
Women N=76 ns/p=0.042 30/62 29/61 14/26 17/29 p=0.003 p=0.002 
Men N=45 ns/ns 16/42 18/42 12/16 14/18 ns ns 
         
OAB  N=83 ns/ns 34/68 34/67 21/31 22/34 p=0.021 p=0.005 
CPP N=23 ns/ns 7/22 7/22 3/7 5/7 ns ns 
Retention N=15 ns/ns 5/14 6/14 2/4 4/6 ns ns 
         
Subjective
responders
N=62 ns/ns 20/54 22/53 10/19 13/22 p=0.006 p=0.006 
Objective  
responders
N=43 ns/ns 13/38 14/37 7/12 7/14 ns p=0.048 
OAB = Overactive Bladder , CPP = Chronic Pelvic Pain, PTNS = Percutaneous Tibial Nerve Stimulation, ns = not significant, 
Pts = Patients 
FEASIBILITY AND CLINICAL RESULTS                 91
and sexual satisfaction, significant improvements were seen in OAB patients never 
having reached an orgasm during sexual activity in the past month, as well as in 
female patients reaching orgasms too fast or too slowly. 17 out of 29 OAB patients 
that, prior to PTNS, did not reach orgasms although being sexually active, did so 
afterwards (p<0.05), whilst 11 out of 26 female patients reaching orgasms too fast 
and 21 out of 32 female patients reaching orgasms too slowly significantly improved 
(both: p<0.05).
Discussion
In a recent review by Shaw on the prevalence of sexual impairment in female 
patients with urinary incontinence 1 figures widely varied between 0.6 and 64%. Most 
studies dealt with female patients with stress incontinence only, mixed groups or 
patients with ‘any involuntary urine loss’. In the few cases clear detrusor instability 
has been regarded, impairment mostly was found in 10-35% of patients, depending 
on the way impairment was defined. More recent reports reconfirm the negative way 
in which OAB may affect sexual function in female patients. 2,14 For other forms of 
LUTD, especially non-urinary retention, as well as for male patients with urinary 
symptoms, data on sexual impairment are very scarce. In a Danish survey in over 
7,000 people Hansen showed recently that lower urinary tract symptoms are an 
independent risk factor for sexual dysfunction in both women and men. 15
In our study, questions of the NSF-9, a standardized Dutch-language questionnaire 
dealing with different aspects of sexual functioning, revealed abnormal sexual 
functioning in 25.3-45.6% of all cases. In patients with OAB, sexual dysfunction has 
been observed in about a quarter to one third of cases being in accordance to the 
above mentioned literature. It should be noted that sexual dysfunction in our study 
might be underreported, as about 12% of the treated patients did not fill out the 
questionnaires. However, due to widely differing definitions of impairment of sexual 
function, urinary incontinence as well as sexual activity in different reports, useful 
comparisons can not be made. This is further hampered by the fact that in the 
Netherlands, validated questionnaires on sexual functioning hardly exist, let alone 
questionnaires that can be used for female as well as male patients. The NSF-9 is 
equally constructed for male and female patients. It is short, enhancing compliance, 
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and especially suitable for the Dutch language, but we are aware of the fact that it 
does not contribute to uniformity in international research.  
Our intent was not only to establish some indication on the prevalence of sexual 
impairment in patients with LUTD, but also to find out whether improvement of the 
latter improved sexual functioning as well. One of the difficulties regarding this 
subject is the possibility that complaints of urinary symptoms may be the result of 
sexual dysfunction rather than the cause. In that case treating the sexual problem 
itself, instead of the LUTD, might be of more importance. 1
In this study, treatment of the LUTD has been performed by means of PTNS. Our 
earlier studies revealed PTNS’ success rates on lower urinary tract symptoms up to 
70% 3-5, much higher than was observed here. It should be mentioned that those 
studies were performed in only a few high volume centers. The data presented in this 
paper are pooled data from our own center with those from several low volume 
hospitals in the Netherlands, that all used the same protocol. Results in these added 
centers were worse, although not statistically significant. Furthermore, a discrepancy 
was observed between the number of subjective and objective responders. One 
should bear in mind that most patients underwent  many therapies before using 
PTNS as a final option. Small changes, not enough for objective success, may 
therefore have been considered enough to pursue chronic treatment. Besides, 
especially in OAB-patients, not only the number of voids/24 hours and the number of 
incontinence episodes/24 hours are of importance. The urge severity and the time 
patients can postpone micturition also play a role. Patients experiencing the most 
improvement of these items, more than of objective criteria, may be subjectively 
successful, objectively they are not. 
Although compliance to the NSF-9 was rather high, the above mentioned low 
objective response rate to PTNS and the also rather small number of patients in each 
investigated subgroups, like, amongst others gender and indication for PTNS, made 
it difficult to obtain fair statistics on separate NSF-9 items per subgroup. It was 
therefore chosen to perform the other way around: separate NSF-9 items have been 
investigated and its changes correlated to the subgroups.
However, bearing these shortcomings in mind, we still feel our study proved that in 
particular sexually impaired female patients suffering from OAB, subjectively 
responding to PTNS, also benefited from LUTD treatment with regard to their sexual 
functioning. They were more satisfied and were more frequently sexually active than 
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before PTNS. A possible explanation might be the positive effects on the fear for 
involuntary urine loss or actual incontinence during sexual activity. Female patients 
with involuntary urine loss frequently feel dirty, fear smells and therefore have a low 
self-esteem, emotions likely to disappear with resolving urinary symptoms. Male 
patients, in whom sexual functioning is highly related to the way erectile functioning is 
experienced and not so much to urinary symptoms during sexual activity, may 
therefore not have the same positive outcome on successful LUTD therapy. 
Conclusions
In conclusion, sexual dysfunction was observed in about one third of patients with 
lower urinary tract disorders and improved significantly on successful therapy for the 
latter. Female patients, patients with OAB and subjective responders were most likely 
to improve.
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Appendix (NSF-9) 
Please read the questions carefully. After you have done so, please select the answer that best describes your 
situation. Do not choose more than one answer for every question 
1. During the past month, how often have you wanted to have  sexual contact? (By sexual contact do not only 
think of intercourse, but also of other sexual activities with a partner) 
 1 never 
2 once 
 3 a couple of times 
 4 once a week 
 5 a couple of times a week 
 6 once a day 
 7 a couple of times a day 
2. During the past month, how often have you had sexual contact? (By sexual contact do not only think of 
intercourse, but also of other sexual activities with a partner) 
 1 never        go to question 9  
2 once 
 3 a couple of times 
 4 once a week 
 5 a couple of times a week 
 6 once a day 
 7 a couple of times a day 
3. During the past month, how often your penis has been less erected / your vagina has been less lubricated
than you wanted? 
 1 not once 
 2 occasionally 
 3 several times 
 4 often 
 5 every time 
4. During the past month, how often your penis has been not as long erected / your vagina has been not as long 
lubricated as you wanted? 
 1 not once 
 2 occasionally 
 3 several times 
 4 often 
 5 every time 
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5. During the past month, how often have you had an orgasm during sexual contact? 
 1 not once        go to question 8 
 2 occasionally 
 3 several times 
 4 often 
 5 every time 
6. During the past month, how often have you had an orgasm not as fast as you wanted? 
 1 not once 
 2 occasionally 
 3 several times 
 4 often 
 5 every time 
7. During the past month, how often have you had an orgasm faster than you wanted? 
 1 not once 
 2 occasionally 
 3 several times 
 4 often 
 5 every time 
8. During the past month, how often have you experienced pain in your genitals before, during or after sexual 
contact? (instead of pain, you can also think of itching or a burning sensation) 
 1 not once 
 2 occasionally 
 3 several times 
 4 often 
 5 every time 
9. How satisfied with your current sex life are you? 
 1 very dissatisfied 
 2 dissatisfied 
 3 neutral 
 4 satisfied 
 5 very satisfied 
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Abstract
Objective The aim of this study was to evaluate urodynamic changes after 
percutaneous tibial nerve stimulation (PTNS) for the treatment of complaints related 
to the overactive bladder syndrome and to search for urodynamic-based predictive 
factors.
Patients and methods Ninety consecutive patients with symptoms related to  
overactive bladder syndrome were enrolled in this study. Patients underwent 12 
PTNS sessions. For evaluating objective success, the primary outcome measure was 
a reduction in number of urinary leakage episodes of 50% or more per 24 hours. 
Patients’ request for continuation of therapy was considered subjective success. This 
study focussed on urodynamic features at baseline and on changes found after 12 
PTNS treatments.
Results The objective success rate was 56% (leakages/24h). Subjective success 
rate was 64%. Frequency/volume chart data and quality of life scores improved 
significantly (p<0.01). Pre- and posturodynamic data were available from 46 
participants. Detrusor instabilities (DI) could be abolished in a few cases only. 
Increments in cystometric bladder capacity and in volume at DI were significant 
(p=0.043 and 0.012, respectively). Subjects without detrusor instabilities at baseline 
were 1.7 times more prone to respond to PTNS (Odds Ratio (OR): 1.75; 95% 
Confidence Interval (CI): 0.67- 4.6). The more the bladder overactivity was 
pronounced, the less these patients were found to respond to PTNS, the area under 
the receiver operating characteristic curve was 0.644 (95% CI: 0.48-0.804).
Conclusions PTNS could not abolish DI. PTNS increased cystometric capacity and 
delayed the onset of DI. Cystometry seemed useful to select good candidates: 
patients without DI or with late DI onset showed to be the best candidates for PTNS.
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Introduction
Electrostimulation has been exploited both for overactive bladder and for 
hypocontractile bladder alike. Recently, percutaneous posterior tibial nerve 
stimulation (PTNS) has been introduced for the treatment of lower urinary tract 
dysfunction. The tibial nerve is a mixed nerve containing L4-S3 fibres, and originates 
from the same spinal segments as the innervation to the bladder and pelvic floor. 
Therefore, it is not surprising that efforts were made to stimulate these fibres to treat 
bladder disturbances. 1-4 In previous studies, we have discussed extensively 
subjective success, quality of life scores and frequency/volume charts. 4-5 Therefore,
this article presents the urodynamic features found in patients who underwent PTNS 
for symptoms of overactive bladder syndrome.  Three issues will be addressed: First, 
the primary outcome measures based on charts and questionnaires will be described 
briefly. Second, the urodynamic changes after PTNS treatment will be discussed and 
lastly, the predictive value of baseline urodynamic parameters on treatment outcome 
will be reported.
Patients and methods 
Between November 1999 and August 2001, a total of 90 consecutive patients with a 
diagnosis of overactive bladder syndrome were enrolled in an international 
multicentre prospective clinical trial in five sites in the Netherlands and one site in 
Italy. Patients underwent 12 sessions of PTNS.
Definition and criteria Overactive bladder syndrome was defined as urgency, 
frequency and/or urge incontinence. For urgency and urge incontinence International 
Continence Society (ICS) definitions were used. 6 For this study, an increased urinary 
frequency was defined as eights voids or more per 24 hours. Stress urinary 
incontinence was excluded through urodynamic investigation. 
Inclusion and exclusion criteria as well as the PTNS technique have been extensively 
described in a previous study. 4 In short, the procedure was as follows: the posterior 
tibial nerve was located through percutaneous insertion of a needle a few inches 
above the medial malleolus. After connection to a low voltage stimulator 
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(Cystomedix, Anoka, MN, USA) and placement of a ground surface electrode on the 
ipsilateral calcaneus, the tibial nerve was stimulated. This resulted in a tickling 
sensation in the sole of the foot and flexion of the toes.
Primary outcome measure, positive response rate and quality of life Following 
the considerations of Blaivas on how to assess new treatment modalities, the 
subsequent parameters were evaluated: the number of leakage episodes, the 
amount of urine loss, urinary frequency and subjective patient assessment. 7 A 
reduction in the number of leakage episodes of at least 50% on 24-hour 
frequency/volume charts was taken as primary outcome measure. Furthermore, a 
reduction in leakage severity of at least 50% was a secondary outcome measure 
(scale score 1, some drops; 2, small amount; 3, severe urine loss necessitating 
change of clothing). A reduction in urinary frequency was regarded clinically 
significant when a normal voiding pattern of less than 8 voids per 24 hours could be 
obtained. Patients’ request for continuation of treatment was regarded a subjective 
success, and these patients were called “positive responders”. In addition, quality of 
life was determined at week 0 and at week 12. For incontinence specific Quality of 
Life the I-QoL was used. 8 For the estimation of generic functional status and well-
being, the MOS 36 items Short-Form health survey (SF-36) was completed. 9 Higher 
scores indicate better quality of life. All patients gave their informed consent. 
Urodynamic data Both at baseline and after 12 sessions, urodynamic investigations 
were performed in all patients. For urodynamic analysis, a standard transurethral 
subtraction cystometry was done in the supine position. Sterile saline at room 
temperature was infused through a double-lumen 8 F catheter at a filling rate of 50 
ml/min. The volume at which detrusor instabilities (volume at DI) occurred was noted. 
DI was defined as an increase of 15 cm water pressure or of lower amplitude if 
accompanied with a distinct sensation of urgency. Methods, definitions and units 
conform to the standards recommended by the International Continence Society, 
except where specifically noted. 6
Statistical analysis and predictive factors Descriptive data were reported as 
median values and range and with a median change and range. Within-group 
comparisons of results were conducted by the nonparametric Wilcoxon signed ranks 
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test. Tests were performed on a two-tailed basis, and level of significance was set at 
5%. To evaluate whether it is possible to predict subjective success with urodynamic 
characteristics, we performed univariate and multivariate logistics regression 
analyses. The dependent variable was “subjective success”, because this is the 
clinically most relevant outcome measure: despite good improvement in 
frequency/volume charts, a patient can experience the net effect as unsatisfactory 
and vice versa. Odds ratios (OR) with their 95% confidence intervals (95%CI) were 
calculated as a measure for the predictive power of each characteristic. Based on the 
outcome of the multivariate analyses, a Receiver Operating Characteristic (ROC) 
curve was constructed in order to visualize the predictive power of the combination of 
the variables. The area under the ROC curve quantified this predictive power. 
Statistical analysis was performed using SPSS 9.0 software  (SPSS, Chicago, IL, 
USA).
Results
Baseline characteristics Ninety patients (67 females and 23 males) with a median 
age of 51 years (range: 19-82) were enrolled in this study (table 1). Duration of 
symptoms ranged between 1 and 56 years with a median of 4.5 years. A total of 80 
of 90 frequency/volume charts were completed correctly and used for further analysis 
(10 of 90: 11% missing values). Sixty of 80 (75%) of these patients were incontinent 
and leaked at least once a day.  From those patient who filled in correctly the 
frequency/volume chart, 73 of 80 (91%) patients had an increased frequency at 
baseline and 7 of 80 (9%) had a normal voiding frequency of less than 8 voids per 24 
hours. Eighty-one I-QoL and 82 SF-36 surveys were found suitable for further 
examination. At baseline, 82 urodynamic reports were suitable for evaluation. DI 
occurred in 48 of 82 (59%) patients.
Reduction in leakage episodes, severity of urine loss and urinary frequency:  
After 12 PTNS treatments, 78 complete voiding charts were available for evaluation 
(12 of 90:13% missing values). All parameters improved significantly (see table 1). 
Seventy-five percent of the subjects with daily incontinence at baseline was reduced 
to 44% (35 of 80) of subjects after 12 PTNS (35 of 78 incontinent; 43 of 78 not incon- 
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Table 1 F/V chart, urodynamic data  and Quality of Life results (all 90 patients) 
Parameter M N Baseline N End Change p-value*
24h F/V chart 
       
Leakages 30 60 5 (1;19)  59 2 (0;16)  -3 (-19;+7) <0.01 
Incontinence severity 30 60 2 (1;3) 58 1 (0;3) -1 (-3;+1) <0.01 
Urinary frequency 10 80 13 (4;41) 75 10 (4;53) -3 (-18;+12) <0.001 
Mean Voided Volume 11 79 135 (20;327) 74 191 (47;410) +27 (-96;+200) <0.001 
Quality of Life scores        
I-QoL 9 81 49 (20;100) 80 67 (20;100) +10 (-31;+88) <0.001 
SF-36 11 79 57(10;93) 82 67 (13;93) +4 (-42;+56) <0.001 
Cystometric data        
Cystometric capacity 7 82 263 (30;745)     
Subjects with DI 42 48 59%     
Volume DI 42 48 150 (30;350)     
Pdet DI 42 48 41 (4;123)     
M = missing values at baseline because not complete or not relevant, N = number of valid values, * =  Wilcoxon signed ranks 
test, significance level set at 5%, F/V = Frequency/Volume, DI = Detrusor Instability, CC = Cystometric Capacity, Pdet DI =  
Detrusor pressure at DI 
tinent, 12 of 90 missing values). End evaluation considered 23 of 60 (38%) patients 
dry, that is cured. However, four of these wished to discontinue treatment. An 
additional 11 of 60 (18%) incontinent subjects achieved at least 50% reduction in the 
number of leakage episodes. This resulted in a success rate of 56% (primary 
outcome measure). In positive responders a median reduction of 100% (+50; -100) 
was found whereas non-responders obtained a median reduction of 33% (+77; -100). 
An at least 50% reduction in incontinence severity was found in 31 of 60 (52%) 
subjects. Positive responders and non-responders achieved a median reduction of 
100% and 23%, respectively. At baseline, 7 of 80 (9%) had a normal voiding 
frequency of less than 8 voids per day, 12 subjects voided 8 to 10 times a day (15%). 
After 12 PTNS sessions 20/80 (25 %) subjects achieved a voiding frequency of less 
than 8 times (primary outcome measure) and another 25 voided 8 to 10 times (31%).
Patients’ assessment: subjective response and quality of life scores Fifty-eight 
of 90 (64%) patients requested continuation of the therapy. I-QoL and SF-36 scores 
improved significantly as shown in table 1. 
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Urodynamic profiles In only 46 patients, urodynamic investigations were performed 
at baseline and after 12 PTNS sessions. Therefore, post-PTNS treatment 
urodynamic findings are based on data of 46 participants only (36 females, 10 males; 
median age: 51 years). Comparable subjective success rates in this subgroup were 
found: 32 of 46 (70%) versus 58 of 90 (64%); this finding reduces the possible bias of 
having only successful patients undergoing a second urodynamic investigation. 
Baseline and end evaluation data are summarised in table 2: a significant increment 
was seen in cystometric bladder capacity and in volume at which first instable 
detrusor contraction occurred. At baseline, DI’s were noted in 34 of 46 participants 
(74%), 31 subjects continued to have DI; however, these instabilities occurred at 
larger bladder volumes. In three patients DI was eliminated and in three others, de 
novo DI was noticed. Detrusor pressures recorded during the instabilities decreased 
only slightly.
Table 2 F/V chart, urodynamic data  and Quality of Life results (46 patients) 
Parameter Baseline End Change p-value* Change in 
responders
N = 32/46 (70%) 
p-value*
24h F/V chart 
      
Leakages 4 (1;19) 3 (1;16) -2 (-19;+7) 0.001 -2(-19;+2) <0.01 
Severity of leakages 2 (1;3) 1.85 (1;3) -1(-3;+1) <0.001 -1 (-3;+1) <0.01 
Urinary frequency 13 (4;32) 9 (5;19) -3(-18;+8) <0.001 -3 (-18;+8) <0.01 
Mean Voided Volume 135 (28;275) 205 (76;300) +50(-50;+200) <0.001 +62 (-50;+200) 0.001 
Quality of Life scores:       
I-QoL 39 (22;94) 66(20;100) +9(-19;+88) <0.001 +19(-14;+88) <0.01 
SF-36 54 (17;93) 64 (19;89) +5 (-42;+55) 0.003 +6 (-18;+56) <0.01 
Cystometric data:       
Cystometric Capacity 243 (30;745) 340 (70;500) +30 (-324;+450) 0.043 +36 (-324;+450) 0.14 
Subjects with DI 34/46 (70%) 34/46 (70%)   23/32 (72%)  
Volume  DI 133 (30;350)  210 (50;375) +60 (-183;+333) 0.012 +115(-183;+333) 0.031 
Pdet DI 35 (4-120) 41 (10-93) -5 (-63; 74) 0.67 -6.5(-46;+64) 0.69 
* =  Wilcoxon signed ranks test, significance level set at 5%, F/V = Frequency/Volume, DI = Detrusor Instability, CC = 
Cystometric Capacity, Pdet DI =  Detrusor pressure at DI 
Influencing factors on outcome Taking the small number of participants into 
account (n=82, although in only 48 patients the features of DI could be analysed), 
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analysis of potential predictive factors among baseline characteristics revealed one 
strong prognostic factor: subjects having detrusor instabilities at baseline (n=48) were 
less likely to respond to PTNS. A stable bladder enhanced the chance for a 
successful outcome of the PTNS therapy by 1.75 times (OR: 1.75; 95%CI: 0.669-
4.57).
Univariate logistic regression analysis showed that none of the baseline 
characteristics (cystometric capacity, volume at DI, detrusor pressure at DI) proved to 
be a significant predictor for subjective success. This finding may also be due to the 
small number of participants with unstable detrusor (n=48) There was some 
suggestion that the volume at DI can predict outcome to a certain extent. For 
example, for each 100 ml “delay in DI onset”, chance for success increased 1.5 times 
(OR: 1.0043; 95% CI: 0.997, 1.012). However, the three baseline characteristics 
showed no statistical significance, a multivariate analysis combining these three 
factors revealed a predictive power of 0.64 (OR: 0.644; 95% CI: 0.484, 0.804), see 
figure 1. Also a slight tendency was seen that could support the idea that stronger 
stimulation inhibit detrusor overactivity: a participant having a 5 mA higher mean 
stimulation intensity had 1.8 times more change for success (OR: 1.13; 95% CI: 0.81; 
1.6).
Discussion
The primary outcome measures that were taken to assess PTNS, were obtained in 
56% of the patients with urinary leakage at baseline; 38% of them showed micturition 
charts without any leakages, 52% of the patients noticed significant reduction in urine 
loss. Only 25% of all participants achieved a normal micturition pattern (less than 8 
voids/24 hours). Patients treated by PTNS seem to regain their control on involuntary 
urine loss, but achievement of a normal micturition pattern is hardly feasible in most 
of them. Additionally, patients’ assessment was determined through QoL 
questionnaires (p<0.001) and the number of requests to continue the treatment 
(64%). All together, it seems that PTNS can be considered as a new treatment 
modality that can be offered to patients with intractable OAB symptoms; nearly 60% 
of such patients will benefit from PTNS. 
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Figure 1 ROC curve constructed to visualize the predictive power for success 
(cystometric capacity, volume at and pressure at detrusor instability combined)  
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This study was mentioned to detect the impact of PTNS by looking to these patients 
in a more objective way, namely by determining urodynamic changes. Examination of 
46 patients with overactive bladder syndrome who underwent 12 PTNS sessions 
revealed significant urodynamic changes, namely increment of total bladder capacity 
and volume at DI. For positive responders the increment in cystometric capacity was 
not significant; this could be due to the rather large baseline capacity positive 
responders already had, which only increased slightly. Non-responders started with a 
median baseline capacity of 155 ml (range: 77-550) and ended up with a capacity of 
250 ml (range: 70-500). For positive responders, this change was 300ml (range 30-
745) at week 0 and 340 ml (range: 103-500) after 12 PTNS sessions. These figures 
strongly suggest that patients with small cystometric capacity were more prone to fail. 
Even though the cystometric capacity of non-responders increased, the resultant 
capacity seemed of small clinical value for this group as they choose not to continue 
with PTNS. Remarkably, logistic regression analysis could not point out baseline 
capacity as a prognostic factor for success (OR: 1.0008; 95%CI: 0.998-1.004). The 
patient group that underwent pre- and posturodynamic evaluation contained more 
patients with an instable bladder than the baseline group did. The reason for this can 
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be sought in the fact that mainly academic centres, that participated, received more 
second opinion patients often with intractable detrusor instabilities. Investigating the 
DI features revealed a significant delay in onset of DI. The clinical relevance of 60 ml 
increment in volume at which the first DI occurs seems perhaps questionable but 
assuming a physiological filling rate of 1 ml/min, such an increment would delay the 
onset of urge or urge-incontinence provoked by the DI, with nearly one hour or in 
case of responders (+115ml) with nearly two hours! 10 The reductions found in 
detrusor pressures during unstable contractions were of minor size and presumable 
of minor clinical relevance. Furthermore, repetitive PTNS could not substantially 
decrease the number of subjects in whom detrusor instabilities were detected. 
Disappearance of DI was only seen in 3/90 patients. This is in contrast with Klingler 
et al. reporting an elimination of DI in 77% of the cases after 12 sessions of PTNS. 3
It is questionable how relevant the finding of persistent DI is in evaluating therapeutic 
effects of neuromodulation. In fact, many neuromodulation studies reported failures 
to suppress DI. 11-14 Nevertheless, the presence of DI at baseline was found to be a 
strong predictive factor for therapeutic failure, especially when it occurred early in the 
filling phase. So, stable bladders were more prone to respond well to PTNS. In 
conclusion, it seems advisable to include only those patients with stable bladders, or 
those with late onset bladder instability. 
A common remark questions how intermittent stimulation in PTNS possibly can 
succeed, comparing with the continuous stimulation patients receive when a sacral 
root neuromodulator is implanted. The inhibitory and long-lasting effect through 
PTNS can be explained by experiments performed in Macaca monkeys. It was 
shown that repetitive tibial nerve stimulation powerfully inhibits nociceptive 
spinothalamic tract cells through A-? fibres, provided a high enough intensity was 
applied. 15 This inhibition was thought to act on a spinal level. Although these 
experiments were not focused on the complex micturition system, extrapolation of 
these findings to voiding dysfunction can be made. Hypothetically, repetitive PTNS 
inhibits pathologic afferent information from the bladder to supraspinal levels, 
resulting in a decreased awareness of pathological sensations (less urge) and 
delayed onset of detrusor instability. Similar studies on these spinothalamic cells, 
demonstrated long-lasting inhibition for 30 minutes. Inhibition occurred more strongly 
as stimulation intensity increased. 16 This finding can explain a carry-over effect 
found upon intermittent stimulation. To our knowledge, no research has been 
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performed investigating how long this inhibition occurs in humans, or how strongly 
this nerve has to be stimulated. Determination of the exact intensity applied through 
PTNS stimulation is troubled because of the inhomogeneous character of each 
nerve, recruitment of fibres by size, physical environment and type of stimulated 
nerve. 17 A stronger stimulation will surely be more effective as has been already 
proved in human experiments using supramaximal stimulation in spinal cord patients. 
18 Also, this study provided some evidence for better therapy outcome in those 
patients in whom stronger stimulation currents were used. Even though the real 
stimulation intensity that reached the tibial nerve remains unknown, a slight tendency 
was seen that could support the former ideas: a participant receiving a 5 mA higher 
mean stimulation intensity, had 1.8 times more change for success. Unfortunately, 
application of higher current intensity through percutaneous needling is hardly 
feasible in individuals with intact sensation. Finding a more adequate way to 
stimulate the posterior tibial nerve, with better placement of the electrode and 
controlled applied intensity should be aimed and searched for.
Many factors seem to influence the outcome of PTNS. Presumably, complex 
interaction of several factors, such as bladder retraining by frequently completed 
voiding diaries, release of enkephalines or other neurotransmitters through needling, 
decreased c-fos expression by tibial nerve stimulation and attribution of some 
placebo effect, will play important roles and finally add up resulting in a successful 
outcome. The urodynamic results refute, however, the possibility of a placebo effect 
being the only explanation for the positive results found in this study. 
Conclusions
PTNS sessions could not eliminate DI but resulted in increased bladder capacity and 
delayed onset of DI to such an extent that the patients experienced a clinical relevant 
decrease in leakage episodes, severity of incontinence and voiding frequency. The 
latter parameters can all be calculated from frequency/volume charts. Therefore, the 
value of urodynamic investigations to evaluate therapeutic effect of neuromodulation 
is debatable. On the other hand, predictive factors related to cystometric parameters 
were found: patients with stable bladders are good candidates for PTNS treatment. 
When bladder instability is present, it seems advisable to exclude those patients with 
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severe forms of bladder overactivity (i.e. early onset of DI) from PTNS treatment. In 
view of the facts that PTNS is an inexpensive treatment modality that is minimally 
invasive and simple to perform, it is an attractive first-line option for patients with 
overactive bladder syndrome before proceeding towards surgical interventions such 
as bladder augmentation or replacement. PTNS is a young therapy requiring further 
research, analysing predictive factors and optimal stimulation parameters. 
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Abstract
Objective To determine urodynamic changes and predictive factors in patients with 
voiding dysfunction who underwent 12 percutaneous tibial nerve stimulations.
Patients and methods Thirty nine patients with chronic voiding dysfunction were 
enrolled in a prospective multicentre trial in the Netherlands (n=19) and in Italy 
(n=20). A 50% reduction in total catheterized volume per 24 hr was taken as a 
primary objective outcome measure. Patients’ request for continuation of treatment 
was regarded as subjective success. Objective urodynamic parameters and bladder 
indices were determined. Odds ratios and their 95% confidence interval were 
computed as a measure for predictive power in order to reveal predictive factors 
(Pdet at Qmax, Qmax, BVE and BCI). 
Results Primary outcome measure was obtained in 41%, an additional 26% reduced 
their 24 hr residuals with more than 25%. Fifty nine percent of patients chose to 
continue treatment. Detrusor pressure at maximal flow, cystometric residuals and 
bladder indices improved significantly for all patients (p<0.05). Patients with minor 
voiding dysfunction were more prone to notice success (Odds ratio: 0.73; 95% CI: 
0.51-0.94).
Conclusions PTNS is a young treatment modality, minimally invasive and easily 
accessible. It might be an attractive first line option for patients with (minor) voiding 
dysfunction.
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Introduction
Voiding dysfunction can be caused by neurological disorders, post surgical 
conditions, infravesical obstruction, bladder overdistention, inflammation, drugs, 
psychogenic factors, learned voiding dysfunction, detrusor myopathy and pelvic floor 
dysfunction. 1 Therapeutic lower urinary tract rehabilitation includes pelvic floor 
training, biofeedback, behavioral modification, catheterization, electrical stimulation 
or bladder expression and bladder reflex triggering in case of neurogenic disorders. 2
Patients might benefit clinically from cholinergic agents. 3,4 Other treatment modalities 
are urethral dilatation, insertion of intraurethral device or surgery to relieve anatomic 
obstruction. Often clean intermittent self-catheterization is the most effective therapy 
for chronic bladder emptying problems. Unfortunately catheterization is at the 
expense of patients’ quality of life. During the last decades neuromodulation has 
gained interest as an alternative treatment for difficult to treat voiding dysfunction 
before proceeding towards more invasive surgical procedures. One of the newest 
modalities is percutaneous  tibial nerve stimulation (PTNS). The posterior tibial nerve 
is a mixed nerve containing L5-S3 fibres, originating from the same spinal segments 
as the parasympatic innervation to the bladder. The first results of PTNS for patients 
with voiding dysfunction were already extensively reported in previous papers. 5,6 
This paper focuses on urodynamic changes found in these patients and on 
determination of urodynamic predictive factors. 
Patients and methods 
Between November 1999 and July 2000, 39 consecutive patients with idiopathic non-
obstructive voiding dysfunction were enrolled in an international prospective 
multicentre clinical trial in the Netherlands (n=19) and Italy (n=20). Patients 
underwent 12 weekly percutaneous stimulations of the posterior tibial nerve.
Definition and criteria Idiopathic non-obstructive voiding dysfunction: all patients 
with abnormal detrusor function (detrusor underactivity or  acontractile detrusor and 
postvoidal residual) conform the definitions from the standardisation report 2002. 2
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Prior to the study, all patients failed in achieving complete bladder emptying , two of 
them had complete urinary retention and thus all patients catheterized. 
In all patients extensive medical history was taken focussing on urinary symptoms, 
previous and present treatments, neurological disease, and medications. Physical 
examination was done to rule out any relevant pathology such as uro-gynaecological 
or neurological abnormalities. Symptoms existed for a minimum of 6 months. 
Exclusion criteria were bladder outlet obstruction related to benign prostatic 
hyperplasia (using the Abrams-Griffiths nomogram), any uro-gynaecological, central 
or peripheral neurological disorders including dysfunctional voiding due to pelvic floor 
overactivity, pregnancy, age under 18 and severe cardiopulmonary disease. 
PTNS procedure was extensively described in a previous paper. 5 In short, through 
percutaneous needling the posterior tibial nerve was stimulated above the medial 
malleolus. After connection to a low voltage stimulator (CystoMedix, Anoka, MN) and 
a ground electrode, this nerve was electrically stimulated which resulted in a sensory 
response (tickling sensation in the sole of the foot) and a typical motor response 
(plantar flexion of digit I or fanning of all toes). Treatment consisted of 12 weekly 
sessions of 30 minutes each. All patients gave their informed consent. 
Primary outcome measure, positive response rate and quality of life In line with 
Blaivas’ proposals concerning how to assess efficacy of neuromodulation, 50% 
reduction in total catheterized volume per 24 hr was taken as primary objective 
outcome measure. Additionally the positive response rate and Quality of Life scores 
displayed patients’ assessment. 7
Request for continuation of treatment was regarded a subjective success and these 
patients were called “positive responders”. Quality of Life scores were determined at 
week 0 and at week 12. For incontinence specific quality of life the I-QoL was used. 8
For the estimation of generic functional status and well-being, the MOS 36 items 
Short-Form health survey (SF-36) was completed.9 Higher scores indicate better 
quality of life.
Urodynamic data Objective assessment of the efficacy of PTNS was done through 
urodynamic investigation and through calculating bladder indices. At baseline and 
after 12 PTNS sessions, a standard transurethral subtraction cystometry was 
performed in the supine position whereas the pressure flow study was carried out in 
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the sitting position. Sterile saline at room temperature was infused through a double 
lumen 8 F catheter at a filling rate of 50 ml/min. The volume at which detrusor 
instabilities (DI) occurred was noted. DI was defined as an increase of 15 cm water 
pressure or of lower amplitude if accompanied with a distinct sensation of urgency. 
Methods, definitions, and units conform to the standards recommended by the 
International Continence Society, except where specifically noted. 2
Bladder indices based on frequency/volume charts and urodynamics An effort 
to measure bladder contractility and voiding efficacy was made. Bladder Contractility 
Index (BCI) was derived from the formula:  BCI = Pdet x Qmax  +  5 x Qmax; such 
that a strong bladder contractility is a BCI of >150, normal contractility a BCI of 100-
150, and a weak contractility a BCI of <100. 10 BCI was thus calculated from the 
urodynamic measurements. Bladder Voiding Efficiency (BVE) reflects bladder 
contractility against urethral resistance and is measured according to the degree of 
bladder emptying: BVE = 100 x (voided volume /total bladder capacity). Total bladder 
capacity is defined as the summation of voided volume and postvoidal residual 
volume. 10 BVE was computed both from urodynamic and voiding/frequency chart 
data. Both bladder indices were determined at baseline and at week 12. 
Statistical analysis and predictive factors Efficacy of PTNS was analysed for all 
patients on an intention-to-treat basis. Descriptive data were reported as median 
values and range, and as mean change with 95% confidence interval (CI). 11 Within-
group comparisons of results were conducted by the non-parametric Wilcoxon signed 
rank test. Tests were performed on a two-tailed basis and level of significance was 
set at 5%. In order to evaluate whether it is possible to predict subjective success 
with baseline characteristics we performed univariate and multivariate logistics 
regression analyses. In our opinion, the clinically most relevant outcome 
measurement is patients’ perception of the PTNS effect on their voiding disorder: 
despite good improvement in frequency/volume charts, a patient can experience the 
net effect as unsatisfactory and vice versa. Odds ratios with their 95% CIs were 
calculated as a measure for the predictive power of each characteristic. Statistical 
analysis was performed using SPSS 9.0 software (SPSS, Chicago). 
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Results
Thirty nine patients (12 men, 27 women) with a median age of 53 years (range: 28-
77) were enrolled in this study. Patients’ baseline characteristics and their medical 
history are summarised in Table 1.
Table 1 Patient characteristics 
(% of patients) All (39) 
Patient characteristics: Median Range
Male/female 12/27  
Age in years (y) 53 28-77 
Duration of symptoms (y) 3 1-36 
Current intensity (mA) 4 1.4-7.6 
Treatments prior to PTNS (%): Number Percent 
Medication for complaints1:
One
Two 
31
19
12
80
49
31
Pelvic floor/bladder retraining: 8 21 
Electrotherapy: 5 13 
Surgical intervention2:
One
Two 
11
8
3
29
21
8
Baseline voiding parameters: Median Range 
Total catheterized volume 800 210-3000 
Mean catheterized volume 241 74-675 
Number of catheterizations 2.5 1-10 
Total voided volume 1000 95-2700 
Bladder Contractility Index 63 37-160 
Bladder Voiding Efficiency (urodynamics) 64 40-96 
Bladder Voiding Efficiency (frequency/volume chart) 56 8-91 
Baseline QoL score: Median Range 
I-QoL 62 26-99 
SF-36 65 19-92 
1Medication used: parasympathomimetica, alpha-blockers, 2Surgical intervention for urinary complaints were: urethral 
dilatation, suspension- and prolaps surgery, transurethral prostatic resection (TURP) and bladder neck incision.  
At baseline, one patient had a mean of 74 ml residual, catheterising 4 times a day on 
frequency/volume charts. All others had residuals larger than 100 ml. 
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Primary outcome measure:  more than 50% decrement in 24 hr total catheter-
rized volume Frequency/volume charts were completed after 12 weeks by 38 
patients. All patients improved significantly in all frequency/volume chart data (See 
table 2). In 16/39 (41%) patients’ 24 hr total catheterized volume reduced with 50% 
or more (= primary outcome measure). Another 10/39 (26%) participants noticed a 
25-50% decrement of their residuals. Thus, 26 (67%) patients noticed a reduction of 
25% or more in 24 hr total catheterized volume. A tendency to increment of the total 
voided volume was found  (p=0.053). PTNS resulted in 15/39 patients with a mean 
catheterized volume smaller than 100 ml (13 patients) or zero (2 patients). Nobody 
became catheterization free, even the 2 patients that had zero residual after 
catheterization, still continued catheterizing themselves once a day. 
Table 2 Frequency/volume chart and Quality of Life results  
Subjective success:  positive responders Twenty three out of thirty nine patients 
(59%) chose to continue treatment. In 13 out of these 23 patients the primary 
outcome measure (more than 50% reduction) was obtained, another eight subjects 
noticed a reduction of their 24 hr residual volume with more than 25%. For non-
responders (n=16) the primary outcome measure was obtained in only two patients: 
two patients had more than 50% reduction in 24 hr catheterized volume and another 
Week 0 Week 12 Median change 
 N Median Range N Median Range N Median Range p-value 
F/V chart data: 
          
Tot CV(ml) 37 800 210-3000 38 450 0-2450 37 -200 -2700;700 <0.01 
Mean CV(ml) 38 241 74-675 38 163 0-163 38 -80 -375;247 <0.01 
No of cath. 38 2.5 1-10 38 2 1-7 38 0 -7;2 0.024 
Tot VV (ml) 37 1000 95-2700 36 1260  50-310 36 275 -500;1720 0.053 
BE 37 64 40-96 38 77 0-100 37 9.5 -38;78 <0.01 
Quality of Life:           
I-QoL 39 62 26-99 39 86 29-100 39 11 -2;60 <0.01 
SF-36 39 65 19-92 38 70 17-91 38 3 -18;50 <0.01 
Tot CV: total catheterized volume, Mean CV: mean catheterized volume, Tot VV: total voided volume, BCI:  Bladder Contractility 
Index, BVE: Bladder Voiding Efficiency index based on the Frequency/volume charts 
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two revealed more than 25% reduced residual volume. From these four patients, one 
patient stopped because of personal reasons, though she had nearly zero residuals. 
The other three persons noticed a good decrease in total amount of catheterized 
volume but they still had the same catheterization rate and were thus not satisfied 
(e.g. from 5x 340 to 4x 220ml times a day ). One patient dropped out of the study 
after six sessions because of aggravation of pre-existing cardiac arrhythmia, 
assumed not to be related to PTNS. 
Urodynamic data At baseline, 37 urodynamic investigations were performed (60% 
of these patients wanted to continue treatment: positive responders), after 12 PTNS 
sessions 27 patients (63% positive responders) underwent a cystometry and 
pressure flow study (Table 3). Patients’ cystometric capacity remained the same, 
detrusor pressure at maximal flow increased statistically significant and a decrement 
in patient’s residual volume after the pressure flow study was seen. Urodynamic 
examination revealed five patients (5/37, 14%) with unstable detrusor activity at 
baseline. After 12 treatment sessions unstable detrusor contractions were seen in 
three participants, DI disappeared in two subjects and seven patients developed de 
novo DI. Added up, 10 participants had DI after 12 PTNS sessions (10/27= 37%). 
Eight out of these 10 patients requested continuation of PTNS, mostly with a 2–3 
weekly interval. Their total catheterized volume decreased with a mean of 51% 
(range: -26%, -87%).
Bladder index based on frequency/volume charts Bladder voiding efficiency 
increased significantly with a median change of  +9.5% (range: -38; +78%). For 
responders this was +18.2% (range: -16; +78%). 
Bladder indices based on urodynamic data For all patients both BCI and bladder 
voiding efficiency increased significantly. The urodynamically based bladder voiding 
efficiency improved in a similar way (median change: +6%, range:  –9; +18%). 
Responders noticed a median percentage increase of +11% (range: -8; +18%). 
Baseline bladder voiding efficiency was not different among responders (median 
BVE: 62; range: 40-83) and non-responders (median BVE: 64; range: 50-96) (p=0.6). 
The BCI rose with 20 points (range: -52, + 70) for all patients. Responders revealed 
an addition of 20 points (range: -15; +70) whereas non-responders noticed a median 
122                   CHAPTER 3
improvement of 15 points (range: -52; +25). At baseline, 23 patients had a weak (BCI 
<100), two a normal (BCI 100-150) and one participant had a strong detrusor 
contractility (BCI >150). After 12 PTNS sessions this was respectively seen in 20, 3 
and 2 patients. The median baseline BCI score was not significantly different 
between responders (median BCI: 65; range: 37-120) and non-responders (median 
BCI: 59; range: 40-160) (p=0.8).
Table 3 Urodynamic results 
Week 0 Week 12 Median change 
 N Median Range N Median Range N Median Range p-value 
All patients: 
          
CC  37 500 165-835 27 500 149-800 27 0 -225;300 0.930 
Pdi  5 37 16-60 10 26.5 10-48 3 1 -2;3 0.59 
Vdi 5 150 50-450 10 245 175-480 3 70 -30;130 0.29 
Pdet at Qmax 27 25 10-70 24 33 10-83 21 8 -5;68 <0.01 
Qmax 25 7 2-27 25 10 4-29 20 1 -12;13 0.13 
Res. volume  31 270 35-755 19 220 50-450 19 -80 -280;100 0.01 
BCI 26 63 37-160 25 83 5-178 20 20 -52;70 <0.01 
BE 31 56 8-91 19 67 56-86 19 6 -8.8;18.1 <0.01 
Subj. responders:           
CC 22 500 165-835 17 500 149-650 17 0 -225;300 0.9 
Pdet at Qmax 16 25 10-70 16 34 15-59 13 8 -5;31 <0.01 
Qmax 16 8.5 2-16 16 10 4-29 13 1 -4;13 0.1 
Res. volume 18 285 80-755 9 130 50-400 9 -100 -200;10 0.01 
BCI 16 65 37-120 16 85 55-178 9 11 -1.5;18.1 <0.01 
BVE 18 62.5 40-83 9 73 60-86 13 20 -15;70 0.011 
CC: Cystometric Capacity in ml, Pdi: Pressure of detrusor instability in cm H2O, Vdi: Volume at first detrusor instability in ml, 
Pdet at Qmax: Detrusor pressure at maximal Flow in cm H2O, Qmax: Maximal Flow in ml/sec,  
Res. volume: Residual volume in ml, BCI: Bladder Contractility Index, BVE: Bladder Voiding Efficiency index  
Predictive factors Univariate logistic regressions analysis showed that none of the 
baseline urodynamic characteristics or bladder indices proved to be a significant 
predictor for subjective success. This may be due to the small number of study 
participants. There was some suggestion that certain characteristics can predict 
outcome to a certain extent. For example, for each 10 cm water increment in 
baseline detrusor pressure at maximal flow rate, the chance of subjective success 
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increased with a factor 1.3 (Odds Ratio (OR): 1.028; 95%CI: 0.977-1.083). Per 10 
ml/sec increments in maximal flow rate, the change for success increased with 1.7 
(OR: 0.947; 95%CI: 0.804-1.112). A 30% higher baseline bladder voiding efficiency 
score was found to result in 1.7 times more chance for patients to notice success. A 
multivariate analysis combining four urodynamic factors (maximal detrusor pressure, 
maximal flow rate, bladder voiding efficiency, and BCI) revealed a predictive power of 
0.73 (OR: 0.73; 95% CI 0.51, 0.94) (See Figure 1).
Figure 1 Univariate logistic regression analysis of  baseline characteristics to 
calculate predictive value for subjective success
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Side-effects No serious side-effects were reported. Transient pain at the stimulation 
site was noticed. Diarrhoea, headaches, calf cramps and low back pain were 
reported. One patient did not complete the treatment because of aggravating pre-
existent heart rhythm problems. However these adverse effects were considered not 
to be related to PTNS. 
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Discussion
The primary outcome measure was obtained in 41% of all patients (percentage 
based on intention-to-treat). An additional 26% of patients noticed a reduction in 24 
hr total catheterized urine by 25-50%. The total of these 2 figures (67%) is 
comparable with the subjective response rate (59%). Nearly all responders also 
diminished their 24 hr residual volume with more than 25%. PTNS resulted in 15/39 
patients with a mean catheterized volume smaller than 100 ml and even the two 
patients that had zero residual after catheterization, still continue catheterization. 
Presumably these patients wanted to be on the safe side by checking once daily their 
residuals. Since PTNS is a young treatment modality, optimal stimulation parameters 
still have to be searched for. More adequate stimulation specified for voiding 
dysfunctional patients and directly placed on the tibial nerve, could hopefully lead to 
catheterization free results. The intention of this study was to determine more 
objective indicators of a successful outcome, namely, derived from urodynamic 
investigations. The total cystometric capacity in patients did not change at all, most 
patients had a normal bladder capacity before entering the study and this remained 
unchanged.
Surprisingly more DI were detected in patients with voiding dysfunction after the 12 
weekly sessions (from 14 to 37% of patients urodynamically investigated). Perhaps 
DI is an essential feature for a good outcome in PTNS for bladder emptying 
problems; the perception of DI may result in an accentuated awareness of bladder 
filling and this is believed to “train” the complex neural regulation system of voiding. 
Although eight out of the 10 patients with DI considered their treatments as 
successful, the number of participants is too small to draw conclusions from these DI-
related data. Moreover, the value of the presence or absence of DI should be further 
investigated as some even question the whole concept of DI since this phenomenon 
can be seen in asymptomatic persons. 12 This study found improvement in detrusor 
pressure at maximal flow, maximal flow rate, cystometric residual volume and 
bladder indices. The BCI increased for most participants but left the main part of 
patients in the “weak detrusor” classification, suggesting that PTNS is not acting 
strongly on the detrusor muscle itself. Unfortunately EMG records of the pelvic floor 
and urethral striated sphincter were not available, it might be possible that PTNS also 
improves the detrusor-sphincter coordination. Uni- and multivariate analysis revealed 
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no spectacular results: participants with only minor voiding dysfunction were more 
prone to be successful. It seems therefore that patients with minimal voiding 
dysfunction are good candidates for PTNS. PTNS results in improved voiding 
parameters, higher quality of life and a high subjective response rate.
PTNS is believed to relieve symptoms related to bladder over- and underactivity, a 
phenomenon also seen in Sacral Nerve Stimulation SNS. 5,13-15 The underlying 
neurophysiological mechanisms of such a bi-polar effect have not yet been 
elucidated. The result achieved by SNS returns to baseline values after switching off 
the device, as opposed to long-term effect of a few weeks after stimulation by PTNS. 
5,15,16 Schultz-Lampel et al. 17 confirmed by cat experiments the hypothesis of a 
rebound phenomenon as mechanism of action for induction of spontaneous voiding 
in patients with chronic retention.
The long-term effect through PTNS could be explained by the carry-over effect found 
in cat experiments where a 5-min stimulation of afferent nerves resulted in more than 
1 hr lasting effect. 18 In rats, PTNS exerted its influence on c-fos expression 
suggesting neuromodulating action. 19 Presumably the combination of needling 
(resulting in a higher concentration of certain neurotransmitters), bladder retraining 
by completing voiding charts and induction of DI in some patients, and to some 
extent the attribution of a placebo-effect (meeting fellow sufferers, having a very 
intensive guidance and attention given by medical care-givers) finally results in a 
higher voiding efficacy.
PTNS is a cheap treatment modality, minimally invasive, and with a simple 
accessible stimulation site. However, in daily practise some logistic problems 
appeared, PTNS is a time consuming procedure both for clinicians and for patients. 
Positive responders need to have PTNS on a regular basis, hereby occupying 
precious out patient clinical time to treat new patients. Most investigators limit the 
number of sessions for this reason. In our clinic we started to train positive 
responders how to insert the needle themselves and how they can apply the 
stimulator at home. Besides more basic research investigating optimal parameters, 
development of an implantable stimulator might be very useful and every effort to 
conduct a placebo controlled or sham study should be encouraged.
In conclusion,  PTNS is an attractive young treatment modality for patients with minor 
chronic voiding disorders, requiring further research to establish optimal stimulation 
parameters.
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Prognostics and maintenance 
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Abstract
Objective In sacral as well as tibial nerve stimulation test stimulation is the main 
prognostic factor for success. In our study we tried to identify prognostic patient 
characteristics to improve patient selection for neuromodulation therapy.
Patients and methods PTNS was applied to 132 patients in 8 study centers (51 
men, 81 women, mean age of 53 years (range: 21-82)). 83 patients were treated for 
overactive bladder, 16 for non-obstructive urinary retention and 33 for chronic pelvic 
pain. All patients had to fill out micturition or pain diaries, as well as quality of life 
questionnaires before and after treatment. Patient characteristics were evaluated for 
their prognostic value for successful outcome of neuromodulation therapy with use of 
logistic regression.  
Results Objective success was seen in 32.6% of patients, subjective success in 
51.5%. Most evaluated clinical parameters proved not to be of prognostic value. A 
history of sexual and/or physical abuse was found in 12 of 103 interviewed patients, 
but did not alter PTNS treatment outcome. 
However, a low total score at baseline in the SF-36 questionnaire proved to be 
predictive for not obtaining objective (OR 0.444 [95% CI: 0.198-0.996], p=0.04) or 
subjective success (OR 0.424 [CI: 0.203-0.887], p=0.02). Especially patients with a 
low SF-36 Mental Component Summary were prone to fail neuromodulation therapy: 
OR 0.123 (95% CI: 0.273-0.552), p=0.006 for objective success. These patients also 
scored worse on disease-specific quality of life questionnaires, although they had no 
different disease severity compared to patients with good mental health. 
Conclusions Bad mental health as measured with the SF-36 Mental Component 
Summary does not depend on symptom severity and is a negative predictive factor 
for success of percutaneous tibial nerve stimulation. It therefore might be used as a 
tool for better patient selection in neuromodulation therapy.
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Introduction
In Sacral Neurostimulation (SNS), the result of Percutaneous Nerve Evaluation 
(PNE) prior to definitive implantation is the most important prognostic factor for 
success. Efforts to establish other predictive parameters were not very successful, 
why at present most is expected from refining the PNE technique. Likewise in 
Percutaneous Tibial Nerve Stimulation (PTNS), the justification of chronic treatment 
(e.g. by implantation of a subcutaneous stimulation device) is also evaluated through 
test stimulations. In our study we tried to identify prognostic patient characteristics to 
improve patient selection for neuromodulation therapy in the future.
Patients and methods 
Patients After approval of the ethical committee, PTNS was applied to 132 patients 
in 8 study centers. The study group consisted of 51 men and 81 women, with a mean 
age of 53 years (range: 21-82). Mean age of men (53.2 years, range: 21-79) and 
women (53.2 years, range: 23-82) did not differ significantly. Sixteen patients (7 
male, 9 female) were treated for non-obstructive urinary retention, 33 (21 male, 12 
female) for Chronic Pelvic Pain (CPP) and 83 (23 male, 60 female) for Overactive 
Bladder (OAB). Median duration of lower urinary tract complaints was 4 years (range: 
1-56). No statistical significant differences in median duration of symptoms were 
seen between sexes or treatment indications. Physical examination did not show 
overt (neurourological) abnormalities in any of these patients. More detailed patient 
characteristics are given in table 1. 
Method of treatment PTNS was applied according to Stoller and Govier. 1,2 A 34 
gauge needle percutaneously inserted approximately 3-4 cm cephalad to the medial 
malleolus and a stick-on electrode placed on the same leg near the arch of the foot 
were used for electrical stimulation with an adjustable pulse intensity (0-10 mA), a 
fixed pulse width of 200 ?sec and a frequency of 20 Hz. The stimulator contained a 
battery of 9 V (Urgent PC?, CystoMedix, Anoka, MN, USA). When an adequate 
motor response, mostly accompanied by a specific sensory response, was obtained,
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Table 1 Patient characteristics 
stimulation current was set at a well-tolerable level. Patients underwent 30-minutes 
outpatient treatment sessions weekly for a period of 12 weeks. In case of sufficient 
improvement of their lower urinary tract symptoms patients were offered chronic 
treatment.
Evaluation of results After informed consent, all patients had to fill out micturition or 
pain diaries as well as general (SF-36 3) and disease-specific quality of life 
questionnaires (McGill Pain Questionnaire Dutch Language Version 4 and (adjusted) 
I-Qol 5) at study entry and at completion of treatment at 12 weeks. Furthermore, 
patient characteristics at baseline were collected as history of complaints, earlier 
treatment modalities, weight and Body Mass Index. To determine a history of sexual 
All OAB CPP NOUR 
N=132 N=83 N=33 N=16 
Men/women 51/81 23/60 21/12 7/9
Mean age 1 53.3 (21-82) 54.1 (21-82) 51.9 (25-79) 51.3 (25-68) 
Median history 1 4 (1-56) 4 (1-56) 4 (2-30) 3 (1-36) 
Previous medications 2 2 (0-5) 2 (0-5) 2 (1-4) 1 (0-2) 
Previous operations 2 0 (0-3) 0 (0-3) 0 (0-2) 0 (0-1) 
Previous physiotherapy 60 (45.5%) 39 (47.0%) 18 (54.5%) 3 (18.8%) 
Previous electrotherapy 18 (13.6%) 9 (10.8%) 8 (24.2%) 1 (6.3%) 
     
Frequency 3  15.0 (4-41)   
Incontinence episodes 3   6.4 (0-22)   
Catheterizations 3    4.9 (2-10) 
VAS for Pain 4   64.9 (22-100)  
     
I-Qol 4  60.8 (22-100)   
Adjusted I-Qol 4    81.8 (38-100) 
PRI-total (McGill) 4   21.7 (5-50)  
     
Mean stimulation 5 3.4 (1.3-7) 3.4 (1.4-6.8) 3.1 (1.3-5.5) 3.7 (1.3-7) 
     
Subjective response 51.5% 55.4% 32.4% 50% 
Objective response 32.6% 37.3% 24.2% 25% 
OAB = Overactive Bladder, CPP = Chronic Pelvic Pain, NOUR = Non-obstructive Urinary retention, VAS = Visual analogue 
Scale, I-QoL = Incontinence Quality of Life, PRI = Pain Rate Intensity, 1years (range), 2number (range), 3mean number/24 
hours (range), 4mean score (range), 5mA (range) 
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and/or physical abuse, patients were interviewed by their investigating urologist 
according to a standardized question form. Also parameters as stimulation intensity 
and center of treatment were evaluated. 
Subjective response was defined as the request of patients for continuous chronic 
treatment to keep the obtained response, objective success as a decrease in 
symptoms (i.e. number of voids/24 hours, number of incontinence episodes/24 hours, 
number of catherizations/24 hours or score on the Visual Analogue Scale for pain) of 
over 50%.
Within-group analysis of results were conducted by the non-parametric Wilcoxon 
signed ranks test for two related samples,  subgroup analysis  by the non-parametric 
Mann-Whitney U-test for two independent samples. Patient characteristics were 
evaluated for their prognostic value for successful outcome of neuromodulation 
therapy with use of logistic regression (Odds ratio,  95% Confidence Interval, (OR 
[95% CI]). Tests were performed on a two-tailed basis and the level of significance 
was set at 5%. Statistical analysis was performed using Statistical Package for the 
Social Sciences version 9.0 software (SPSS, Chicago, ILL, USA). 
Results
Objective success was seen in 32.6% of all patients, subjective success in 51.5%. 
For OAB these figures were 37.3% and 55.4%, for CPP 24.2% and 42.4% and for 
non-obstructive urinary retention 25% and 50%, respectively. Gender, age, weight, 
Body Mass Index, indication for PTNS, duration of complaints, number and kind of 
treatments used before, PTNS study center and stimulation parameters all 
statistically proved not to be of prognostic value. The same goes for number of 
incontinence episodes per 24 hours, frequency per 24 hours, number of 
catheterizations per 24 hours, pain intensity (Visual Analogue Scale for pain) and 
total scores at the (adjusted) I-QoL and McGill disease-specific quality of life 
questionnaires.
As one study center did not wish to participate in the collection of data on a possible 
history of sexual and/or physical abuse (SPA), only data on 103 patients were 
available (table 2). Of these 103 patients, 12 (11.7%) confirmed a history of abuse. 
Sexual abuse was more likely to have serious impact on patients’ lives at present 
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(87.5%), compared to cases in which only physical abuse was involved (25%, 
p<0.05). Nevertheless, a history of sexual and/or physical abuse did not negatively 
influence PTNS treatment results.   
Table 2 Patient characteristics of victims of sexual and/or physical abuse  
Sex Age
(years) 
Form of  abuse Age at onset 
sexual abuse 
Current impact 
of abuse 
Form of
LUTD
Subjective
Response
Objective  
Response
Patient 1 M 40 Physical No Pain No No
Patient 2 M 30 Physical  No OAB No  Yes 
Patient 3 M 57 Physical  Yes OAB Yes No 
Patient 4 F 74 Physical  No OAB No No 
Patient 5 M 61 Sexual 18 Yes OAB No No 
Patient 6 F 29 Sexual 8 Yes OAB Yes Yes 
Patient 7 F 43 Sexual 18 No OAB Yes No 
Patient 8 F 54 Sexual 12 Yes OAB No No 
Patient 9 F 53 Sexual Not known Yes Retention No No 
Patient 10 M 49 Physical/sexual 10 Yes Pain Yes Yes 
Patient 11 F 25 Physical/sexual 11 Yes Pain No No 
Patient 12 F 48 Physical/sexual 7 Yes Retention Yes Yes 
When evaluating the SF-36 questionnaires, a low total score at baseline (? 50 out of 
a maximum of 100 points) proved to be predictive for not obtaining objective (OR 
0.444 [95% CI: 0.198-0.996], p=0.04) and/or subjective success (OR 0.424 [95% CI: 
0.203-0.887], p=0.02). The SF-36 questionnaire can also be divided in Physical and 
Mental Component Summaries (PCS and MCS). The PCS did not prove to be of 
prognostic value, but patients with a low MCS (? 30 out of a maximum of 50 points) 
were very likely to objectively fail neuromodulation therapy (OR 0.123 [95% CI: 
0.273-0.552], p=0.006) (table 3). Although disease-specific qualily of life questionnai 
res themselves proved not to be of prognostic value, OAB and CPP patients with a 
low MCS scored significantly worse on the I-Qol and McGill questionnaires 
respectively. In OAB patients with a low MCS the I-QoL score was 46.5 +/- 13.69 
versus 64.69 +/- 19.51 in patients with a good mental health (the higher, the better, 
p<0.005). CPP patients with a MCS ? 30 scored a total Pain Rate Intensity on the 
McGill questionnaire of 32.63 +/- 6.02 versus 16.25 +/- 8.58 for CPP patients with a 
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high MCS (the lower, the better, p<0.05). However, patients with a bad mental health 
had no statistical worse disease severity when measured by number of voids, 
incontinence episodes, catherizations or the VAS for pain. 
Table 3 Prognostic value of tested parameters
Parameter Subjective response Objective response 
 (OR (95% CI) significance) (OR (95% CI) significance) 
Gender (male/female) 0.748 (0.370-1.509) ns 0.729 (0.341-1.560) ns 
Age (?70/>70 years) 1 2.917 (0.865-9.832) ns 1.267 (0.373-4.305) ns 
Weight (?70/>70 kg) 1 0.915 (0.398-2.101) ns 0.754 (0.313-1.817) ns 
Body Mass Index (<25/?25) 1 0.821 (0.362-1.862) ns 0.846 (0.357-2.003) ns 
Duration of complaints (<1/?1 year) 1 0.698 (0.227-2.143) ns 0.584 (0.151-2.251) ns 
   
Previous medication (y/n) 0.349 (0.065-1.872) ns 0.740 (0.137-3.988) ns 
Previous operations (y/n) 0.972 (0.477-1.978) ns 0.547 (0.257-1.165) ns 
Previous physiotherapy (y/n) 1.110 (0.555-2.220) ns 1.058 (0.504-2.218) ns 
Previous electrotherapy (y/n) 0.912 (0.336-2.474) ns 0.678 (0.224-2.049) ns 
Previous alternative therapies (y/n) 0.759 (0.335-1.722) ns 0.499 (0.194-1.280) ns 
   
Indication (OAB/rest) 1.526 (0.750-3.104) ns 1.991 (0.902-4.398) ns 
Indication (CPP/rest) 0.614 (0.277-1.361) ns 0.549 (0.223-1.347) ns 
Indication (retention/rest) 1.071 (0.377-3.048) ns 1.603 (0.484-5.303) ns 
VAS score in CPP (?50/>50)1 0.667 (0.135-3.303) ns 1.056 (0.167-6.679) ns 
Frequency in OAB (?8/>8)1,2 1.000 (0.999-1.001) ns 1.000 (0.999-1.002) ns 
Incontinence in OAB (?3/>3)1,2 1.161 (0.697-1.935) ns 1.746 (0.610-5.000) ns 
CIC in retention (?4/>4)1,2 2.222 (0.280-17.63) ns 2.750 (1.258-6.010) ns 
PRI-totaal in CPP (?30/>30)1 1.001 (0.999-1.002) ns 1.000 (0.998-1.002) ns 
I-QOL in OAB (?50/>50)1 2.071 (0.724-5.927) ns 0.752 (0.256-0.212) ns 
I-QOL in retention (?50/>50)1 1.000 (0.999-1.001) ns 1.000 (0.997-1.002) ns 
   
SF-36 total score (?50/>50) 0.424 (0.203-0.887) p=0.02 0.444 (0.198-0.996) p=0.04 
SF-36 PCS (?30/>30) 1.719 (0.779-3.797) ns 1.797 (0.746-4.328) ns 
SF-36 MCS (?30/>30) 1.835 (0.771-4.372) ns 0.123 (0.273-0.552) p=0.006 
OR = Odds Ratio, CI = Confidence Interval, Ns= not significant, y/n = yes/no, OAB = Overactive Bladder, CPP = Chronic 
Pelvic Pain, VAS = Visual Analogue Scale (?100), CIC = Clean Intermittent Catheterization, I-QOL = Incontinence Quality Of 
Life (?100), PRI = Pain Rate Intensity (McGill) (?50), PCS = Physical Component Summary (?50), MCS = Mental Component 
Summary (?50), 1other border values were also tested, proven not significant as well, and therefore not shown in this table, 
2number/episodes per 24 hours 
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Discussion
To refine the PNE technique, the results of which mainly determine the success of 
SNS, the two-stage procedure 6 is developed. In this procedure, a permanent lead is 
implanted and temporarily connected to an external stimulator for an evaluation 
period of 4 days. Subsequently, a permanent subcutaneous stimulator is implanted in 
case of success. In patients considered a failure of conventional PNE-testing, an 
improvement of 60-90% could be achieved by the two-stage procedure.
Various clinical parameters were evaluated for their prognostic value. However, age, 
duration of complaints, number and kind of former treatments, indication for 
neuromodulation therapy and different neurostimulation parameters were not proven 
to be predictive for treatment outcome. 7-9 Although some studies suggest the 
opposite 7,10, overall, neither gender seems to influence treatment outcome. 8,9 The 
only factor rather consistently reported to predict poor treatment outcome is the 
history or presence of psychological disorders or poor mental health. 9,11,12
As PTNS is a relatively new neuromodulation modality, only scarce data are 
available on parameters influencing its therapy success. Therefore, as in SNS, trial 
sessions are recommended to evaluate the justification of maintenance therapy. 
Especially regarding the development of a subcutaneous implant 13, accurate 
prognostic parameters to predict success of treatment minimizing unnecessary 
laborious trial sessions will be helpful.  
In our recent international multicenter studies on PTNS, overall baseline urodynamic 
features failed to reach statistical significant predictive power in univariate analysis. 
14,15 This may be due to rather small study groups. Nevertheless, in OAB patients it 
was strongly suggestive that patients with detrusor instability (DI) do worse on PTNS 
compared to those with stable bladders, as did patients with low bladder volumes at 
DI or with very small bladder capacity at baseline. 14 In patients with voiding 
dysfunction only multivariate analysis combining maximal detrusor pressure, maximal 
flow rate, bladder voiding efficacy and bladder contractility index at baseline showed 
statistical significant predictive power. 15
In this study on various clinical parameters in a much larger group of patients, most 
parameters did not influence the outcome of neuromodulation therapy. This is in 
concordance with what is known in SNS 16 and earlier studies on PTNS. 17,18 It 
means that old patients, patients with severe symptoms and patients with a long 
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history of complaints should not be ruled out for therapy, like patients with a high 
Body Mass Index, because even in those patients the tibial nerve can well be 
reached for stimulation. Stimulation intensity probably is not of prognostic value 
because high intensity parameters are more indicative for less well positioning of the 
stimulation needle than for actual higher stimulation of the nerve itself. Although it is 
generally accepted that OAB and non-obstructive urinary retention are better 
indications for neuromodulation than CPP, in this study the actual indication for 
therapy proved not to be a prognostic factor, possibly caused by the relatively small 
number of patients with non-obstructive urinary retention and CPP respectively.  
Our earlier studies revealed success rates up to 70% 17,18, much higher than was 
found here. It should be mentioned that those studies were performed in only a few 
high volume centers. The data presented in this paper are pooled data from our own 
center with those from several low volume hospitals in the Netherlands, that all 
performed PTNS using the same protocol. Results in this added centers were worse, 
although not statiscally significant. Nevertheless, these low success rates emphasize 
the need for pre-PTNS selection criteria investigated in our study to increase overall 
success rates and decrease the number of unnecessarily treated patients. 
In our selected group of patients, almost 12% admitted a history of sexual and/or 
physical abuse. For the Dutch population comparable figures are only available from 
patients for the first time visiting a gynecological outpatient clinic, revealing former 
sexual abuse in 15.4% and physical abuse in 7.4% of patients. Whether there was 
some degree of overlap was not mentioned. 19 Comparison of our data with general 
data from the Dutch population is hampered by major discrepancies between 
frequencies found in national registration systems, surveys in an open population and 
studies in general practice, respectively. 20 Data of few international reports dealing 
with former SPA are neither useful to evaluate our findings as they are mainly 
restricted to patients with CPP in which prevalences of sexual abuse merely may be 
as high as 64%. 21,22 Despite what one might expect however, a history of SPA did 
not influence the chances for a successful outcome of PTNS in a negative way, not 
even in patients still experiencing consequences of this abuse at present. 
Nevertheless, the results of our study corroborates with general clinical experience 
that patients who mentally suffer the most from their complaints are less susceptible 
to successful outcome of treatment. These patients proved not to have more severe 
symptoms, but they considered their disease-specific quality of life worse than did 
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patients with good mental health. Whether bad mental health is caused by the 
complaints or contributes to their origin remains unanswered, but measuring mental 
health with the SF-36 Mental Component Summary may be a useful tool for better 
patient selection for neuromodulation therapy. We recommend further studies on this 
particular issue to reaffirm our findings so that in the future patients with bad mental 
health can be informed about the poor chances for success or even can be excluded 
from neuromodulative therapy.
Conclusions
Bad mental health is a negative predictive factor for success of percutaneous tibial 
nerve stimulation and depends not on symptom severity. As the same was 
suggested in an earlier study on sacral neurostimulation, the SF-36 Mental 
Component Summary might be used as a tool for better patient selection in 
neuromodulation therapy.
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Abstract
Objective To determine the effect of pausing Percutaneous Tibial Nerve Stimulation 
(PTNS) in successfully treated patients and the reproducibility of successful 
treatment.
Patients and methods 11 patients (mean age 51 years) with refractory overactive 
bladder syndrome (> 7 voids and/or > 3 urge incontinence episodes per day) were
successfully treated with PTNS and continued treatment. Patients filled out bladder 
diaries and quality of life questionnaires (SF-36 and I-QoL) before (T1) and after a 6-
week pause (T2) of maintenance PTNS and again after re-treatment (T3). The first 
objective was defined as > 50% increase of the number of incontinence episodes 
and/or micturition frequency on bladder diary after the 6-week pause of maintenance 
PTNS. The second objective was defined as a > 50% reduction of the number of 
incontinence episodes and/or micturition frequency on bladder diary after re-
treatment.
Results At T2, 7/11 patients (64%) had a > 50% increase of the number of 
incontinence episodes and/or micturition frequency on bladder diary after the 6-week 
pause of maintenance PTNS. Mean voided volume, nocturia, number of incontinence 
episodes and incontinence severity had significantly (p<0.05) deteriorated. At T3, 
9/11 patients (82%) had a > 50% reduction of the number of incontinence episodes 
and/or micturition frequency on bladder diary after re-treatment. Nocturia, number of 
incontinence episodes, incontinence severity, mean voided volume and quality of life 
had significantly (p<0.05) improved. 
Conclusions Continuous therapy is a necessity in successfully PTNS treated 
patients. The efficacy of PTNS can be reproduced in formerly successfully treated 
patients.
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Introduction
Percutaneous Tibial Nerve Stimulation (PTNS) is an alternative therapy for refractory 
non-neurogenic lower urinary tract dysfunction. 1 After successful treatment patients 
are put on maintenance therapy. 2 So far there have been no reports on long-term 
results in treatment of patients with overactive bladder syndrome (OAB), nor are any 
data available on the effect of prolonged interruption of the maintenance treatment, 
nor concerning the question if the efficacy of the therapy can be reproduced.
The present study was performed to evaluate the effect of prolonged interruption of 
the maintenance therapy on the complaints of patients with overactive bladder 
syndrome. A second goal was to investigate whether the efficacy of the therapy can 
be reproduced. 
Patients and methods 
Methods Between November 2003 and January 2004, 11 patients were enrolled in a 
clinical trial. Patients were evaluated at the outpatients’ clinic for overactive bladder 
syndrome (OAB) by history and physical and urological examination, including 
urodynamic evaluation. Methods, units and definitions used in this study meet the 
standard recommended by the International Continence Society, 3 except for the 24-
hour bladder diaries. 4 These bladder diaries are sufficient to evaluate the patients’ 
micturition complaints. 5-7
OAB was defined as more than 7 voids per day and/or a sudden insuppressibly urge 
to void, culminating in urinary leakage at least 3 times per day on bladder diary. All 
medication that could influence bladder function was stopped at least 2 weeks before 
treatment or continued without dosage changes during the entire study. Specific 
exclusion criteria for PTNS as described by van Balken et al. were used (see table 
1). 1
Patients All patients, 5 men and 6 women with a mean age of 51 years (range 33-
66), were diagnosed with OAB (2 patients had urgency/frequency syndrome and 9 
patients had urge urinary incontinence). All patients were refractory to conservative 
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Table 1 Exclusion criteria 
Younger than 18 years 
Symptoms existing for less than 6 months 
Pregnancy or intention to become pregnant during the course of the study 
Active urinary tract or recurrent urinary tract infection  (5 or more recurrent infections during the last 12 months), 
carcinoma in situ, bladder malignancy, interstitial cystitis 
Bladder or kidney stone 
Severe cardiopulmonary disease 
Use of pentosan polysulfate sodium or bladder installations, including dimethyl sulfoxide, Bacillus Calmette-Guerin,  
chloropectin or heparin 
Uncontrolled diabetes 
Diabetes with peripheral nerve involvement 
Neurological disease like multiple sclerosis, Parkinson’s disease, cerebrovascular accident, bifid spine or spinal 
cord lesion 
Physiotherapy during the study 
Bladder outlet obstruction (Abrams-Griffiths nomogram) 
Transurethral instrumentation 4 weeks or less before or during the study 
treatment. Oral medication was unsuccessful in all and patients had had mean 3 
prescriptions (range 1-8) for their complaints. Mostly anticholinergics, alpha-blockers, 
antidepressants, antibiotics, and desmopressin were prescribed. 6 patients were 
treated with physiotherapy or bladder training, 5 with sacral nerve stimulation and 4 
with other treatments, all unsuccessfully. 4 patients had had unsuccessful surgical 
treatment (range 1-2 operations). The performed surgical therapies were 
colposuspension, urethra dilatation, bladder distension, bulk injections and 
transurethral resection of the prostate.
All patients were previously successfully treated with PTNS (> 50% reduction of 
incontinence episodes and/or micturition frequency on bladder diary) and had 
continued treatment. 5 patients had maintenance PTNS in an outpatients setting, and 
all were diagnosed with urge urinary incontinence. 6 patients performed self-
administrated home treatment, either by transcutaneous stimulation with 2 surface 
electrodes (5 patients) or percutaneous tibial nerve stimulation (1 patient). Of these 
patients 4 were diagnosed with urge urinary incontinence and 2 patients with 
urgency/frequency syndrome. Maintenance therapy was performed during a mean 
period of 13 months (range 1-36 months). 
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Method of treatment All patients paused maintenance PTNS for a period 6-week, 
and were re-treated after this period in outpatients’ setting. PTNS was performed as 
described by van Balken et al. 1 A low-voltage (9V) stimulator (Urgent-PCTM,
CystoMedix Inc, Anoka, MN, USA) was used. The stimulator had an adjustable 
stimulation intensity 0-10 mA and fixed stimulation parameters: pulse width 200 
microseconds, stimulation frequency 20 Hz.  All patients had a sensory response to 
the stimulation: a radiating sensation at the sole of the foot and in the toes. 
Stimulation at the intensity of the motor response was too painful for almost all 
patients, so the current was set at a well-tolerable level resulting in the sensory 
response. If patients had adapted to the stimulation the current was adjusted, usually 
as soon as the sensation faded away. Patients were treated with 30-minute treatment 
sessions 3 times a week during a 4-week period. PTNS was performed on Monday, 
Wednesday and Friday of each week. 
Evaluation of results At baseline (before the 6-week pause of maintenance PTNS, 
T1) patients were evaluated by 24-hour bladder diaries, as well as general (36-item 
short-form health survey, SF-36) 8 and disease specific quality of life (incontinence-
specific quality of life assessment, I-QoL) questionnaires. 9 This procedure was 
repeated after the 6-week pause (T2), and after PTNS re-treatment (T3). In the 
bladder diary micturition frequency, voided volume (cc), number of incontinence 
episodes, severity of urine loss and the number of used pads were recorded. The 
severity of urine loss was described on a scale of 0-3 (i.e. 0– no urine loss, 1– loss of 
some drops, 2– loss of small amount and 3– change of clothes due to urine loss).
The first objective was defined as > 50% increase of the number of incontinence 
episodes and/or number of voids on bladder diary after the 6-week interruption of the 
maintenance PTNS. The second objective was defined as > 50% reduction of the 
number of incontinence episodes and/or number of voids on bladder diary after 
PTNS re-treatment. Comparison of the results before and after pausing maintenance 
PTNS and re-treatment were conducted with the Wilcoxon signed Ranks Test; the 
statistical analysis was performed with commercial software (SPSS version 10, 
Chicago, IL, USA). 
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Results
At T1 (before the 6-week interruption of maintenance PTNS), the patients who 
performed self-administrated home treatment (i.e. self-treatment group, 6 patients) 
tended to have lesser voiding parameters and quality of life compared to the patients 
who received maintenance treatment in an outpatient setting (i.e. outpatient group, 5 
patients) (table 2 and 3). However statistical significance could not be determined 
since the patient groups were too small. 
At T2 (after 6-week pause of maintenance PTNS) 7 out of the 11 patients (64%) met 
the first objective and had > 50% increase of the number of incontinence episodes 
and/or number of voids on bladder diary. 2 patients, who performed self-
administrated home treatment, had a deterioration of their symptoms but did not 
meet the first objective and 2 patients had no change of their symptoms on bladder 
diary, of which 1 performed self-treatment and another had maintenance treatment in 
an outpatient setting. All patients experienced a subjective deterioration of their 
symptoms. There was an objective significant deterioration (p<0.05) of nocturia, 
mean voided volume, and number incontinences episodes and the SF-36 domain 
pain (table 2 and 3).
The self-treatment group tended to still have slightly lesser voiding and quality of life 
parameters, compared to the outpatient group. However, statistical significance could 
again not be determined due to the small patient groups. 
During PTNS a mean pulse intensity of 3.8 mA (range 1.6-7.8) was used. 
Complications of the therapy – minor bleeding or a temporary painful/numb feeling at 
the insertion site or under the sole of the foot – rarely occurred.
At T3 (after PTNS re-treatment) 9 out of the 11 patients (82%)met the second 
objective and had a > 50% reduction of the number of incontinence episodes and/or 
number of voids on bladder diary. 2 patients had no improvement on bladder diary, of 
which 1 patient performed self-treatment and another had maintenance PTNS in an 
outpatient setting. 8 patients (73%) did again subjectively improve and wanted to 
continue the treatment. There was a significant (p<0.05) improvement of nocturia, 
mean voided volume, number of incontinence episodes, incontinence severity, I-QoL 
score and the SF-36 domains physical, role emotional, social function, pain and 
mental health (table 2 and 3).
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At T3 (after PTNS re-treatment) the difference with the data at T1 (before the 6-week 
interruption) tended to be the largest in the self-treatment group. Again statistical 
significance could not be determined due to the small patient groups. 
Table 2 Voiding parameters at T1 to T3 in 11 patients 
Parameters per 24 hour Mean (SD) 
 T1• T2•• T3•••
Number of voids 
   
Home1 12.5 (7.3) 13.0 (8.3) 8.5 (1.9) 
Clinic2 9.2 (2.9) 10.8 (4.1) 10.0 (3.9) 
All patients 11.0 (5.8) 12.0 (6.5) 9.2 (2.9) 
Nocturia    
Home1 1.7 (1.4) 3.7 (4.2) 0.7 (0.5) 
Clinic2 1.0 (0.7) 2.2 (1.3) 0.6 (0.9) 
All patients 1.4 (1.1) 3.0 (3.2)* 0.6 (0.7)* 
Mean voided volume (cc)    
Home1 190.3 (123.3) 95.8 (62.0) 222.0 (124.2) 
Clinic2 174.0 (60.1) 121.6 (37.1) 146.0 (45.4) 
All patients 182.9 (95.5) 107.6 (51.5)*  187.5 (100.6)* 
Number of incontinence episodes    
Home1 1.3 (2.4) 3.5 (4.5) 1.0 (1.5) 
Clinic2 2.6 (2.7) 12.0 (16.8) 5.6 (6.4) 
All patients 1.9 (2.5) 7.4 (12.0)* 3.1 (4.9)* 
Incontinence severity3    
Home1 0.3 (0.5) 1.2 (1.2) 0.8 (0.5) 
Clinic2 1.0 (0.7) 1.4 (0.5) 0.6 (0.5) 
All patients 0.6 (0.7) 1.3 (0.9) 0.6 (0.5)* 
Number of used pads    
Home1 1.5 (2.0) 2.2 (2.9) 0.7 (1.5) 
Clinic2 2.0 (1.0) 3.6 (2.4) 2.6 (1.5) 
All patients 1.7 (1.6) 2.8 (2.6) 1.6 (1.5)* 
•Baseline, ••After 6-week pause of maintenance PTNS, •••After PTNS-retreatment, *p<0.05, 16 patients who performed self-
administrated maintenance PTNS at home, 25 patients who had maintenance PTNS in an outpatient setting, 30= no urine 
loss, 1= loss of some drops, 2= loss of small amount and 3= change of clothes due to urine loss 
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Table 3 Quality of life parameters at T1 to T3 in 11 patients 
Parameters per 24 hour Mean (SD) 
 T1• T2•• T3•••
SF-36 Physical 
   
Home1 80.8 (16.9) 75.8 (28.4) 96.7 (4.1) 
Clinic2 79.0 (21.0) 70.0 (22.1) 81.0 (19.5) 
All patients 80.0 (5.4) 73.2 (7.4) 89.5 (4.5)* 
SF-36 Role physical    
Home1 62.5 (49.4) 45.8 (51.0) 95.8 (10.2) 
Clinic2 55.0 (51.2) 55.0 (51.2) 70.0 (44.7) 
All patients 59.1 (14.4) 50.0 (14.7) 84.1 (9.7) 
SF-36 Role emotional    
Home1 94.5 (13.6) 61.1 (39.0) 94.5 (13.6) 
Clinic2 73.3 (43.5) 66.8 (40.8) 93.3 (14.9) 
All patients 84.9 (9.4) 63.6 (11.4) 93.9 (4.1)* 
SF-36 Social function    
Home1 66.7 (20.4) 58.3 (30.3) 81.3 (19.0) 
Clinic2 75.0 (23.4) 50.0 (15.3) 80.0 (14.3) 
All patients 70.5 (6.4) 54.5 (7.2) 80.7 (4.9)* 
SF-36 Pain    
Home1 79.5 (27.9) 64.3 (30.7) 82.8 (18.8) 
Clinic2 73.4 (30.6) 51.2 (16.8) 75.0 (25.4) 
All patients 76.7 (8.4) 58.4 (7.6)* 79.3 (6.4)* 
SF-36 Mental health    
Home1 61.3 (12.08) 58.0 (18.5) 72.0 (13.4) 
Clinic2 72.0 (17.2) 69.6 (16.4) 80.0 (14.7) 
All patients 66.2 (4.6) 63.3 (5.4) 75.6 (4.2)* 
SF-36 Vitality    
Home1 60.0 (23.2) 46.7 (24.2) 67.5 (12.9) 
Clinic2 65.0 (25.5) 67.0 (20.8) 71.0 (20.4) 
All patients 62.3 (7.0) 55.9 (7.3) 69.1 (4.8) 
SF-36 General health    
Home1 61.8 (27.8) 56.0 (24.1) 66.3 (12.6) 
Clinic2 64.4 (14.1) 58.4 (26.5) 66.2 (20.5) 
All patients 63.0 (6.5) 57.1 (7.2) 66.3 (4.7) 
I-QoL    
Home1 67.3 (19.7) 61.0 (15.9) 88.0 (15.7) 
Clinic2 80.2 (14.7) 67.0 (23.7) 77.8 (18.3) 
All patients 73.2 (18.1) 63.7 (19.0) 83.4 (16.9)* 
•Baseline, ••After 6-week pause of maintenance PTNS, •••After PTNS-retreatment, *p<0.05, 16 patients self-administrating 
maintenance PTNS at home, 25 patients who had maintenance PTNS in an outpatient setting 
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Discussion
The present study stresses that maintenance treatment is a necessity in successfully 
PTNS treated patients. All patients had subjective and 9 out of 11 patients an 
objective deterioration of complaints after the 6-week pause of maintenance therapy. 
Moreover, there was a significant deterioration of mean voided volume, nocturia, 
number of incontinence episodes and quality of life (table 2 and 3). The observation 
that not all parameters did significantly change is obviously caused by the small 
patient population. Furthermore, 2 patients did not respond to the interruption of 
maintenance PTNS or re-treatment. In retrospect, PTNS was probably not effective 
in these patients.
Another explanation could be that 6 out of the 11 patients who performed self-
administrated home therapy – either percutaneous or transcutaneous tibial nerve 
stimulation – could have done this suboptimally. This is supported by the tendency 
that the voiding and quality of life parameters of the self-treatment group seemed to 
be lesser than the outpatient group. Moreover, the difference between the voiding 
and quality of life parameters at T1 and T3 seemed to be the larger for the self-
treatment group than for the outpatient group, however not significant.
The difference between both groups was to be expected, since all patients of the 
self-treatment group, except one, performed transcutaneous maintenance PTNS. Up 
till now, no comparing study has been performed to determine whether 
transcutaneous stimulation is as effective as percutaneous treatment. PTNS seems 
to be more effective, since the electrical field is created between a stick-electrode 
and a needle, which is close to the tibial nerve. Low currency is needed for the motor 
response (flexing the big toe and/or fanning of the other toes) and sensory response 
(a radiating sensation is felt at the sole of the foot and in the toes) to occur. In the 
case of transcutaneous stimulation, the electrical field is created between two surface 
stick-electrodes. The current has to overcome the impedance of the skin before it has 
its effect on the tibial nerve. Therefore, is in theory, for transcutaneous stimulation a 
larger current needed to evoke the motor and sensory responses compared to the 
percutaneous needle stimulation. When larger amplitude is applied, more afferent 
nerves located in the skin are recruited and stimulated, which can lead to a painful 
sensation. This could result in suboptimal stimulation when patients stimulate 
themselves at a well-tolerable level.
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Our results have implications beyond the basic idea that maintenance therapy is 
indispensable to keep up positive clinical results. Obviously, such maintenance 
programs put great strains on caregivers and hospital facilities. Each patient that is 
put on a maintenance schedule will visit the outpatients department at least 20 to 30 
times per annum. This problem was the basis for new developments in the field of 
tibial nerve stimulation. Currently clinical work is undertaken to develop an 
implantable device that allows a patient to stimulate himself at home as frequently as 
the individual situation requires. In prospect, this implantable device will lessen the 
burden on medical professionals and institutions. 
Conclusions
Maintenance treatment is to be a necessity in successfully PTNS treated patients, 
since they experience a subjective an objective deterioration of their complaints when 
it is not provided. The efficacy of PTNS is reproducible in these patients.   
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Abstract
Objective To investigate feasibility and safety of implant driven tibial nerve 
stimulation.
Patients and Methods 8 patients with refractory overactive bladder (OAB) were 
successfully treated with Percutaneous Tibial Nerve Stimulation and implanted. 
Patients were evaluated with bladder diaries, quality of life questionnaires, and 
physical examination before implantation, and at 3, 6 and 12 months of follow up. 
The primary objective was > 50% reduction of the number of incontinence episodes 
and/or voids on bladder diary. The Wilcoxon Signed Ranks Test was used.
Results At 3, 6 and 12 months respectively 5, 6 and 4 patients met the primary 
objective. At 3 and 6-month follow up voiding and quality of life parameters had 
significantly (p<0.05) improved. Urinary tract infection, temporarily walking difficulties, 
and spontaneous radiating sensations were reported as adverse events and no local 
infection, erosion or dislocation.
Conclusions Implant driven tibial nerve stimulation seems to be feasible and safe.
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Introduction
Overactive bladder syndrome (OAB, overactive bladder wet and dry) is a common 
urological problem in many countries. It has been estimated that OAB affects 
approximately 17% of the adult population in Europe and the United States 1,2, with 
an estimated worldwide prevalence of 50-100 million. 3 The economic burden of OAB 
can only be estimated since the disorder is underreported and often overlooked by 
physicians. 4 Total annual costs, including treatment and diagnosis, absorbent 
products, related medical conditions, assisted living or nursing home care, lost wages 
and cleaning expenses are estimated to range from $16 billion to $26 billion each 
year in the United States, depending on the studied age group. 5,6 In the future the 
impact of OAB will probably increase even further, since the world population is aging 
4 and the prevalence increases with age. 7
OAB is initially treated with conservative therapy. If refractory, irreversible surgery 
can be advocated. However, this is not widespread due to high recurrence and 
complication rates. 8 Percutaneous Tibial Nerve Stimulation (PTNS) is an alternative 
therapy in the treatment of refractory OAB, with reported clinical success rates of 63-
71%. 8-10 It is known that PTNS maintenance therapy is a necessity in successfully 
treated patients 11, usually once every 2-3 weeks. 9 This is demanding for both 
patients and outpatient departments. Therefore, it would be advantageous if the 
patients themselves at the location and time of their choice could perform 
maintenance therapy. Surface electrodes can be used for tibial nerve stimulation, as 
has been demonstrated by Andrews. 12 However, there are indications 
transcutaneous tibial nerve stimulation may be less effective than percutaneous 
stimulation. 13
Ongoing research has led to the design and development of an innovative 
subcutaneous implant – Urgent-SQTM (CystoMedix Inc., Anoka, MN, USA) – that 
enables self-treatment. This pilot study presents results concerning the feasibility and 
safety at 12 months of follow up in 8 patients with refractory OAB. 
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Patients and methods 
Methods With the approval of the institutional review board 8 patients with refractory 
OAB were enrolled in a prospective pilot study between November 2002 and January 
2004. All patients gave written informed consent to the study. Implantations were 
performed in either November 2003 or January 2004. 
Methods, units and definitions used in this study all conform to the standards 
recommended by the International Continence Society 14, except for the 24-hour 
bladder diary. 15 A 24-hour bladder diary is sufficient to evaluate the patients’ 
micturition complaints. 16-18 OAB was defined as more than 7 voids and/or a sudden 
compelling urge to void, culminating in urinary leakage at least 3 times per 24 hours 
on bladder diary. All medication that could influence bladder function was stopped at 
least 2 weeks before treatment or continued without dose changes during the entire 
study. For this study specific exclusion criteria as described by van Balken et al. were 
used. 8
The primary objective of the study was defined as > 50% reduction of the number of 
incontinence episodes and/or voids on bladder diary after implant driven tibial nerve 
stimulation. Apart from feasibility a secondary objective was to evaluate the safety of 
the implant. 
Patients 2 male and 6 female patients (mean age 56 years, range 46-66) had had 
OAB complaints for a mean period of 10 years (range 1-30) and were enrolled in the 
study. Prior to enrolment, patients were evaluated for OAB by history, physical 
examination and urological examination, including urodynamic investigation. All 
patients had an urodynamic evaluation without abnormalities, except for one patient 
who showed late onset detrusor overactivity. All patients had been unsuccessfully 
treated with conservative treatment. 3 patients had had unsuccessful surgery (range 
1-2 operations) for their symptoms. Colposuspension, Botulinum toxin A injections in 
the bladder and urethral dilatation were performed. All patients had been successfully 
treated with PTNS (> 50% reduction of the number incontinence episodes and/or 
voids on bladder diary).  
Method of treatment PTNS was performed as described by van Balken et al. 8
Patients were treated with 30-minute sessions 3 times a week during a 4-week 
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period. Until implantation no maintenance PTNS was provided for a mean period of 8 
months (range 3-12). 
The Urgent-SQTM consists of an external electromagnetic pulse generator with radio 
frequency (RF) transmission capability (figure 1a) and an internal electromagnetic 
pulse receiver, the body, with two leads and monopolar electrodes, which are 
covered by medical grade silicones with the leads having platinum electrodes (figure 
1b). The electrodes are approximately 1 cm2. The body has a diameter of 
approximately 4 cm and receives RF electromagnetic pulses from the generator 
transforming them into current pulses. Stimulation parameters are: 0-19 mA 
amplitude, 12 or 20 Hz pulse rate and 200 microseconds pulse width. The maximum 
amplitude was not altered during follow up. The pulses are biphasic and symmetrical. 
The 12 Hz pulse rate was chosen, since 1 patient did only respond to PTNS at 12 
Hz. The external stimulator has to be placed directly on the skin over the internal 
body in order to activate it. Therefore, the amplitude will not be influenced by the coil 
position and the internal body will not be activated by other frequency devices, like 
mobile phones. 
Pre- and postoperatively prophylactic oral antibiotics (500 mg amoxicilline) were 
given. Patients were implanted in the supine position and were covered with sterile 
drapes after an antiseptic scrub of the lower leg. After spinal or general anaesthesia 
an incision of 5-7 cm was made approximately 5 cm above the medial malleolus, 
parallel to the tibia. Muscle relaxants were avoided in order not to blur a motor 
response of the foot musculature. After incising the fascia of the flexor tendons the 
electrodes were placed near the neurovascular bundle that contains the tibial nerve, 
without exposing it. The electrodes were parallel placed and the distance between 
them was approximately 1 cm. The internal body was placed in a subcutaneous 
pocket overlying the tibia. During the procedure the implant was activated at regular 
intervals to confirm correct functioning and placement. Similar to percutaneous 
stimulation, hallux flexion can be observed when positioned correctly. If correct 
placement was confirmed the implant was fixed, and the wound was closed.  
Motor and sensory responses were evaluated postoperatively at day 10 and at follow 
up at 3, 6 and 12 months. The responses were tested by a physician, who correctly 
placed the external stimulator and slowly increased the amplitude until the sensory 
response was present. The amplitude was further increased until the motor response 
occurred or to maximum amplitude (19 mA), which was not painful for the patients. 
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There were no limitations to test the responses. Therapy was started at home 
postoperatively at day 10, each session lasting 30 minutes 3 times a week. The 
stimulation was performed at the amplitude resulting n the sensory response and 
adjusted when it had faded, as has been described for PTNS. 8
Patients were evaluated by 24-hour bladder diaries, and quality of life questionnaires:  
SF-36 (social function 19) and I-QoL (index of quality of life 20) before implantation and 
at follow up of 3, 6, and 12 months of implant driven tibial nerve stimulation. Physical 
examination and urinalysis were performed at all visits. X-rays in 2 directions of the 
medial ankle were made 1 day and 1 month postoperatively to verify the position of 
the implant. During follow up no urodynamic evaluations were performed, nor was 
sham stimulation performed, nor were the stimulators turned off. Furthermore, it was 
not possible to determine whether the patients had actually treated themselves, nor 
changed the stimulation frequency and amplitude. 
Changes in the voiding and quality of life parameters were tested on statistical 
significance using the Wilcoxon Signed Ranks Test. 
Results
After cessation of the PTNS treatment in all patients voiding and quality of life 
parameters returned to baseline values as before PTNS.
The surgical procedure was straightforward without complications. Mean operating 
time was 25 minutes (range 20-30). Patients were discharged after 2 days of bed rest 
and leg elevation. The implant was not visible from the outside. 
The individual results during follow up are presented in table 1 and 2. The motor 
responses were present intra-operatively in all patients and in none at postoperative 
day 10. The sensory response (i.e. a radiating sensation at the sole of the foot and 
toes) was present 10 days postoperatively in 6 patients. 7 patients were treated with 
a frequency setting at 20 Hz and 12 Hz in 1 patient. 
At the 1-month follow up, X-rays showed no dislocation of the implant and no cable 
breach in all patients. For home-based stimulation, patients adjusted the stimulation 
schedule to their individual needs.  
At the 3-months follow up, 5 patients met the primary objective and were considered 
a success. There was a significant improvement in number of voids, incontinence
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Table 1 The individual results during follow up in 8 patients 
Patient
 1 2 3 4 5 6 7 8 
Sex M1 F1 F1 F1 M1 F1 F2 F1
Age (years) 49 65 66 46 50 48 62 64 
Postoperative day 10 *  * *     
Responses m- 
s+
m-
s+
m-
s+
m-
s+
m-
s- 
m-
s+
m-
s- 
m-
s+
Stimulation frequency b c a b a b c c 
3 months of STNS         
Responses m+ 
s+
m+
s+
m+
s+
m+
s+
m+
s+
m-
s+
m+
s+
m-
s+
Successful treatment - + - - + + + + 
6 months of STNS   ‡      
Responses m+ 
s+
m+
s+
m+
s+
m+
s+
m+
s+
m-
s+
m+
s+
m-
s+
Successful treatment + + - + + - ?  + + 
12 months of STNS 
Responses m+ 
s+
m+
s+
m+
s+
m+
s+
m+
s+
#
m+
s+
m-
s- 
Successful treatment - + - + + - + -?
+= present, - = absent, 1 = 20 Hz pulse rate, 2 =12Hz pulse rate, M = male, F = female, * = walking difficulties,  ‡ = urinary tract 
infection, ? unexplainable loss of efficacy, # = dropped out of the study, a = daily stimulation, b = stimulation 3 times a week, c= 
weekly stimulation, m = motor response, s =sensory response  
episodes and I-Qol score (table 3). The motor and sensory responses were 
respectively present in 6 and 8 patients. 3 patients still performed implant driven tibial 
nerve stimulation 3 times per week, 2 patients once per week and 3 patients daily.
At the 6-month follow up, 6 patients met the primary objective. Compared to the 3-
month follow up, voiding and quality of life parameters had not significantly changed 
except for the SF-36 domain general health (p<0.05). Compared to before  
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Table 2 Individual voiding and quality of life parameters in 8 patients at baseline, 3 
and 6 months of follow up and in 7 patients at 12 months of follow up 
Patient number Parameters per 24 hour 
1 2 3 4 5 6 7 8 
Number of voids 
Baseline 16 9 15 12 23 14 8 18 
3-month follow up 10 9 9 8 9 13 6 11 
6-month follow up 7 13 13 9 11 17 8 9 
12-month follow up 9 12 16 10 9  10 15 
Nocturia         
Baseline 5 1 3 3 3 2 1 5 
3-month follow up 5 1 0 0 2 3 0 3 
6-month follow up 3 2 1 0 1 3 1 2 
12-month follow up 3 3 2 2 2  1 2 
Mean voided volume (cc)         
Baseline 104 209 120 170 17 90 127 153 
3-month follow up 135 242 233 123 27 65 117 145 
6-month follow up 114 174 133 206 32 49 114 133 
12-month follow up 156 158 222 190 44  167 142 
Number of incontinence episodes         
Baseline 0 3 0 12 0 40 6 13 
3-month follow up 0 1 0 5 0 17 2 6 
6-month follow up 0 0 0 6 0 21 0 2 
12-month follow up 0 1 0 4 0  0 8 
Incontinence severity1         
Baseline 0 2 0 2 0 1 2 2 
3-month follow up 0 1 0 1 0 1 2 2 
6-month follow up 0 0 0 1 0 1 0 2 
12-month follow up 0 1 0 1 0  0 2 
Number of used pads         
Baseline 0 3 2 4 0 6 6 2 
3-month follow up 0 2 1 2 0 5 2 3 
6-month follow up 0 2 2 0 0 6 1 2 
12-month follow up 0 2 2 2 0  2 7 
I-QoL score         
Baseline 69 88 68 62 51 47 80 48 
3-month follow up 84 97 98 71 96 61 101 52 
6-month follow up 84 105 89 80 96 52 105 81 
12-month follow up 82 99 76 81 97  99 51 
1 0= no urine loss, 1= loss of some drops, 2= loss of small amount, 3= need for change of clothes  
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Table 3 Voiding and quality of life parameters before implantation, at 3 and 6 months 
of implant driven tibial nerve stimulation in 8 patients, and at 12 months in 7 patients 
Mean (SD) Parameters per 24 hours 
Before
Implantation
3-month
follow up 
6-month
follow up 
12-month of 
follow up 
Number of voids 14.4 (4.9) 9.4 (2.1)* 10.9 (3.3) 11.6 (2.9) 
Nocturia 2.9 (1.6) 1.8 (1.8) 1.6 (1.1) 2.1 (0.7) 
Mean voided volume (cc) 123.8 (57.6) 135.9 (73.9) 119.4 (58.0) 154.1 (55.3) 
Number of incontinence episodes 9.3 (13.5) 3.9 (5.8)* 3.6 (7.3)* 1.9 (3.0) 
Number of used pads 2.9 (2.4) 1.9 (1.6) 1.6 (2.0) 2.1 (2.3) 
I-QoL score 64.1 (15.1) 82.5 (18.9)* 86.5 (17.1)* 83.6 (17.2) 
* = compared to before implantation and p<0.05 
implantation, number of incontinence episodes, I-QoL score (table 3), and SF-36 
(social function and vitality) had significantly (p<0.05) improved. Compared to the 
results after PTNS, voiding and quality of life parameters were similar, except for 
mean voided volume, which was significantly decreased  (p<0.05). Patients had not 
changed their treatment schedule.
At the 12-month follow up, 5 patients had improved on bladder diary and 4 of these 
patients met the primary objective. Compared to the data before implantation and at 
6-month follow up there were no significant changes in the voiding and quality of life 
parameters. Compared to the results of PTNS, voiding and quality of life parameters 
were similar as well and without significant differences. The motor response was 
present in 6 and the sensory response in 7 patients. Patients had not changed their 
treatment schedule.  All patients who completed the 1-year follow up were satisfied 
with the results of the implant.  
Directly after the operation 3 patients reported difficulties when walking or standing 
on the operated leg due to wound pain. Two of these patients received physiotherapy 
for their complaints, which had disappeared within 2-3 weeks without further 
intervention. Moreover, these patients had not used the prescribed analgesics. 
Postoperatively, 7 patients reported spontaneous radiating sensations (i.e. sensory 
response without activation of the implant), which disappeared without any 
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intervention within 3 months in all patients except one. Before the 3-month follow up 
and at 6 months one patient had a urinary tract infection, which was treated with 
antibiotics. During follow up no other adverse events were reported, such as local 
infection, dislocation or erosion. The adverse events are summarised in table 4. 
Table 4 Reported adverse events 
Adverse events Number of patients 
Walking difficulties 3
Spontaneous sensory response 7 
Urinary tract infection 2 
At 6 months of implant driven tibial nerve stimulation, one patient had an 
unexplainable loss of efficacy though still having the sensory response (the motor 
response had been present only intra-operatively). Technical problems like lead 
dislocation were ruled out on X-ray. However, lead wire breakage can not be ruled 
out since no surface mapping was performed. Switching the stimulation frequency to 
12 Hz had no result; neither had PTNS re-treatment. Afterwards the patient dropped 
out of the study and was considered unsuccessfully.   
At 12-month follow up, another patient had an unexplainable loss of efficacy. This 
patient had lost the sensory response to the implant driven tibial nerve stimulation 
(the motor response had only intra-operatively been present). Technical (dislocation) 
and physical causes were ruled out on respectively X-ray and physical examination, 
including neurological examination. However, since no surface mapping was 
performed, lead wire breakage can not be ruled out. The patient was successfully re-
treated with PTNS. Afterwards, the UrgentSQTM was explanted at the patients’ 
request. During explantation the implant was activated, which did not result in a 
motor response. The device was examined; however no results are available yet. 
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Discussion
Implant driven tibial nerve stimulation is feasible, since both sensory and motor 
responses were present postoperatively. The occurring loss of the motor response at 
maximal amplitude (temporarily in 6 and lasting in 2 patients) may have been caused 
by edema and/or fibrosis around the electrodes, since after the edema had 
disappeared the response occurred in 6 out of the 8 patients.
At 3, 6 and 12 months of follow up, respectively 5, 6 and 4 patients were successfully 
treated. The fact that not all voiding and quality of life parameters improved 
significantly at follow up can most probably be explained by the small number of 
patients included in this pilot study, the fact that at the 6-month evaluation one patient 
had a urinary tract infection (the patient was not re-evaluated after treatment) and by 
the unexplainable loss of stimulation efficacy in 2 patients at 6 and 12 months of 
follow up. Moreover, when the data at 6 months of implant driven tibial nerve 
stimulation are corrected for the urinary tract infection and the unexplainable loss of 
efficacy, these are similar to the data after PTNS.  
Due to the small patient population it was impossible to determine whether the 
preoperative urodynamic outcome correlates with the efficacy of the implant. 
However, it is to be expected that patients with urodynamic stable bladders or late 
onset detrusor overactivity are the best candidates for implant driven tibial nerve 
stimulation, as has been described for PTNS. 21
Also, because of the small patient population, it was impossible to determine whether 
the presence of the motor and/or sensory responses correlates with the efficacy of 
the implant. To date this has not been determined for PTNS either. Percutaneous 
tibial nerve stimulation is performed at an amplitude resulting in the sensory 
response with adjustment of the amplitude when the response has faded. 8,9
Moreover, stimulation at an amplitude resulting in the motor response is too painful 
for most patients. Therefore, implant driven tibial nerve stimulation was performed 
similar to PTNS. As with PTNS, implant driven stimulation at the level of the motor 
response is too painful for most patients. 
The observation that not all patients who respond well on percutaneous stimulation 
do the same on subcutaneous stimulation, is known from studies concerning sacral 
nerve stimulation; the same goes for loss of efficacy. 22-24 The difference between 
percutaneous and implant driven tibial nerve stimulation could be that for implant 
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driven stimulation is was impossible to determine whether the patients had actually 
treated themselves or not. Moreover the stimulation amplitude was not recorded, so it 
is possible that the patients had treated themselves at too low amplitude. Another 
possibility is that the placebo effect is larger for implant driven tibial nerve stimulation 
than for PTNS. For the latter a randomized double-blind placebo-controlled study is 
being performed to determine whether PTNS is more than a placebo effect, however 
results are not available yet. It seems likely that the PTNS placebo effect is similar to 
that of pharmacotherapy in the treatment of OAB. Pharmacotherapeutic placebo-
controlled trials have reported placebo-effects of 28-43% in patients with urge urinary 
incontinence. 25-27 A larger study is needed to make conclusions concerning the 
efficacy of the implant.
Patients were discharged after 2 days, which is a relatively long period for such a 
procedure. This was caused by the fact that these patients were the first to be 
operated on, which led to increased caution. Probably we were too careful and we 
anticipate that future patients will be discharged at the same day.  
During the 12-month follow up implant driven tibial nerve stimulation proved to be 
safe. No local infection, spontaneous dislocation or erosion of the Urgent SQTM
equipment had occurred during follow up; one stimulator unit failed. Postoperatively, 
3 patients had walking difficulties due to pain caused by the surgery. These 
complaints had disappeared completely within 2-3 weeks. Moreover, these patients 
used no prescribed analgesics. During the 12-month follow up 2 patients had a 
urinary tract infection. These patients were known to have had some recurrent 
urinary tract infections in the past. 7 patients did mention postoperatively a sudden 
radiating sensation, which disappeared without intervention within 3 months in all 
patients except one. In this patient the sudden radiating sensations are still present, 
but occur rarely. Long-term follow up is needed to determine the safety of the implant 
during chronic use. 
Other implantable devices are available for neuromodulative treatment of lower 
urinary tract dysfunction. 28-30 For all devices a pre-operative eligibility test is 
performed to determine whether the patient is a deemed candidate. Of these 
implantable devices sacral nerve stimulation (SNS) is proven to be effective and 
safe. 30-33 Side effects have been reported such as pain in the buttocks, pelvic area, 
lower extremities and at the pulse generator (Interstim®, Medtronic, Minneapolis, 
Minnesota, USA) site, lead migration, infection at test stimulation lead site, transient 
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electric shock, re-operations due to technical problems and adverse change of 
urinary, bowel or sexual function. 30-36 For pudendal nerve stimulation by the Bion®
rechargeable battery-powered microstimulator (Advanced Bionic Corp., Valencia 
California, USA) vaginal fungus infection, allergic reaction, vaginal dryness during 
intercourse, mechanical irritation during bicycle riding and altered bowel functions 
have been reported 28, as is skin erosion at the connection site between lead and 
extension cable for pudendal nerve stimulation by definitive quadripolar tined lead, as 
is used for SNS. 29 For PTNS minimal hematoma and transient pain at the insertion 
site have been described. 9,37 The Urgent SQTM could be an alternative.  Implant 
driven tibial nerve stimulation is minimal invasive and adverse events like infection or 
dislocation did not occur in this study. Furthermore, the internal body contains no 
internal battery that has to be replaced in time, as is the case with SNS and the 
devices for pudendal nerve stimulation. Patients experience no mechanical problems 
due to the implant, which is invisible at the outside.  Finally, during the 12-month 
follow up only urinary tract infection, transient walking difficulties and spontaneous 
sensory responses were reported as adverse events. All patients, who completed the 
1-year follow up, were satisfied with the result. In order to define the proper place of 
the Urgent SQTM in the treatment of lower urinary tract dysfunction, comparative 
studies are needed. 
Conclusions
Implant driven tibial nerve stimulation with the Urgent SQ™ device seems to be 
feasible and safe during short-term follow up in patients with refractory OAB.  A study 
with a larger population and long-term follow up has to be performed to determine the 
efficacy and long-term safety of the implant. 
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Figure 1 External stimulator (A) and the internal body with cables and electrodes of 
the Urgent SQTM (B)
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EPILOGUE
Synopsis and future perspectives 

Synopsis
In case lower urinary tract dysfunction fails conservative treatment and surgical 
therapy with all its disadvantages looms to the horizon, neuromodulation may be a 
welcome alternative. So far, of many methods investigated over the years, sacral 
neuromodulation still is the most successful. However, this technique is expensive 
and requires explicit surgical skill. Not surprisingly, the search for even better 
alternatives is ongoing. This thesis focuses on a currently developed 
neuromodulative treatment modality, percutaneous tibial nerve stimulation or PTNS. 
Chapter 1 Neurostimulation and neuromodulation techniques are not new. From the 
discovery of electricity, its possible use in medicine was explored. In this chapter the 
use of electrical stimulation and neuromodulation to treat patients with lower urinary 
tract dysfunction as investigated over the years, is reviewed. Data are given on 
treatment procedures, stimulation parameters and clinical results as well as on 
particular advantages and disadvantages. Various forms of electrical stimulation of 
the bladder, the pudendal nerves, transcutaneous electrical nerve stimulation or 
TENS, electrical stimulation of the sacral spine or roots and finally the electrical 
stimulation of the lower limb, including its most recent variant, PTNS, are described 
in detail. 
It can be concluded from this chapter that in many reports important information is 
missing and good randomized placebo controlled studies have seldom been 
performed. Therefor, it is very difficult to compare different treatment modalities or to 
judge them on their true merits. Furthermore, there is considerable variety in the 
treatment parameters and schedules reported as well as in criteria for success, 
hampering comparison of both studies concerning different and identical techniques. 
Finally, patients included in the studies often differ, especially with regard to the 
definition and duration of their symptoms and the various treatments applied before. 
This also hinders the determination of prognostic factors for successful treatment 
outcome.
However, in general one might say that different forms of electrical neurostimulation 
and neuromodulation on an intention-to-treat basis result in a 30 to 50% clinical 
success. Influencing lower urinary tract innervation at the level of the sacral roots 
seems to stand the test of time in both neurological and non-neurological patients. It 
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has the advantage of pre-implant testing possibilities to improve patient selection and 
thereby treatment outcome, but it has the drawback of invasiveness. Non-invasive 
techniques lack screening tests and in case of success patients almost always need 
maintenance therapy. It is with this information in mind that one should regard the 
development and possible clinical value of the new treatment option of PTNS.
Chapter 2 To explore the possible value of PTNS, first a feasibility study was 
performed in 49 patients with overactive bladder or non-obstructive urinary retention, 
indications well known from other neuromodulative treatment options. PTNS was 
evaluated in a prospective multicenter trial in 37 patients who presented with 
symptoms of bladder overactivity, that is the urgency and frequency syndrome and/or 
urge incontinence, and 12 with non-obstructive urinary retention. Data were collected 
by means of voiding diaries and quality of life questionnaires before and after 
treatment. Patients were classified in responders, those in whom therapy was 
successful and chose to continue treatment after the initial 12 weeks, and non-
responders, those who chose to stop treatment. Overall, a positive response was 
seen in 60% of all patients. In patients with bladder overactivity a statistically 
significant decrease was observed in leakage episodes, number of pads used, 
voiding frequency and nocturia, and an equal increase in mean and smallest volume 
voided. Improvements were also seen in patients with non-obstructive urinary 
retention, where the number of catheterizations, total and mean volume catheterized, 
and total and mean volume voided changed. Disease specific quality of life and some 
domains of general quality of life improved, especially in patients with bladder 
overactivity. Besides, only mild side effects were observed. 
Encouraged by these results, subsequently several indications were studied in more 
detail. Overactive bladder and non-obstructive urinary retention were evaluated by 
Vandoninck et al. 1-2 This chapter presents the research on chronic pelvic pain (CPP) 
as the main indication for PTNS. In a prospective multicentre trial PTNS was 
evaluated in 33 patients. Effects were recorded by Visual Analogue Scale (VAS) for 
pain diaries, the McGill pain questionnaire and the SF-36 general quality of life 
questionnaire at baseline and after 12 weeks of treatment. Subjective response was 
defined as in earlier studies (patients’ request to continue chronic treatment to keep 
the obtained success), but now also more objective responses (decrease in mean 
VAS >50% and VAS <3 after treatment) were included. A subjective response was 
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seen in 42% of all patients. In 7 patients (21%) mean VAS decreased >50%, in 6 
cases (18%) the decrease was >25%. After 12 weeks of treatment 7 patients (21%) 
ended up with a mean VAS <3. In all patients quality of life (SF-36) significantly 
improved, as did the total pain rate intensity (McGill). These very modest results in 
CPP, however, are in concordance with the results of other neuromodulation 
techniques. 
Finally, the potentially beneficial effect of successful PTNS treatment of lower urinary 
tract dysfunction on sexual functioning in the three indication groups combined was 
investigated. Therefor, 121 patients with an overactive bladder (N=83), chronic pelvic 
pain (n=23) and non-obstructive retention (n=15) which were treated with PTNS were 
evaluated. To obtain information on their sexual function a self-administered 
standardized questionnaire was filled out prior to therapy as well as after 12 weeks of 
treatment. Prior to therapy different aspects of sexual life were considered not normal 
in 25.3 to 45.6% of the cases. This improved significantly after treatment. Patients 
most likely to benefit were women, patients with an overactive bladder and subjective 
responders, whereas the aspects of sexual life which mostly improved were overall 
satisfaction, libido and the frequency of sexual activities. 
Chapter 2 leads to the conclusion that clinical success through PTNS can safely be 
obtained in especially overactive bladder and non-obstructive urinary retention, while 
the outcome in chronic pelvic pain is only modest. Apart from positive effects on 
lower urinary tract dysfunction itself, PTNS may also improve sexual dysfunction, 
observed in a lot of these patients as well.
Chapter 3 Stimulated by the promising results in especially overactive bladder and 
voiding disorders further research was done to affirm the value of PTNS. Although 
one can obtain rather objective parameters from (micturition) diaries in particular, 
urodynamic studies may provide more robust data on the effectiveness of 
percutaneous tibial nerve stimulation. Therefore, studies on urodynamics prior to 
PTNS as well as after finishing treatment were performed in patients with overactive 
bladder and  non-obstructive urinary retention, respectively.
In the first study, 90 consecutive patients with symptoms related to overactive 
bladder syndrome each underwent 12 PTNS sessions. Objective success, the 
primary outcome measure defined as reduction in the number of urinary leakage 
episodes of 50% or more per 24 hours, could be obtained in 56%. Patients’ request 
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for continuation of therapy, considered subjective success, was seen in 64% of 
cases. Furthermore, frequency/volume chart data and quality of life scores improved 
significantly (p<0.01). Of 46 participants with pre- and post-treatment urodynamic 
data, only a few showed complete abolishment of detrusor instabilities (DI). 
Nevertheless, increments in cystometric bladder capacity (p=0.043) and in volume at 
DI (p=0.012) were significant. Subjects without DI at baseline appeared 1.7 times 
more prone to respond to PTNS (OR: 1.75; 95% CI: 0.67-4.6). The more the bladder 
overactivity was pronounced, the less these patients were found to respond to PTNS 
(area under the ROC curve 0.64 (95% CI: 0.48-0.80)). 
In the second study, 39 patients with chronic voiding dysfunction were enrolled in a 
comparable prospective trial. In this group, a ?50% reduction in total catheterized 
volume per 24 hr, the primary objective outcome measure, was obtained in 41% of 
patients. An additional 26% reduced their 24 hr residuals with more than 25%, while 
59% of patients chose to continue treatment. Pre- and post-treatment urodynamic 
data were available in 27 cases. Detrusor pressure at maximal flow, cystometric 
residuals and various bladder indices (bladder contractility index and bladder voiding 
efficiency) improved significantly for all patients (p<0.05). Patients with minor voiding 
dysfunction were more prone to notice success (OR: 0.73; 95% CI: 0.51-0.94). 
From this chapter it can be concluded that PTNS not only results in clinical, but also 
in more objective urodynamic changes. In overactive bladder patients PTNS 
increases cystometric capacity and delays the onset of, but not abolishes detrusor 
instability. In patients with voiding disorders PTNS improves parameters regarding 
more effective bladder emptying. In addition, this chapter shows that urodynamics 
can provide some helpful criteria for PTNS candidate selection. These data should 
further objectively affirm PTNS significance. 
Chapter 4 In chapter 4 two studies are presented regarding refinement of PTNS 
therapy. First, in addition to the urodynamic parameters with predictive importance 
shown in chapter 3, it was tried to establish clinical parameters with prognostic value 
for successful treatment outcome.  
For this purpose, PTNS was applied to 51 men and 81 women with a mean age of 53 
years (range: 21-82). Of them, 83 were treated for overactive bladder, 16 for non-
obstructive urinary retention and 33 for chronic pelvic pain. All patients had to fill out 
micturition or pain diaries as well as quality of life questionnaires before and after 
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treatment. Also data on history, physical examination and stimulation specifics were 
collected. Objective success (?50% improvement of specified symptoms) was seen 
in 32.6% of patients, subjective success in 51.5%. Unfortunately, most evaluated 
clinical parameters proved not to be of prognostic value. Even a history of sexual 
and/or physical abuse, found in 12 of 103 interviewed patients did not alter PTNS 
treatment outcome. However, a low total score at baseline in the SF-36 questionnaire 
proved to be predictive for not obtaining objective (OR 0.44; 95% CI: 0.2-1, p=0.04) 
nor subjective success (OR 0.42; 95% CI: 0.20-0.89, p=0.02). Especially patients 
with a low SF-36 Mental Component Summary were prone to fail neuromodulation 
therapy: OR 0.12 (95% CI: 0.27-0.55), p=0.006 for objective success. These patients 
also scored worse on disease-specific quality of life questionnaires, although they 
had no different disease severity compared to patients with good mental health. 
Apart from evaluating which patients may be best suited to start therapy, it is also 
important to evaluate how, if possible, positive results can be sustained. The second 
study in this chapter was performed to investigate whether maintenance therapy 
once successful outcome had been obtained is really necessary.
Eleven patients (mean age: 51 years) with refractory overactive bladder syndrome (> 
7 voids and/or > 3 urge incontinence episodes per day) were successfully treated 
with PTNS and started maintenance therapy. Patients filled out bladder diaries and 
quality of life questionnaires (SF-36 and I-QoL) before and after a 6-week pause of 
maintenance PTNS and again after re-treatment. The first objective was defined as 
>50% increase of the number of incontinence episodes and/or micturition frequency 
after the 6-week pause of maintenance PTNS. The second objective was defined as 
a >50% reduction of the same parameters after re-treatment. After the 6-week pause, 
7/11 patients (64%) met the first objective. Mean voided volume, nocturia, number of 
incontinence episodes and incontinence severity significantly deteriorated (p<0.05). 
The second objective was reached in 9/11 patients (82%). Nocturia, number of 
incontinence episodes, incontinence severity, mean voided volume and quality of life 
significantly (p<0.05) improved. 
It can be concluded from this chapter that most clinical parameters are of no value in 
predicting PTNS treatment outcome. Only bad mental health as measured with the 
SF-36 Mental Component Summary proved a negative predictive factor for success 
and may therefore be used as a tool for better patient selection. In case patients are 
treated successfully, they do need continuous therapy to maintain their results. 
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Chapter 5 After it became clear that in case of successful PTNS treatment 
maintenance therapy proved to be a necessity, ways were looked at to ease this 
problem as it is demanding for both patients and outpatient departments. In 
concordance with other neuromodulation techniques an implantable device was 
designed. It resulted in an implant for radiographically controlled subcutaneous tibial 
nerve stimulation (STNS).  
In this chapter the first results on feasibility and safety of STNS are presented. Eight 
patients with refractory overactive bladder successfully treated with PTNS received a 
subcutaneous implant after a washout period of 3 to 12 months. Evaluation was done 
by means of bladder diaries, quality of life questionnaires and physical examination 
before implantation and at 3, 6 and 12 months of follow up. At the three consecutive 
postimplantation evaluation points the primary objective of >50% reduction of the 
number of incontinence episodes and/or voids on bladder diary was met by 5, 6 and 
4 patients respectively. Furthermore, at 3 and 6-month follow up voiding and quality 
of life parameters had significantly (p<0.05) improved. STNS proved to be safe as the 
only adverse events reported were urinary tract infection, temporarily walking 
difficulties and spontaneous radiating sensations. There were no reports on local 
infection, erosion or dislocation.
It can be concluded from this chapter that implant driven STNS seems to be both 
feasible and safe. In addition, it should convince the reader that much effort is made 
to keep improving tibial nerve stimulation, including its major drawback: maintenance 
therapy.
Future perspectives 
The studies presented in this thesis are only few; so many questions remain 
unanswered. The near future of PTNS is therefore most probably dedicated to further 
research, which will not only clarify the many dark areas left behind, but may also 
shine a light on ongoing mysteries in other neuromodulation techniques. A 
widespread application of PTNS as ready to use neuromodulation therapy, at least in 
Europe seems less likely as the percutaneous route necessitates maintenance 
therapy too demanding for patients as well as outpatient departments. As PTNS is 
reimbursed in the United States, financial stimuli to develop an implantable device to 
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overcome these drawbacks are almost completely absent. Not surprisingly, many 
enthusiastic urologists that started PTNS shortly after its introduction a few years 
ago, slightly disappointed in the further developments abandoned the technique.
What are the main issues in percutaneous tibial nerve stimulation that have to be 
resolved?
Does PTNS work? Despite changes in symptoms, quality of life items, urodynamic 
features and LUTD accompanying sexual functioning, there are also central nervous 
system changes all very indicative for the action of PTNS. However, a placebo effect 
can not completely ruled out. Although the issue has already been discussed in some 
of the articles in this thesis a placebo controlled trial still needs to be performed. 
However, because of the very specific features of the PTNS technique, a blinded (let 
alone a double blinded) randomized controlled trial is almost impossible to conduct. 
In addition it should be noted that almost none of the even most established 
neuromodulation techniques have been properly ran against placebo. This issue is 
one of the most challenging for the nearby future.
How does PTNS work? Nowadays it is well accepted that effects of especially 
sacral root neuromodulation take place at the spinal and supraspinal level. Spinal 
tract neurons involved in the micturition reflex are inhibited, as are interneurons 
involved in spinal segmental reflexes and postganglionic neurons. 3 Furthermore, 
there may be inhibition of the primary afferent pathway, and indirect suppression of 
guarding reflexes by turning off bladder input to internal sphincter sympathetic or 
external urethral  sphincter interneurons. 4 In urinary retention, the obtained effects 
are believed by some authors to be the result of changed pelvic floor behavior 
directly 5,6, or as part of retuning of a brainstem ‘on-off’ switch mechanism. 3,7
However, a lot of the assumptions made above need to be evidenced further.  
Although many investigators mainly focus on clinical results, basic research is as 
evenly important. Clarifying the many unsolved issues will eventually lead to a better 
understanding of how neuromodulation really works and ultimately will improve 
therapy outcome. This is especially true for a new treatment modality as 
percutaneous tibial nerve stimulation.  One way to explore basic issues is by means 
of animal experiments. For example it is shown that PTNS actually changes spinal 
neuronal cell activity in rats by reducing the metabolic marker c-fos protein in the 
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spinal micturition center. 8 In another experiment in anesthetised cats, arguments 
were found that PTNS works through sacral reflex pathways instead of through 
activation of pain, sympathetic or cervico-thoracic reflex pathways. 9 In addition to 
animal experiments new exciting ways to study central nervous processes have 
become available, especially functional PET scanning. It has already shown some 
effects in sacral neuromodulation for urinary retention 10, but much more research is 
awaited for.
What is the best way to perform PTNS? Almost all research done on PTNS used 
the same stimulation protocol: PTNS was performed in 10 to 12 weekly sessions, 
each lasting for 30 minutes. Stimulation parameters were preset and rather fixed and 
every time only one needle was inserted. It may be well anticipated that changes in 
treatment scheme and/or stimulation parameters could lead to a different, possibly 
even better outcome. The same goes for bilateral instead of unilateral therapy. 
Compared to the once-a-week protocol, an accelerated scheme of 3 to 4 times a 
week for example seems not to significantly influence treatment outcome, although 
there are some conflicting reports on its effect on the necessity of maintenance 
therapy afterwards. 11,12 On the other hand, it is evident that an accelerated scheme 
has the advantage of achieving clinical results faster. 13
Regarding stimulation parameters, it is rather widely agreed that pulse intensity in 
neuromodulation should be set at a well tolerable level. Frequency however, for 
PTNS set at 20 Hz, has been varied in the different neuromodulation techniques from 
5-20 Hz, but even frequencies up to 150 Hz are reported. As it is suggested that 
frequency is optimal at more unpleasantly low levels (5-6 Hz) 14, studies on PTNS 
with pulse frequencies below 20 Hz may produce interesting results. The same goes 
for changes in pulse duration, in PTNS set at 0.2 msec, but in other techniques also 
up to 0.5  or even over 1 msec.
Besides research on stimulation scheme and parameters it may also be interesting to 
evaluate the possible beneficial effect of stimulating both legs at the same time. At 
least in sacral neuromodulation there is some evidence that bilateral stimulation may 
improve results not so much in relieving symptoms better than unilateral stimulation 
once successful, as well in improving the chance that patients react at all. 15-17 Of
course a positive outcome of bilateral stimulation in PTNS would create some new 
problems with regard to a possible implantable device. 
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And this will eventually be the way we are heading: a readily available subcutaneous 
implantable device, easily controllable by patients themselves in flexible, 
individualized treatment schemes. Unnecessary to state that there is still a long way 
to go. 
In whom should PTNS be performed? As percutaneous tibial nerve stimulation 
with its 10 to 12 half-an-hour sessions before results are obtained is elaborative, 
predictive factors for successful outcome are urgently needed. Some studies in 
sacral as well as tibial nerve stimulation have now been performed (see chapter 4 of 
this thesis), resulting in the best candidates being psychological sound patients with 
not too severe bladder overactivity or non-obstructive urinary retention. More 
research should be done to tighten these criteria for neuromodulation therapy 
increasing positive results. As soon as an subcutaneous implant for chronic tibial 
nerve stimulation is readily available, by analogy with sacral neuromodulation 
additional efforts should be undertaken to refine the pre-implant testing phase in 
order to decrease the amount of unnecessarily treated patients. 
In contrast, optimizing the success of PTNS treatment will without a doubt lead to the 
exploration of its value in other indication groups, something that can already be 
seen in sacral neuromodulation. Most likely to be subject of further investigation 
seem to be children, neurologic patients and patients with fecal incontinence.
Till now, almost all stimulation and neuromodulation techniques were tested in adults 
only, with the exception of intravesical electrostimulation in children with neurogenic 
voiding disorders and TENS in non-neurogenic incontinence. The majority of 
neuromodulation techniques namely seem less suitable to children because of their 
invasive nature and the necessity to apply current in the anal and/or genital area. 
Although percutaneous tibial nerve stimulation is not ‘non-invasive’, its focus on the 
ankle might be less threatening to children, offering a possibility for PTNS use in this 
young age group. Promising results reported in the first two studies in 31 and 23 
children respectively 18,19 warrant further evaluation.
The second challenging patient group consists of neurological patients. In most 
neuromodulative therapies this group is not included. However, it can be argued that 
neuromodulation treatment in selected cases, especially in multiple sclerosis, may be 
of benefit as well. Up to now, experience in this field is very limited and contradictive 
20-22, but results are encouraging enough to justify more research.  
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Finally, an area generally spoken beyond the interest of most urologists but in many 
ways comparable to lower urinary tract dysfunction, is that of fecal incontinence. As 
goes for urinary leakage, fecal incontinence has a high impact on patients’ quality of 
life but seems even more difficult to discuss for both patients and care-givers. As the 
first steps are taken in exploring the value of sacral neuromodulation in this field 23, it 
can be anticipated that research on PTNS for this indication will also be performed. 24
It is the fate of science: with every question answered, even more questions arise. 
With this thesis I hope I’ve been able to raise a lot of new questions. 
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Synopsis en toekomstverwachtingen 

Synopsis
Wanneer bij disfunctie van de lagere urinewegen conservatieve behandeling faalt en 
operatieve therapie met al haar nadelen opdoemt aan de horizon, kan neuro-
modulatie een welkom alternatief zijn. Tot nu toe is sacrale neuromodulatie van de 
vele methoden onderzocht in de laatste jaren het succesvolst gebleken. Het betreft 
hier echter een dure techniek die speciale vaardigheden vereist. Het zal dan ook 
niemand verbazen dat de zoektocht naar nog betere alternatieven voortgaat. Dit 
proefschrift richt zich op een van de meest recente neuromodulatievormen: de 
percutane stimulatie van de nervus tibialis ofwel Percutaneous Tibial Nerve 
Stimulation (PTNS). 
Hoofdstuk 1 Neurostimulatie- en -modulatietechnieken zijn niet nieuw. Spoedig na 
de ontdekking van elektriciteit werden de mogelijkheden voor toepassing binnen de 
geneeskunde al onderzocht. In dit hoofdstuk wordt het gebruik van elektrische 
stimulatie en neuromodulatie voor de behandeling van patiënten met disfunctie van 
de lagere urinewegen door de jaren heen beschreven. Informatie over 
behandelprocedures, stimulatieparameters, klinische resultaten, maar ook specifieke 
voor- en nadelen passeren de revue. Dientengevolge kan men lezen over 
verscheidene vormen van elektrische stimulatie van de blaas, van de nervi pudendi, 
over transcutane elektrische zenuwstimulatie of TENS en over elektrische stimulatie 
van het sacrale ruggenmerg of zijn wortels en tenslotte over elektrische stimulatie 
van de onderste extremiteit inclusief haar  modernste variant, PTNS. 
Uit dit hoofdstuk kan worden geconcludeerd dat in veel publicaties relevante 
informatie ontbreekt en dat goede, gerandomiseerde en placebogecontroleerde 
studies zeldzaam zijn. Hierdoor is het amper mogelijk de verschillende modulatie-
technieken met elkaar te vergelijken dan wel naar waarde te schatten. Bovendien 
bestaat er een aanzienlijke variatie in gerapporteerde behandelschema’s en -para-
meters, maar ook in criteria voor succes, wat een verdere barrière vormt voor een 
goede vergelijking van studies zowel over verschillende neuromodulatievormen als 
over identieke technieken onderling. Tenslotte zijn patiëntengroepen in de studies 
beschreven niet uniform, voornamelijk waar het gaat om definitie en duur van de 
klachten en de eerder toegepaste therapieën. Buiten het feit dat dit de onderlinge 
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vergelijking nog eens verder bemoeilijkt, staat het ook de determinatie van 
prognostische factoren voor een succesvol behandelresultaat in de weg. 
Desalniettemin kan men in het algemeen stellen dat neuromodulatie resulteert in een 
30-50% kans op klinisch succes (‘intention to treat’). Het beïnvloeden van de 
innervatie van de lagere urinewegen op het niveau van de sacrale wortels blijkt tot op 
heden het meest solide, zowel bij neurologische als bij niet-neurologische patiënten. 
Het heeft het voordeel van een testmogelijkheid vóór definitieve implantatie, 
waardoor een striktere patiëntenselectie kan plaatsvinden met als gevolg een 
verbetering van het behandelresultaat, het nadeel is echter de invasiviteit. Niet-
invasieve technieken ontberen screeningsmogelijkheden en in geval van succes zijn 
patiënten vrijwel altijd gebonden aan een onderhoudsbehandeling. Het is tegen deze 
achtergrond dat de ontwikkeling en de mogelijk klinische waarde van de nieuwe 
neuromodulatietechniek PTNS dient te worden bezien. 
Hoofdstuk 2 Om de mogelijke waarde van PTNS te onderzoeken werd allereerst 
een haalbaarheidsstudie uitgevoerd bij 49 patiënten met overactieve blaas of niet-
obstructieve urineretentie, indicaties bekend van andere neuromodulatievormen. 
PTNS werd in een prospectieve, multicentrische studie geëvalueerd bij 37 patiënten 
met symptomen van een overactieve blaas (dat wil zeggen: urgency/frequency 
syndroom en/of urge incontinentie) en 12 met niet-obstructieve urineretentie. Data 
werden verzameld met behulp van mictiedagboeken en ‘kwaliteit van leven’- 
vragenlijsten voor en na behandeling. Patiënten werden ingedeeld in responders, zij 
die succesvol reageerden op de therapie en na de initiële 12 weken verkozen door te 
gaan,  en niet-responders, zij die de behandeling staakten. Een positieve respons 
werd gezien bij 60% van de patiënten. Bij patiënten met overactieve blaas werd een 
statistisch significante daling gezien van het aantal incontinentie-episodes, gebruikte 
verbandjes, mictiefrequentie en de nycturie, terwijl een vergelijkbare stijging werd 
gezien in het gemiddelde en het kleinste geplaste volume. Bij niet-obstructieve 
urineretentie werden eveneens veranderingen gezien in het aantal katheterisaties, 
het gemiddelde en totale gekatheteriseerde volume en het gemiddelde en totale 
geplaste volume. Ziektespecifieke ‘kwaliteit van leven’-vragenlijsten en enkele 
domeinen van de algemene ‘kwaliteit van leven’-vragenlijst verbeterden, vooral bij 
blaasoveractiviteit. Slechts zeer milde bijwerkingen werden waargenomen. 
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Aangemoedigd door deze resultaten werden verschillende indicatiegebieden meer in 
detail bestudeerd. Evaluatie van blaasoveractiviteit en niet-obstructieve urineretentie 
vond plaats door Vandoninck et al. 1,2 Dit hoofdstuk presenteert de uitkomsten van 
PTNS als behandeling van chronische bekkenpijn. In een prospectieve, 
multicentrische studie werd PTNS geëvalueerd bij 33 patiënten met deze 
aandoening. Effecten werden gevolgd middels Visual Analogue Scale (VAS) voor 
pijn dagboeken, de McGill pijn vragenlijst en de SF-36 vragenlijst voor de algemene 
kwaliteit van leven, afgenomen voor en na 12 weken therapie. Subjectieve respons 
was gedefinieerd als boven beschreven (het verzoek van patiënt het behaalde 
resultaat te behouden middels onderhoudsbehandeling), maar nu werd ook een 
meer objectief responscriterium (daling van het gemiddelde VAS van meer dan 50% 
en een VAS van minder dan 3 na behandeling) geïncludeerd. Een subjectieve 
respons werd bij 42% van de patiënten gezien. Bij 7 patiënten (21%) daalde de 
gemiddelde VAS meer dan 50%, in nog eens 6 gevallen (18%) met meer dan 25%. 
Na 12 weken therapie eindigden 7 patiënten (21%) met een VAS onder de 3. In de 
gehele patiëntengroep verbeterde de kwaliteit van leven (SF-36) significant, net als 
de totale pijn intensiteit (McGill). Deze zeer bescheiden resultaten zijn in 
overeenstemming met uitkomsten van andere neuromodulatievormen bij chronische 
bekkenpijn.
Tenslotte werd onderzocht in hoeverre, voor de drie indicatiegebieden 
gecombineerd, een succesvolle PTNS therapie ook  een verbetering van het 
seksueel functioneren tot gevolg had. Hiertoe werden 121 met PTNS behandelde 
patiënten met een overactieve blaas (N=83), chronische bekkenpijn (N=23) of niet-
obstructieve urineretentie (N=15) geëvalueerd. Om informatie te verkrijgen over het 
seksueel functioneren werd een gestandaardiseerde vragenlijst door patiënten 
ingevuld voor en na 12 weken PTNS. Voorafgaand aan de therapie werden diverse 
aspecten van het seksueel functioneren als afwijkend beschouwd in 25,3 tot 45,6% 
van de gevallen. Dit verbeterde significant na behandeling. Patiënten die het meest 
profiteerden waren vrouwen, patiënten met een overactieve blaas en subjectieve 
responders. De aspecten van het seksueel functioneren die het best reageerden 
bleken de tevredenheid over en de frequentie van de seksuele activiteiten, alsmede 
het libido.  
Hoofdstuk 2 leidt tot de conclusie dat klinisch succes middels PTNS veilig kan 
worden verkregen bij vooral overactieve blaas en niet-obstructieve urineretentie, 
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terwijl het succes bij chronische bekkenpijn slechts bescheiden is. Naast positieve 
effecten op disfunctie van de lagere urinewegen kan PTNS ook een verbetering 
geven van de hiermee nogal eens gepaard gaande seksuele disfunctie. 
Hoofdstuk 3 Aangemoedigd door de veelbelovende uitkomsten bij vooral 
overactieve blaas en mictiestoornissen werd verder onderzoek ingezet om de 
waarde van PTNS te bevestigen. Hoewel men redelijk objectieve parameters kan 
onttrekken uit met name (mictie)dagboeken is het urodynamisch onderzoek 
waarschijnlijk meer geschikt om hardere data over de effectiviteit van PTNS te 
verzamelen. Derhalve werden urodynamische onderzoeken uitgevoerd voor en na 
PTNS bij zowel overactieve blaas als niet-obstructieve urineretentie patiënten. 
In de eerste studie ondergingen 90 patiënten met symptomen gerelateerd aan 
overactieve blaas elk 12 PTNS sessies. Objectief succes, het primaire 
onderzoeksdoel gedefinieerd als een reductie in het aantal incontinentie-episodes 
van meer dan 50% per 24 uur, werd gezien in 56% van de gevallen. Een verzoek tot 
onderhoudsbehandeling, beschouwd als subjectief succes, werd gedaan door 64% 
van de patiënten. Daarnaast verbeterden parameters uit de mictiedagboeken en de 
kwaliteit van leven vragenlijsten significant (p<0,01). Van 46 patiënten met 
urodynamische data van voor en na PTNS lieten slechts enkele een volledig 
verdwijnen van de detrusor instabiliteiten (DI) zien. Desalniettemin bleken toename in 
cystometrische blaascapaciteit (p=0,043) en het volume waarbij DI optrad (p=0,012) 
significant. Patiënten zonder DI voor PTNS bleken een 1,7 maal grotere kans op 
respons te hebben dan zij met DI (OR: 1,75; 95% CI: 0,67- 4,6).  Daarnaast: hoe 
meer uitgesproken de blaasoveractiviteit was, hoe kleiner de kans bleek op een 
succesvol resultaat (oppervlakte onder de ROC curve 0,64 (95% CI: 0,48-0,80)). 
In de tweede studie werden 39 patiënten met chronische mictieproblemen 
opgenomen in een vergelijkbare prospectieve studie. In deze groep werd een ?50%
afname van het totaal gekatheteriseerde volume per 24 uur -het primaire einddoel- 
gezien bij 41% van de patiënten. Nog eens 26% verbeterde zijn residuen met meer 
dan 25%, terwijl 59% van de patiënten verzocht om onderhoudsbehandeling. 
Urodynamische data van voor en na PTNS waren beschikbaar van 27 patiënten. 
Detrusordruk bij maximale flow, cystometrische residuen en blaas indices (‘bladder 
contractility index’ en ‘bladder voiding efficiency’) verbeterden significant voor de 
gehele groep (p<0,05). Patiënten met een beperkte mictiestoornis bleken een grotere 
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kans op succes te hebben dan zij met meer uitgesproken problematiek (OR: 0,73; 
95% CI: 0,51-0,94). 
Vanuit dit hoofdstuk kan worden geconcludeerd dat PTNS niet alleen resulteert in 
klinische, maar ook in –meer objectieve- urodynamische veranderingen. Bij patiënten 
met een overactieve blaas verbetert PTNS de cystometrische capaciteit en vertraagt 
(maar onderdrukt niet) het moment van detrusor instabiliteit. Bij patiënten met niet-
obstructieve urineretentie verbetert PTNS parameters die betrekking hebben op een 
effectievere blaaslediging. Verder laat dit hoofdstuk zien dat urodynamica 
behulpzaam kan zijn bij het opstellen van criteria voor een betere patiëntenselectie. 
Voornoemde data zouden verdere ondersteuning moeten bieden aan de betekenis 
van PTNS. 
Hoofdstuk 4 In hoofdstuk 4 worden twee studies gepresenteerd die betrekking 
hebben op verfijning van de PTNS therapie. Allereerst werd, volgend op enkele 
urodynamische parameters met mogelijk prognostische betekenis getoond in 
hoofdstuk 3, gezocht naar klinische parameters met een voorspellende waarde voor 
een succesvolle uitkomst van de behandeling. 
Hiertoe werd PTNS toegepast bij 51 mannen en 81 vrouwen met een gemiddelde 
leeftijd van 53 jaar (bereik: 21-82 jaar). Van hen werden er 83 behandeld voor een 
overactieve blaas, 16 voor niet-obstructieve urineretentie en 33 voor chronische 
bekkenpijn. Alle patiënten moesten mictie- of pijndagboeken invullen, evenals 
‘kwaliteit van leven’-vragenlijsten, zowel voor als na behandeling. Ook werden data 
verzameld betreffende voorgeschiedenis, lichamelijk onderzoek en stimulatie-
bijzonderheden. Objectief succes (meer dan 50% verbetering van specifieke 
symptomen) werd gezien bij 32,6%, subjectief succes bij 51,5% van de patiënten. 
Helaas bleken de meeste geëvalueerde parameters niet van prognostische waarde. 
Zelfs een voorgeschiedenis van seksueel en/of lichamelijk misbruik, gevonden bij 12 
van 103 onderzochte patiënten, bleek de uitkomst van PTNS niet te beïnvloeden. 
Daarentegen bleek een lage totaalscore voor PTNS behaald met de SF-36 algehele 
‘kwaliteit van leven’-vragenlijst voorspellend voor het niet behalen van een objectieve 
(OR 0,44; 95% CI: 0,2-1, p=0,04), noch een subjectieve respons (OR 0,42; 95% CI: 
0,20-0,89, p=0,02). Vooral patiënten met een lage SF-36 Mental Component 
Summary liepen risico op falen van neuromodulatie therapie: OR 0,12 (95% CI: 0,27-
0,55), p=0,006 voor objectief succes. Deze patiënten scoorden eveneens slechter op 
EPILOOG                    199
de ziektespecifieke ‘kwaliteit van leven’-vragenlijsten, ofschoon ze qua ernst van hun 
ziekte niet verschilden van patiënten met een goede mentale gezondheid.
Behalve onderzoek naar welke patiënten het meest geschikt zijn om therapie te 
starten dient ook te worden bestudeerd hoe, als mogelijk, behandeling kan worden 
beëindigd. De tweede studie in dit hoofdstuk werd verricht met als vraagstelling of 
onderhoudsbehandeling in geval van een positief behandelresultaat werkelijk 
noodzakelijk is. 
Elf patiënten (gemiddelde leeftijd: 51 jaar) met refractaire blaasoveractiviteit (meer 
dan 7 micties en/of meer dan 3 urge incontinentie-episodes per dag), succesvol 
behandeld met PTNS, startten onderhoudstherapie. Patiënten vulden mictiedag-
boeken in, net als kwaliteit van leven vragenlijsten (SF-36 en I-Qol), voor en na een 
pauze van zes weken in de onderhoudstherapie en ook weer na herstart van de 
PTNS. De eerste doelstelling bestond uit een meer dan 50% toename van het aantal 
incontinentie-episodes en/of de mictiefrequentie na 6 weken behandelpauze. De 
tweede doelstelling bestond uit een meer dan 50% reductie van de symptomen na 
herstart van de therapie. Na de 6 weken onderbreking voldeden 7 van de 11 
patiënten (64%) aan de doelstelling. Het gemiddelde geplaste volume, de nycturie, 
het aantal incontinentie-episodes en de incontinentie-ernst verslechterden significant 
(p<0,05). De tweede doelstelling werd gehaald in 9 van de 11 gevallen (82%). 
Nycturie, het aantal incontinentie-episodes, de incontinentie-ernst, het gemiddeld 
geplaste volume en de kwaliteit van leven verbeterden significant (p<0,05). 
Vanuit dit hoofdstuk kan worden geconcludeerd dat de meeste klinische parameters 
van geen waarde zijn waar het het voorspellen van het behandelresultaat betreft. 
Slechts een slechte mentale gezondheid, zoals gemeten via de SF-36 Mental 
Component Summary bleek negatief voorspellend voor succes en zou derhalve 
gebruikt kunnen worden voor een betere patiëntenselectie. Wanneer patiënten met 
succes behandeld zijn blijkt onderhoudstherapie noodzakelijk. 
Hoofdstuk 5 Nadat duidelijk werd dat in geval van een succesvolle PTNS 
behandeling onderhoudstherapie noodzakelijk bleek, werden wegen gezocht dit 
probleem te verlichten aangezien het veel vraagt van zowel de patiënten als de 
poliklinische praktijk. Overeenkomstig andere neuromodulatie-technieken werd een 
implantaat ontwikkeld, resulterend in een apparaatje voor radiografisch gecontro-
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leerde subcutane stimulatie van de nervus tibialis ofwel Subcutaneous Tibial Nerve 
Stimulation (STNS). 
In dit hoofdstuk worden de eerste resultaten betreffende haalbaarheid en veiligheid 
van STNS gepresenteerd. Acht patiënten met refractaire blaasoveractiviteit die 
succesvol behandeld werden met PTNS ontvingen na een pauze van 3 tot 12 
maanden een subcutaan implantaat. Evaluatie vond plaats middels 
mictiedagboeken, ‘kwaliteit van leven’-vragenlijsten en lichamelijk onderzoek, 
afgenomen voor implantatie en 3, 6 en 12 maanden nadien. Op de drie opvolgende 
evaluatiemomenten haalden respectievelijk 5, 6 en 4 patiënten de primaire objectieve 
doelstelling van minstens 50% vermindering van het aantal incontinentie-episodes 
en/of micties in het mictiedagboek. Daarnaast bleken bij 3 en 6 maanden follow up, 
mictie en kwaliteit van leven parameters significant verbeterd (p<0,05). Ook bleek 
STNS veilig aangezien de enige bijwerkingen die gevonden werden bestonden uit 
urineweginfecties, tijdelijke moeilijkheden met lopen en spontane, uitstralende 
sensaties. Er werden geen lokale infecties, erosies of dislocaties gevonden.
Er kan vanuit dit hoofdstuk worden geconcludeerd dat STNS middels een implantaat 
zowel mogelijk als veilig is. Daarenboven zou dit hoofdstuk de lezer moeten 
overtuigen van de vele inspanningen die geleverd worden om PTNS verder te 
verbeteren, inclusief het belangrijkste nadeel: onderhoudstherapie. 
Toekomstverwachtingen
In dit proefschrift worden slechts enkele studies gepresenteerd; veel vragen blijven 
onbeantwoord. Voor PTNS zal de nabije toekomst daarom vooral bestaan uit verder 
onderzoek, niet alleen naar zaken over PTNS die onderbelicht bleven, maar ook naar 
nog steeds bestaande onduidelijkheden betreffende neuromodulatie in het 
algemeen. Een opkomst van PTNS als een makkelijk toegankelijke en veelgebruikte 
neuromodulatie techniek is -vooral in Europa- niet voor de hand liggend, aangezien 
de percutane route een onderhoudsbehandeling vraagt met een te grote belasting 
voor patiënten en poliklinieken. Daar PTNS wel vergoed wordt in de Verenigde 
Staten ontbreken financiële prikkels om een implantaat te ontwikkelen dat dit nadeel 
het hoofd biedt vrijwel volledig. Het is dan ook niet verwonderlijk dat veel urologen 
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die enthousiast startten met PTNS vlak na de introductie enkele jaren geleden 
teleurgesteld raakten in de verdere ontwikkelingen en de techniek verlieten.
Wat zijn de belangrijkste kwesties binnen percutaeous tibial nerve stimulation die 
opgelost dienen te worden? 
Werkt PTNS? Hoewel verbeteringen kunnen worden aangetoond in symptomen, 
kwaliteit van leven, urodynamische parameters en met disfunctie van de lagere 
urinewegen gepaard gaand seksueel disfunctioneren, zijn er ook veranderingen in 
het centrale zenuwstelsel die duiden op de werking van PTNS. Toch is het waar: tot 
op heden kan een placebo-effect niet geheel worden uitgesloten. Hoewel dit 
onderwerp reeds enige malen werd bediscussieerd in artikelen opgenomen in dit 
proefschrift, is een placebogecontroleerde studie nog niet verricht: de specifieke 
kenmerken van de PTNS techniek maken een geblindeerde (laat staan een 
dubbelblinde), gerandomiseerde, gecontroleerde trial bijna onmogelijk om uit te 
voeren. Daarbij, bijna geen van zelfs de meest gevestigde neuromodulatietechnieken 
werd in het verleden serieus vergeleken met placebo. Dit onderwerp zal een van de 
meest uitdagende zijn voor de nabije toekomst. 
Hoe werkt PTNS? Tegenwoordig is het algemeen geaccepteerd dat effecten van 
vooral sacrale zenuwstimulatie plaatsvinden op spinaal en supraspinaal niveau door 
inhibitie van spinale neuronen betrokken bij de mictiereflex, van interneuronen 
betrokken bij spinale segmentale reflexen en van postganglion neuronen. 3 Verder
spelen mogelijk de inhibitie van de primaire banen richting ruggenmerg en indirecte 
suppressie van ‘guarding reflexes -door middel van het uitschakelen van signalen 
vanuit de blaas naar sympathische interne sphincter of externe urethrale sphincter 
interneuronen- een rol. 4 Bij niet-obstructieve urineretentie worden de verkregen 
resultaten door sommige auteurs toegeschreven aan directe veranderingen in de 
bekkenbodem 5,6, dan wel aan hernieuwde afstemming van het ‘on/off switch’-
mechanisme in de hersenstam. 3,7 Veel van de voornoemde aannames dienen echter 
nog nader te worden onderbouwd. 
Hoewel de meeste onderzoekers zich vooral richten op klinische resultaten is basaal 
onderzoek minstens zo belangrijk: verheldering van de vele onopgeloste 
vraagstukken zal uiteindelijk leiden tot een beter begrip van de echte werking van  
neuromodulatie en van daar naar  de verbetering van behandelresultaten. Eén van 
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de mogelijkheden om basaal onderzoek te verrichten is met behulp van 
dierenexperimenten. Zo is bijvoorbeeld bij ratten aangetoond dat PTNS de activiteit 
in spinale neuronale cellen beïnvloedt door middel van verlaging van de metabole 
marker c-fos in het spinale mictiecentrum. 8 In een ander experiment uitgevoerd op 
katten onder anesthesie, werden argumenten gevonden om aan te nemen dat PTNS 
werkt via sacrale reflexbanen in plaats van via pijn-, sympathische of 
cervicothoracale reflexbanen. 9 Naast dierenexperimenten zijn nieuwe, 
veelbelovende afbeeldingstechnieken beschikbaar gekomen om het centrale 
zenuwstelsel te bestuderen, met name ‘functional PET-scanning’. PET heeft reeds 
effecten aangetoond van sacrale neuromodulatie voor niet-obstructieve urineretentie 
10, maar er is veel meer onderzoek noodzakelijk. 
Wat is de beste manier om PTNS toe te passen? Bijna al het onderzoek tot op 
heden uitgevoerd maakte gebruik van het zelfde stimulatieprotocol: PTNS werd 
toegepast in 10 tot 12 wekelijkse sessies van 30 minuten elk. Stimulatieparameters 
waren vooraf ingesteld en vrijwel gefixeerd en iedere keer werd via één naald 
gestimuleerd. Het is niet onaannemelijk dat verandering in behandelschema en/of 
stimulatieparameters resulteert in andere, misschien zelfs betere therapie-
uitkomsten. Hetzelfde geldt voor bilaterale stimulatie. 
Met betrekking tot één keer per week PTNS kan gesteld worden dat een versneld 
schema van 3 tot 4 maal per week stimuleren de behandeluitkomst niet duidelijk 
beïnvloedt, hoewel er tegenstrijdige uitkomsten zijn betreffende de noodzaak tot 
onderhoudstherapie nadien. 11,12 Natuurlijk heeft een versneld schema wel het 
voordeel van eerdere duidelijkheid over het klinisch resultaat. 13
Voor wat betreft stimulatieparameters: het is alom geaccepteerd dat de pulsintensiteit 
bij neuromodulatie wordt ingesteld op een nog goed te verdragen niveau. De 
pulsfrequentie echter, bij PTNS 20 Hz, varieert voor verschillende 
neuromodulatietechnieken van 5 tot 20 Hz, hoewel zelfs frequenties tot 150 Hz zijn 
beschreven. Aangezien gesteld wordt dat de meest optimale frequentie op een voor 
patiënten onaangenamer laag niveau ligt (5-6 Hz) 14 kunnen studies naar PTNS bij 
frequenties onder de 20 Hz interessante resultaten opleveren. Hetzelfde geldt voor 
verandering in pulsduur, 0,2 msec bij PTNS, en hoger (0,5 tot zelfs 1 msec) bij 
andere technieken.
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Naast onderzoek naar behandelschema en stimulatie parameters kan het ook 
interessant zijn de mogelijke additionele effecten te onderzoeken van gelijktijdige 
stimulatie van beide benen. Voor sacrale stimulatie is beschreven dat bilaterale 
stimulatie in geval van succes misschien niet zo zeer symptomen beter bestrijdt dan 
unilaterale behandeling, maar wel de kans doet toenemen dat een patiënt überhaupt 
reageert. 15-17 Uiteraard zouden uitkomsten ten gunste van bilaterale stimulatie 
nieuwe obstakels opwerpen ten aanzien van de ontwikkeling van een implantaat. 
En dat is toch waar we uiteindelijk naar toe zullen gaan: een vrij beschikbaar 
subcutaan implantaat, makkelijk te bedienen door patiënten zelf volgens flexibele, 
geïndividualiseerde behandelschema’s. Onnodig te zeggen dat er nog een lange 
weg te gaan is. 
Bij welke patiënten zou PTNS moeten worden toegepast? Aangezien PTNS, met 
10 tot 12 sessies van een half uur voordat resultaat kan worden gezien, bewerkelijk 
is, worden voorspellende parameters voor een succesvolle behandeling node gemist. 
Enkele onderzoeken hiernaar zijn gedaan voor zowel sacrale als tibialis stimulatie 
(zie hoofdstuk 4 van dit proefschrift), met als beste kandidaten mentaal gezonde 
patiënten met een matig ernstige overactieve blaas of niet-obstructieve urineretentie. 
Verder onderzoek dient plaats te vinden om de criteria voor neuromodulatietherapie
te verfijnen ten einde tot betere therapieresultaten te komen. Zodra een subcutaan 
implantaat voor chronische tibialis stimulatie beschikbaar komt, dienen naar analogie 
van de sacrale neuromodulatie verdere inspanningen te worden verricht om de 
testfase vóór implantatie te optimaliseren met als doel verdere vermindering van het 
aantal onnodig behandelde patiënten. 
Hier tegenover staat dat met een verbetering van de resultaten van PTNS 
behandeling ongetwijfeld gezocht zal worden naar de mogelijke waarde voor andere 
indicatiegroepen, iets wat ook al gezien wordt bij sacrale neuromodulatie. De meest 
waarschijnlijk nader te bestuderen groepen zijn: kinderen, neurologische patiënten 
en patiënten met faecale incontinentie. 
Tot op heden zijn vrijwel alle stimulatie- en neuromodulatietechnieken uitgetest op 
volwassenen, met als uitzondering intravesicale stimulatie bij kinderen met 
neurogene mictiestoornissen en TENS bij kinderen met niet-neurogene incontinentie. 
De meerderheid van de neuromodulatietechnieken is namelijk minder geschikt voor 
kinderen vanwege het invasieve karakter en de noodzaak met stroom te werken in 
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de anale en/of genitale regio. Hoewel PTNS niet ‘niet-invasief’ is, kan het feit dat het 
via de enkel werkt toch minder bedreigend zijn voor kinderen, zodat zich een 
mogelijkheid voordoet PTNS toe te passen in een jonge leeftijdscategorie. 
Veelbelovende resultaten uit de eerste twee studies onder respectievelijk 31 en 23 
kinderen 18,19 nodigen in ieder geval uit tot nadere evaluatie. 
De tweede patiëntengroep die nader onderzoek waard is, is die van de 
neurologische patiënten. In veel studies naar neuromodulatie zijn deze patiënten niet 
opgenomen. Toch kan, in geselecteerde gevallen van vooral multiple sclerosis, 
worden verondersteld dat ook bij hen positief resultaat kan worden behaald. 
Momenteel is ervaring op dit gebied beperkt en tegenstrijdig 20-22, maar resultaten zijn 
bemoedigend genoeg om verder onderzoek te rechtvaardigen.  
Een gebied tenslotte waarin veel urologen niet geïnteresseerd zijn, maar dat veel 
gemeen heeft met disfunctie van de lagere urinewegen is dat van de faecale 
incontinentie. Net als urineverlies heeft faecale incontinentie een grote invloed op de 
kwaliteit van leven, maar het onderwerp is zo mogelijk nog moeilijker bespreekbaar 
voor zowel patiënten als zorgverleners. Aangezien de eerste stappen worden gezet 
in de evaluatie van sacrale neuromodulatie ter bestrijding van deze aandoening 23
kan worden verondersteld dat ook onderzoek naar PTNS zal worden uitgevoerd. 24
Het is het lot van de wetenschap: elk antwoord op een vraag levert weer meer 
nieuwe vragen op. Met dit proefschrift hoop ik in staat te zijn geweest vele nieuwe 
vragen op te roepen.
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Abbreviations
AMFES Acute Maximal Functional Electrical Stimulation 
BCI  Bladder Contractility Index 
BVE  Bladder Voiding Efficiency 
CI  Confidence Interval 
CNS  Central Nervous System 
CPP  Chronic Pelvic Pain 
DI  Detrusor Instability 
EMG  ElectroMyoGraphy` 
FES  Functional Electrical Stimulation 
GABA  Gamma Amino Butyric Acid 
IC  Interstitial Cystitis 
ICS  International Continence Society 
I-QoL  Incontinence Quality of Life 
LUTD  Lower Urinary Tract Dysfunction 
MCS  Mental Component Summary (subgroup SF-36 questionnaire) 
MES  Maximal Electrical Stimulation 
MPQ  McGill Pain Questionnaire 
NMDA N-Methyl D-aspartatic Acid 
NOUR Non-Obstructive Urinary Retention 
NSF-9 Nine questions regarding Sexual Functioning
NWC  Number of Words Chosen (subgroup McGill pain questionnaire) 
OAB  OverActive Bladder 
OR  Odds Ratio 
PCS  Physical Component Summary (subgroup SF-36 questionnaire) 
Pdet  Detrusor Pressure 
PNE  Peripheral/Percutaneous Nerve Evaluation 
PNS  Pudendal Nerve Stimulation 
PRI  Pain Rate Intensity (subgroup McGill pain questionnaire) 
PTNS  Percutaneous Tibial Nerve Stimulation 
Qmax  Maximal Flow rate 
RF  Radio Frequency 
ROC  Receiver Operating Characteristic (Curve) 
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SD  Standard Deviation 
SF-36  Short Form 36 (quality of life questionnaire) 
SNS  Sacral Nerve Stimulation 
SPA  Sexual and/or Physical Abuse 
STNS  Subcutaneous Tibial Nerve Stimulation 
TENS  Transcutaneous Electrical Nerve Stimulation 
UF  Urgency/Frequency 
UI  Urge Incontinence 
VAS  Visual Analogue Scale 
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Dankwoord
Prof. Dr. B.L.H. Bemelmans, beste Bart. Dank, dank, dank. Na een keuzecoschap bij 
jou als zaalarts en een (functionele) opleiding bij jou als staflid ben ik trots één van je 
eerste promovendi te zijn nu je professor bent. Maar met de bul in mijn handen stopt 
ben ik bang de verdere achtervolging… Je losse manier van begeleiden gaf me alle 
vrijheid promoveren op zoveel mogelijk eigen wijze en tempo te doen, iets wat zeker 
bijgedragen heeft aan de succesvolle afronding hiervan. We kunnen denk ik beiden 
tevreden zijn over het eindresultaat, waarvan ik ooit mopperde “dat het geen Donald 
Duck moest worden” en jij, een zeker karaktertrekje van je promovendus duidelijk 
onderkennend, aangaf “dat je er ook niet mee naar Stockholm hoefde”.
Dr. H. Vergunst, beste Henk. Als Agnio werd ik meer dan een half jaar lang je directe 
assistent en reken maar, dat tekent je. Nu nog weet ik een foramen in de 
endopelviene fascie nutteloos bij naam te noemen, staan mij Latijnse spreuken over 
runderen en Jupiter bij en sta ik nog steeds paf van alle methodes die “volgens V.” 
genoemd werden. Evengoed: ze kunnen kletsen wat ze willen, maar PTNS in 
Nederland begon toch echt zo’n beetje in het CWZ. Dank voor je inzet om mij daar 
als promovendus meer werk van te laten maken. Je uitbundige vooral tekstuele 
commentaar bij elk ingeleverd manuscript dreef me af en toe tot waanzin, maar 
leverde -eerlijk is eerlijk- eigenlijk altijd een betere tekst op.
Drs. V. Vandoninck, beste Vera. Daar zaten we dan, allebei net met onze 
onderzoeken begonnen, verontrust met Bemelmans om de tafel bij jou thuis, bang 
als we waren dat we elkaars vijvertje zouden leegvissen. Nu, enkele jaren later 
kunnen we –mede dankzij jouw Italiaanse connecties- allebei een mooie serie 
artikelen op tafel leggen. ‘Papa’ en ‘proefschrift’ zijn al amper compatible, maar 
‘mama’ en ‘promoveren’ misschien al helemaal niet. Ik vind het dan ook geweldig dat 
ook jij binnenkort je ‘s’-je kwijtraakt! 
Dr. F. van der Pal, beste Floor. Als laatste van ons drie begonnen aan het PTNS-
project en -ondanks de diverse obstakels- als eerste klaar: daar stond je toekomstige 
‘baas’ mooi te kijken! Ik heb onze gedachtewisselingen over onwelwillende katten, 
implantaten van het formaat Sovjet-makelij en de positie van PTNS-naaldjes in 
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kadaverenkels altijd erg aangenaam gevonden en je vasthoudendheid om toch te 
komen tot een acceptabele vorm voor de placebo-studie zij geprezen. Ik kijk er naar 
uit binnenkort een bijdrage te mogen leveren aan je opleiding in Arnhem. 
Dr. J.J. Bade, M.Th.J. van Balken-van Dijk, Dr. A.F. Bierkens, Dr. K.P.J. Delaere, 
K.W.H. Gisolf, Prof. Dr. L.A.L.M. Kiemeney, B.C. Knipscheer, E.J. Messelink, P. 
Pasker-de Jong, Dr. Ir. N.J.M. Rijkhoff, I. van Rooij, J. Streppel en ik vrees nog 
enkele hier niet genoemde mensen droegen actief bij aan het verzamelen van data, 
het kritisch beoordelen van manuscripten op inhoud of Engels taalgebruik en de 
statistische verwerkingsmethoden. Dank hiervoor, dit is ook een beetje jullie boekje.  
E.F. Agro, C. Caltagirone, S. Lucia, F. Micali and F. Petta, thank you for participating 
in the trials. Your unselfish willingness to share your data with us attributed to the 
realization of -in the near future- two thesises. Of course I’ll follow your continued 
work on PTNS with great interest. 
Hooggeleerden Prof. Dr. Ph.E.V.A. van Kerrebroeck, Prof. Dr. R. Koenen, Prof. Dr. 
E.J.H. Meuleman, Prof. Dr. C.H. Polman en Prof. Dr. W.W.A. Zuurmond ben ik 
erkentelijk voor het feit dat zij zitting wilden nemen in mijn manuscriptcommissie. 
Mijn opleiders, Dr. M. Eeftinck Schattenkerk, Dr. H.F.M. Karthaus en Prof. Dr. F.M.J. 
Debruyne dank ik alle hartelijk voor hun bijdrage aan mijn vorming.
Prof. Dr. J.A. Witjes, beste Fred, sommige leermeesters betekenen meer voor je dan 
andere. Ik ben je voor het in opleiding komen en het vorm geven aan mijn ambities 
veel verschuldigd, net als voor het belangrijkste deel van mijn ‘operatieve 
vaardigheden’. Je eigen briljant-arrogante, maar zo vreselijk geruststellende “Papa is 
bij je, er kan niks gebeuren” tijdens een grote ingreep zegt eigenlijk alles.  
Dr. J.P.F.A. Heesakkers, beste John. Met Bart samen maakte je van mij een 
‘functioneel uroloog’. Daar heb ik, ondanks een urologisch klimaat waarin eigenlijk 
alleen kanker en kijkoperaties ‘hot’ en ‘sexy’ zijn, nog steeds geen spijt van. Dat één 
blik in mijn wachtkamer onmiddellijk duidelijk maakt wie er poli heeft moge een teken 
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zijn dat je in mijn vorming geslaagd bent. Dank voor de kansen die je me geeft me 
ook nu op dit gebied te profileren en ik kijk uit naar verdere samenwerking in de 
toekomst.
Prof. Dr. W. Artibani and Dr. F. Pesce, thank you very much for the fantastic time I 
spent with you in Verona. Regretfully, my PTNS demonstration in an Italian patient 
was far from a success. Bianca and I still share warm memories on your hospitality, 
and the pleasant stay at your department boosted my ‘functional urology ambitions’. 
Francesco, the book on urodynamics you gave me, with hearty dedication, has been 
of great use! 
Maatschap urologie Arnhem/Velp/Zevenaar, beste maten. Doorgaans is dit de plek 
waar collega’s bedankt worden voor de mogelijkheid die zij -door hem wat te ontzien- 
de promovendus boden in alle rust zijn proefschrift af te ronden. Dat is toch niet 
helemaal gelukt! Veel is gebeurd, maar ik ben blij met jullie samen dit jaar een frisse 
start te mogen maken. Dank voor de mogelijkheden die jullie mij geven de 
functionele urologie in ons ziekenhuis zo breed mogelijk uit te kunnen dragen. 
Papa, mama, Martijn, Petra. Het moge dan niet altijd feest zijn, sommige gezinnen 
krijgen wel heel wat voor de kiezen. Het is fijn dat we de laatste jaren overwegend 
leukere zaken kunnen delen; zo is het heerlijk om te zien hoeveel plezier onze 
mannen jullie hebben gebracht. Dank voor de interesse in mijn wetenschappelijke 
activiteiten en de soms zelfs actieve taalkundige ondersteuning, hoewel niet elk 
creatief vertaalvoorstel betreffende vooral faecale incontinentie publicatie gehaald 
heeft, gelukkig. Tinus, reken maar dat ik je in rokkostuum had gehesen. En al had al 
jouw commentaar op de tradities van een promotieplechtigheid mijn spanningsniveau 
zeker niet verlaagd, ik zou het er zo graag voor over hebben gehad.
Ton, Riet, Bastiaan. Dank voor het feit dat jullie mij warm in jullie familie hebben 
opgenomen. Het feit dat ergens in kleine lettertjes blijkbaar staat dat jullie Bianca 
écht niet meer terugnemen doet daar niets aan af, net als het feit dat jullie je er 
steeds in lijken te vergissen dat een ‘warm nest’ per se ‘rood’ zou moeten zijn. Ik voel 
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me prettig bij jullie en ben oprecht dankbaar voor jullie support en interesse in de 
afgelopen jaren. 
Gea, je had hier natuurlijk bij moeten zijn. Ik mis je vaak en ben je oneindig dankbaar 
voor steun in eens moeilijker tijden. Ik vind het geweldig dat Christiaan mijn paranimf 
wil zijn, ook al spreekt hij het woord telkens verkeerd uit en denkt hij bij het functie-
profiel op de één of andere manier steeds aan vrouwen. 
Beste Remko, er was geen twijfel over mogelijk: jij móest een van mijn paranimfen 
worden. Al een kleine helft van mijn leven gaat er geen belabberd of memorabel 
moment voorbij of je bent er een belangrijke deelgenoot van. Ik weet dat jij je hand 
niet omdraait voor het zo nodig van mij overnemen van de verdediging van dit boekje 
“vol spelfouten” en dat geeft een zeer gerust gevoel. Al ben ik blij als we samen een 
dikke, lange jongen (70% luchtvochtigheid natuurlijk) uit warmer streken kunnen 
opsteken op de goede afloop.
Lieve Bicie, ik weet het: je gelooft er he-le-maal níets van dat de afronding van dit 
proefschrift het aanbreken van rustiger tijden betekent. En waarschijnlijk heb je gelijk. 
Ondanks de stappen terug die je er nogal eens voor moet doen geef je me zeeën 
van ruimte me als een ‘uroholic’ te gedragen en  de waardering hiervoor, die je lang 
niet altijd voelt, kan niet met een stukje tekst worden weergegeven. Je bent mijn 
sociale helft en mijn grote liefde en we weten intussen allebei dat er wel heel wat 
moet gebeuren wil daar iets aan veranderen. Ik ben dan ook weergaloos gelukkig dat 
er na onze prachtmannen Wouter en Jochem nog een ongetwijfeld grote boef of 
eigenwijze griet bijkomt en ik hoop dat het op jou lijkt. Dank je lieve schat, ik love 
you.
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